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Abstract 
The natural product simocyclinone D8 (SD8) is a potent DNA gyrase inhibitor 
produced by Streptomyces antibioticus Tü6040. The biosynthetic 
simocyclinone (sim) gene cluster has been sequenced and a hypothetical 
biosynthetic pathway has been proposed. The tetraene linker in SD8 was 
suggested to be the product of a modular type I polyketide synthase working 
in trans with two monofunctional enzymes. SimC7, which belongs to the 
short-chain dehydrogenase/reductase (SDR) superfamily of proteins, was 
proposed to supply the dehydratase activity missing from two modules of the 
polyketide synthase.  
In this study, I report the structure and function of recombinant S. antibioticus 
SimC7. Because the natural simocyclinone producer is genetically 
intractable, the ~72-kb sim cluster was isolated on a single phage artificial 
chromosome (PAC) clone for heterologous production in a 
Streptomyces coelicolor strain engineered for improved antibiotic production. 
Deletion of simC7 resulted in production of a novel simocyclinone, 
7-oxo-SD8, which carried a normal tetraene linker but was altered in the 
angucyclinone. I demonstrate that SimC7 is an NAD(P)H-dependent 
polyketide ketoreductase that catalyses the reduction of the C-7 carbonyl of 
the angucyclinone and the resulting hydroxyl group is essential for antibiotic 
activity. SimC7 shares little sequence similarity with characterized 
ketoreductases, suggesting it might have a distinct catalytic mechanism. To 
investigate this possibility, I determined the structures of SimC7 alone, in 
complex with NADP+, and in complex with NADP+ and the substrate 7-oxo-
SD8. These structures show that SimC7 is distinct from previously 
characterized polyketide ketoreductases, lacking the conserved catalytic 
triad (Ser-Tyr-Lys), including the active site tyrosine that acts as central acid-
base catalyst in canonical SDR proteins. Taken together with functional 
analyses of active site mutants, my data suggest SimC7 catalyses a 
substrate-assisted, two-step reaction for reduction of the C-7 carbonyl group 
involving intramolecular transfer of a substrate-derived proton to generate a 
phenolate intermediate.  
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1.1 Importance of antibiotics 
Antibiotics are bioactive agents that inhibit cellular growth (bacteriostatic) or 
are toxic to cells (bactericidal). The name ‘antimicrobials’ has been 
commonly accepted as a synonym for antibiotics because they target mostly 
bacterial or fungal cells (Wright, 2007). Since the discovery of penicillin in 
1928 (Fleming, 1929) and its introduction to the clinic in the 1940’s (Chain et 
al., 2005), antibiotics have become one of the most important agents for 
medical applications. Most antibiotic classes were discovered between 1945 
and 1960, often referred to as the ‘golden age’ of antibiotic discovery. This 
trend reversed subsequently with the number of newly discovered 
compounds decreasing continuously (Watve et al., 2001; Walsh, 2003; 
Wright, 2007). Since the introduction of the first antibiotics, bacterial strains 
have developed resistances against most clinically important antibiotics. 
Multiple antibiotic-resistant strains have emerged (often referred to as 
‘superbugs’), such as methicillin-resistant Staphylococcus aureus (MRSA) or 
vancomycin-resistant Enterococci (VRE). The introduction or excessive use 
of new antibiotics was generally followed by a wave of newly resistant 
bacteria (Chambers and Deleo, 2009). The time period from the introduction 
of an antibiotic until the first case of resistance varies but often takes less 
than a decade (Schmieder and Edwards, 2012). For example, the 
identification of MRSA was reported just one year after the introduction of 
methicillin in 1960 (Palumbi, 2001).  
The development of new antibiotics has slowed down over the past 25 years. 
As an illustration, the Food and Drug Administration (FDA) approved 16 new 
antibiotics between 1983 and 1987, but only six between 2003 and 2007 
(Spellberg et al., 2008). The reason for this decline is not only reduced 
discovery of novel antibiotics by classic approaches, but also a strong 
increase in the economic costs associated with the long development 
process required for the production of new pharmaceuticals. The average 
development cost for a new antibiotic was estimated to be about $400-800 
million in 2002 (DiMasi et al., 2003). However, this should be measured 
against the costs arising from drug-resistant organisms, which probably 
21 
exceed $100 billion per year in the United States (Palumbi, 2001; Payne et 
al., 2007). The lack of novel antibiotics and the continuous increase in 
multiply resistant bacteria are two major challenges that need to be 
addressed in the near future. 
 
1.2 DNA topoisomerases 
Topoisomerases are enzymes that control the topology (i.e. spatial structure) 
of DNA (Bates and Maxwell, 2007) by removing or inducing additional turns 
into DNA and by resolving mechanically interlocked DNA such as catenanes 
and knots (Schoeffler and Berger, 2008). Topoisomerases are divided into 
two functional groups depending on whether they transiently break one 
(type I) or both (type II) DNA strands during their catalytic cycle (Liu et al., 
1980). A summary of DNA topoisomerases and their specific functions can 
be found in Table 1.1. In most organisms DNA is negatively supercoiled. 
Supercoiling is not only important to compact the bacterial genome inside 
cells, it also plays an important role in transcription and DNA replication. The 
temporary separation of the DNA strands for the synthesis of DNA or RNA 
introduces additional supercoils next to the separated DNA segment. 
Topoisomerases induce compensatory positive supercoils ahead and 
negative supercoils behind the replication complex to relieve some of the 
stress in the DNA and thus maintain DNA topology around the DNA region 
that is unwound (Albert et al., 1996; Rampakakis et al., 2010).  
Type II topoisomerases catalyse the interconversion of DNA topoisomers by 
making a transient double-stranded break in DNA and then transporting one 
DNA segment through another. Bacterial genomes encode two type II 
topoisomerases, DNA gyrase and topoisomerase IV (Topo IV), which are 
both heterotetramers. This is in contrast to eukaryotic type II 
topoisomerases, which are homodimers (Champoux, 2001). Except for an 
insertion of 170 amino acids near the C-terminus of GyrB, DNA gyrase and 
Topo IV share ~40% sequence identity. Both can relax supercoiled DNA, but  
22 
Table 1.1  
Classification and activities of DNA topoisomerases.  
Table adapted from Bush et al. (2015). 
1) -ve indicates negatively supercoiled DNA; +ve indicates positively supercoiled DNA. 
2) Only if one substrate is nicked or single-stranded. 
3) Decatenation activity of E. coli DNA gyrase is weak. 
      Activities 
Topoisomerase Type Organisms Subunit  Strand  Bond Catenation/ Knotting/ Relaxation Supercoiling 
   structure cleavage formed decatenation unknotting -ve 
1) +ve 1) -ve 1) +ve 1) 
Topo I IA Bacteria Monomer 1 5’ Yes Yes 
2) Yes 2) No No No 
 IB 
Eukaryotes, 
Viruses 
Monomer 1 3’ Yes Yes 2) Yes 2) Yes No No 
Topo II IIA Eukaryotes Homo-dimer 2 5’ Yes Yes Yes Yes No No 
Topo III IA 
Bacteria, 
Eukaryotes 
Monomer 1 5’ Yes Yes 2) Yes No No No 
Topo IV IIA Bacteria Hetero-tetramer 2 5’ Yes Yes Yes Yes No No 
Topo V IB/ IC Bacteria Monomer 1 3’ unknown unknown Yes Yes No No 
Topo VI IIB Archaea Hetero-tetramer 2 5’ Yes unknown Yes Yes No No 
DNA gyrase IIA Bacteria Hetero-tetramer 2 5’ Yes 
3) Yes Yes Yes Yes No 
Reverse gyrase IA 
Bacteria, 
Archaea 
Monomer 1 5’ No No Yes No No Yes 
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DNA gyrase is the only bacterial enzyme that can introduce negative 
supercoils into DNA (Table 1.1). 
 
1.2.1 DNA gyrase 
DNA gyrase is a type II DNA topoisomerase that introduces negative 
supercoils into DNA driven by hydrolysis of adenosine triphosphate (ATP) 
(Bates and Maxwell, 2007). The fact that DNA gyrase is essential in bacteria 
but absent from humans makes it a selective target for antimicrobials 
(Maxwell, 1997). This has made DNA gyrase one of the best-validated 
targets for antibacterial therapies (Heide, 2013). 
DNA gyrase consists of two A subunits (GyrA; 97 kDa in E. coli) and two B 
subunits (GyrB; 90 kDa in E. coli), which form an A2B2 heterotetramer (Collin 
et al., 2011). Structural studies on DNA gyrase have revealed a detailed 
picture of its molecular mechanism. Although there is currently no high-
resolution structure of the entire enzyme complex due to its flexibility, the 
structure and function of various fragments of DNA gyrase have been solved 
separately (Figure 1.1). This revealed that GyrA is involved in interactions 
with DNA including binding and cleavage via an active-site tyrosine (Tyr122 
in E. coli), whereas GyrB contains an ATPase domain required for the 
transient cleavage of DNA (Figure 1.1) (Collin et al., 2011).  
The current model for DNA supercoiling by DNA gyrase is known as the two-
gate mechanism (Figure 1.2). During each cycle, two negative supercoils 
are introduced into the DNA substrate at the expense of hydrolysis of two 
ATP molecules (Bates and Maxwell, 2007). Three interfaces of DNA gyrase 
are important for conformational changes: The N-terminal domain of GyrB 
(N-gate), the gyrase-DNA interface (DNA-gate), and the C-terminal domain 
of GyrB (C-gate). First, the DNA-gate of the enzyme associates with a DNA 
segment, which is named the DNA gate segment (G-segment). The C-
terminal domain of GyrA assists in winding the adjacent DNA around the 
enzyme in a right-handed supercoil of about 130 base pairs to position a 
second DNA segment (the DNA transfer segment or T-segment) in a positive  
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Figure 1.1  
Predicted heterotetrameric structure and domain architecture of DNA 
gyrase.  
The predicted overall structure of DNA gyrase was assembled from known 
structures of DNA gyrase fragments including a GyrB 43-kDa fragment (PDB 
accession number 1EI1), a GyrB-GyrA fusion construct (PDB accession 
number 3NUH), and the GyrA 35-kDa C-terminal domain (PDB accession 
number 3L6V). Black bars indicate catalytic residues, GHKL is the ATPase 
domain, TOPRIM is the topoisomerase/primase domain, WHD is the winged-
helix domain and CTD is the C-terminal domain. Figure from Bush et al., 
2015. 
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crossover above the G-segment and in between the N-gate of GyrB (Figure 
1.2). Binding of ATP to GyrB closes the N-gate and consequently traps the 
T-segment to prepare for the passage of one DNA segment through the 
other. Cleavage of the G-segment covalently links the enzyme with the DNA 
substrate. The G-segment is transiently cleaved in a trans-esterification 
between the active site tyrosine (Tyr122) in both GyrA subunits and the 
phosphoryl groups in the backbone of both DNA strands to generate two 
DNA-phosphotyrosyl bonds. Hydrolysis of the first ATP induces a 
conformational change in DNA gyrase to transport the T-segment through 
the transiently opened G-segment and the C-gate of the enzyme. The 
G-segment is subsequently re-ligated and hydrolysis of the second ATP 
opens the N-gate to reset the enzyme for the next cycle (Nollmann et al., 
2007; Collin et al., 2011).  
DNA gyrase can be inhibited at various steps in its catalytic cycle, such as 
DNA binding, DNA cleavage, DNA strand passage, and ATP hydrolysis 
(Figure 1.2) (Collin et al., 2011). Several classes of DNA gyrase-specific 
inhibitors have been discovered and described. The two most important 
classes of DNA gyrase inhibitors, namely the quinolones and the 
aminocoumarins, were discovered more than a decade before the enzyme 
itself was discovered in 1976 (Gellert et al., 1976). The aminocoumarins will 
be discussed in the next chapter. The most clinically successful class of 
inhibitors are the quinolones, a class of synthetic antibiotics with potent 
activity against DNA gyrase. After the discovery of nalidixic acid in 1962 and 
its introduction for clinical use in 1967, the quinolones have been developed 
for more than five decades, giving rise to four generations of compounds with 
continuously improving physicochemical properties (Emmerson and Jones, 
2003). The development of the fluoroquinolones in the 1970s gave rise to 
some of the most potent DNA gyrase inhibitors such as ciprofloxacin, with 
broad activity against Gram-negative bacteria. Fluoroquinolones stabilise the 
covalent DNA-protein complex, which leads to protein-stabilised breaks in 
the genome and, ultimately, cell death (Collin et al., 2011). The irreversible 
inhibition of DNA gyrase by the fluoroquinolones explains their potency and 
clinical success compared to competitive and reversible inhibitors such as  
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Figure 1.2  
Model for negative supercoiling of DNA by DNA gyrase.  
Association of the DNA gyrase subunits positions the DNA gate (G) segment 
above the GyrA dimer interface and the DNA transfer (T) segment in a 
positive crossover by wrapping the DNA around the C-terminal domain of 
GyrA. Binding of ATP captures the T-segment by the two GyrB subunits and 
the G-segment is transiently cleaved by covalently linking the 3’-phosphate 
of the DNA backbone to the active site tyrosine in GyrB. Hydrolysis of the 
first ATP initiates rotation of GyrB, which opens the DNA gate and allows 
transport of the T-segment through the cleaved G-segment. The G-segment 
is re-ligated and hydrolysis of the second ATP resets the enzyme. Inhibitors 
of DNA gyrase are indicated in red. The N- and C-terminal domain of GyrA 
are coloured in light and dark blue and the N- and C-terminal domain of GyrB 
are coloured in yellow and orange, respectively. The figure was modified 
from (Collin et al., 2011; Ehmann and Lahiri, 2014).  
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the aminocoumarins. Fluoroquinolones are known to inhibit DNA gyrase in 
Gram-negative bacteria but their primary target in many pathogenic Gram-
positive bacteria is topoisomerase IV (Topo IV) (Collin et al., 2011). This is 
not surprising given the structural and sequence similarity between Topo IV 
and DNA gyrase. Recent crystal structures of the stabilised DNA-cleavage 
complex of gyrase from S. aureus (Bax et al., 2010) and Topo IV from 
Streptococcus pneumoniae and Acinetobacter baumannii (Laponogov et al., 
2009; Wohlkonig et al., 2010) have revealed that fluoroquinolones intercalate 
at the highly bent DNA gate. The binding site of fluoroquinolones is near the 
active site tyrosine and can shift slightly depending on the structure of 
fluoroquinolone. Although fluoroquinolones are extremely effective 
antibiotics, the continuous increase in bacterial resistances limits their 
application. Resistance against fluoroquinolones emerges from mutations in 
amino acid residues near the drug binding site (Laponogov et al., 2009; Bax 
et al., 2010; Wohlkonig et al., 2010).  
A number of other DNA gyrase inhibitors have been discovered in recent 
years in attempts to find alternative therapeutics. These include inhibitors 
that stabilise the DNA-protein intermediate (GSK299423 and the peptide 
Microcin B17), that inhibit ATP-hydrolysis by GyrB (closthioamide, 
cyclothialidine, gyramide A), or prevent DNA strand passage (CcdB protein) 
(Figure 1.2) (Goetschi et al., 1993; Bahassi et al., 1999; Parks et al., 2007; 
Bax et al., 2010; Foss et al., 2011; Chiriac et al., 2015).  
  
28 
1.3 Aminocoumarins 
Aminocoumarins are potent inhibitors of bacterial DNA gyrase. The defining 
feature of the aminocoumarins is their characteristic structural core (3-amino-
4,7-dihydroxycoumarin), which is usually decorated with various sugar-, acyl- 
or other groups (Figure 1.3). All the known aminocoumarins are produced by 
strains of the genus Streptomyces, although related genera have also been 
reported to produce coumermycin (Actinoallomurus) and simocyclinones 
(Kitasatospora) (Pozzi et al., 2011; Bilyk et al., 2016). The three ‘classic’ 
aminocoumarins are novobiocin, clorobiocin, and coumermycin A1 
(Steffensky et al., 2000; Wang et al., 2000; Pojer et al., 2002). Their 
biosynthesis and mode of action has been studied in such detail that they 
have developed into a model system for generating new antibiotics by 
different approaches. These intensive genetic and biochemical studies have 
made novobiocin and clorobiocin two of the best studied secondary 
metabolites (Heide, 2013). All ‘classic’ aminocoumarins competitively inhibit 
GyrB by interfering with ATP hydrolysis because their binding site overlaps 
the ATP binding pocket in the ATPase domain of GyrB, as seen in the crystal 
structures of GyrB from E. coli (Holdgate et al., 1997) and 
Staphylococcus aureus (Lu et al., 2014) in complex with novobiocin (see 
below, Figure 1.7).  
Beside the three ‘classic’ aminocoumarins, only two further aminocoumarins 
have been discovered, namely rubradirin and the simocyclinones, of which 
the latter will be discussed in the following section (Figure 1.3). In contrast to 
the above mentioned and well-studied ‘classic’ aminocoumarins, the 
biosynthetic pathways for the simocyclinones and rubradirin are covered by 
only a few experimental studies and remain largely hypothetical. Rubradirin 
not only lacks the deoxysugar at the 7-hydroxyl group of the aminocoumarin, 
which is typical for the ‘classic’ aminocoumarins, but it also has a completely 
different mode of action, inhibiting bacterial RNA polymerase instead of DNA 
gyrase (Kim et al., 2008a). 
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Figure 1.3  
Structures of known aminocoumarin antibiotics.  
Aminocoumarins are divided into ‘classic’ aminocoumarins (novobiocin, 
clorobiocin, and coumermycin A1) and unusual aminocoumarins 
(simocyclinone D8 and rubradirin) based on their mode of action. Whereas 
the ‘classic’ aminocoumarins inhibit GyrB, simocyclinone inhibits GyrA by a 
different mode of action and rubradirin targets RNA polymerase. The 
aminocoumarin core (blue) is either chlorinated at position 8 (SD8 and 
clorobiocin), methylated (novobiocin and coumermycin A1) or unmodified 
(rubradirin). 
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1.3.1 Biosynthesis of aminocoumarins 
Aminocoumarins are synthesised from L-tyrosine, which undergoes 
hydroxylation, dehydrogenation, and lactonisation in only a few biosynthetic 
steps. In novobiocin biosynthesis, NovH first activates L-tyrosine with ATP 
and then attaches it via a thioester to its peptidyl carrier protein (PCP) 
domain. The enzyme-linked tyrosine is subsequently β-hydroxylated by NovI, 
a cytochrome P450 monooxygenase, and then oxidised to β-keto-tyrosine by 
the heterotetrameric oxidoreductase NovJ/NovK. The last step in 
aminocoumarin biosynthesis, the cyclisation of the intermediate to a 3-
amino-4,7-dihydroxycoumarin, remains speculative (Heide, 2009). It was 
initially assumed that the oxidoreductase NovC first introduces a hydroxyl 
group at position 2 of the aromatic ring and that this hydroxyl group makes a 
nucleophilic attack on the thioester bond to yield the final enol lactone of the 
B ring (Chen and Walsh, 2001). However, a later study revealed that novC 
was in fact not required for aminocoumarin biosynthesis and orthologs of 
novC are absent in other aminocoumarin gene clusters (Eustaquio et al., 
2005). The genes for novobiocin biosynthesis (novHIJK) are part of a single 
operon and their genomic arrangement is very similar to orthologs in the 
clorobiocin (cloHIJK) and coumermycin A1 (couHIJK) biosynthetic gene 
clusters. The arrangement of the corresponding genes is slightly different in 
the simocyclinone (simD6, simD1, simD2, and simD3; previously named 
simHIJ2K) and the rubradirin (rubC1-3) biosynthetic gene clusters. An 
ortholog of novK (simD3) is located upstream of the remaining genes in the 
simocyclinone gene cluster but is absent from the rubradirin cluster, where 
most likely RubC3 catalyses the corresponding oxidation step (Heide, 2009). 
 
1.3.2 Resistance mechanisms against aminocoumarins 
Production of bioactive secondary metabolites requires effective resistance 
mechanisms to protect the host organism. Usually, specific resistance 
gene(s) are located within or immediately adjacent to the biosynthetic gene 
cluster. In the case of aminocoumarin antibiotics, the producing strains have 
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to protect their own essential DNA gyrase from inhibition. The ‘classic’ 
aminocoumarin gene clusters have resistance genes next to the biosynthetic 
genes. All Streptomyces species have the typical ‘housekeeping’ gyrBS gene 
encoding a novobiocin-sensitive GyrB subunit. But in addition, for example, 
the novobiocin producer, Streptomyces sphaeroides NCIB 11891, has a 
second gene (gyrBR) adjacent to the novobiocin biosynthetic gene cluster, 
which encodes a novobiocin-resistant subunit of DNA gyrase (Steffensky et 
al., 2000). Resistance against novobiocin is mediated by increased 
expression of the resistant gyrase subunit, which is triggered by reduced 
negative supercoiling of the genome. The promoter of the novobiocin-
resistant gyrase subunit responds to changes in DNA topology and is 
activated when negative supercoiling is reduced (Thiara and Cundliffe, 
1989). Orthologs of a resistant GyrB subunit are also encoded by genes next 
to the clorobiocin and coumermycin A1 biosynthetic gene clusters (Schmutz 
et al., 2003). In addition, the clorobiocin and coumermycin A1 clusters contain 
a second resistance gene (parYR), which encodes an aminocoumarin-
resistant subunit of Topo IV (Schmutz et al., 2004). These observations imply 
that clorobiocin and coumermycin A1 inhibit DNA gyrase and Topo IV, 
whereas novobiocin presumably targets only DNA gyrase. 
 
1.4 Simocyclinones 
Simocyclinones represent a new class of DNA gyrase inhibitors that are 
naturally produced by Streptomyces antibioticus Tü6040, a strain isolated 
from a soil sample collected in Iguaçu in Argentina as part of a search for 
strains producing novel secondary metabolites (Schimana et al., 2000). 
Simocyclinone D8 (SD8) is a structurally unique hybrid antibiotic with two 
active ends, an angucyclinone and a chlorinated aminocoumarin, which are 
linked by a D-olivose deoxysugar and a tetraene linker (also referred to as an 
octatetraene dicarboxylate) (Schimana et al., 2001; Holzenkampfer et al., 
2002). Thus, SD8 is an aminocoumarin, but also an angucyclinone, a class 
of antibiotics with more than 200 known representatives characterised by a 
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tetracyclic angular benz[α]anthracene ring system (Rohr and Thiericke, 1992; 
Kharel et al., 2012). 
About 14 different simocyclinones have been identified via nuclear magnetic 
resonance (NMR) or mass spectrometry (MS), which represent either 
intermediates or derivatives of SD8, the ultimate biosynthetic product (Figure 
1.4). Simocyclinone production strongly depends on available carbon- and 
nitrogen-sources, which influence the ratio and composition of the 
simocyclinones produced (Schimana et al., 2001). Production of SD8 is 
favoured by using glycerol and L-glutamine as the respective carbon and 
nitrogen sources in the culture medium. Production of up to 300 mg SD8 per 
litre was observed after about 6 days fermentation when supplemented with 
starch and L-glutamine. The remaining simocyclinone intermediates are only 
present in small amounts under these conditions. The composition of 
simocyclinone intermediates significantly changes when using mannitol and 
L-arginine as the respective carbon and nitrogen sources (Schimana et al., 
2001).  
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Figure 1.4  
Classification of simocyclinones according to the main structural 
components.  
Four groups of simocyclinones have been classified (A to D) based on 
intermediates identified by mass spectrometry (yellow) or NMR (blue). 
Simocyclinone biosynthesis starts with the angucyclinone (aglycone, A-
group), followed by attachment of the deoxysugar D-olivose (B-group), the 
tetraene linker (C-group), and the aminocoumarin (D-group). Hypothetical 
intermediates are shown in grey boxes. Figure adapted from (Theobald et 
al., 2000).   
34 
1.4.1 Biosynthesis of simocyclinones 
The simocyclinone (sim) biosynthetic gene cluster from S. antibioticus 
Tü6040 has been cloned and sequenced and a hypothetical pathway has 
been proposed (Figure 1.5) (Galm et al., 2002; Trefzer et al., 2002). The four 
structural elements of SD8 are synthesized separately and linked in a few 
enzymatic steps (Figure 1.4 and Figure 1.5). SD8 is made from three 
primary metabolites (Galm et al., 2002; Trefzer et al., 2002), which explains 
the observed carbon and nitrogen source dependent variations in the 
composition of simocyclinones (Schimana et al., 2001). Previous studies 
have shown that aminocoumarins are synthesised from L-tyrosine (Bunton et 
al., 1963; Chen and Walsh, 2001) and D-olivose is derived from D-glucose 
(Wang et al., 2011). Feeding experiments with stable isotopes of malonic 
acid revealed that the polyketide-derived angucyclinone and tetraene linker 
are made from acetate units although direct feeding of acetate itself was not 
possible because simocyclinone production was inhibited by this approach 
(Holzenkampfer et al., 2002). Culturing S. antibioticus Tü6040 in an 18O2-rich 
atmosphere showed that four oxygen atoms are incorporated by oxygenases 
from molecular oxygen (Holzenkampfer and Zeeck, 2002), consistent with a 
previously proposed cyclisation mechanism for novobiocin (Chen and Walsh, 
2001). Cyclisation of the aminocoumarin precursor in novobiocin was 
predicted to arise from the introduction of a hydroxyl group at position 2 in 
2,4-dihydroxy-β-keto-phenylalanine, which then attacks the thioester that 
links the activated aminocoumarin precursor to the peptidyl carrier protein 
(Chen and Walsh, 2001). 
By the end of this thesis the sim gene cluster was sequenced three times. 
The three sources of the gene cluster are the original sequence from its 
discovery in 2002, the sequence from PAC-12I, which was subject to 
mutational analysis in this study (see chapter 3.2), and the sequence from 
the genome draft of S. antibioticus Tü6040 (see chapter 6.7). Comparison of 
the newly obtained sequences (i.e. PAC-12I and the S. antibioticus draft 
genome) with the previously published sequences of the sim gene cluster 
(Galm et al., 2002; Trefzer et al., 2002) revealed no significant differences.  
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Figure 1.5  
Proposed biosynthetic pathway for simocyclinone D8.  
Protein domains: KS, ketosynthase; AT, acyltransferase; ACP, acyl carrier 
protein; DH, dehydratase; KR, ketoreductase; ER, enoyl reductase; TE, 
thioesterase. Figure from Trefzer et al. (2002). KSQ denotes an initiation 
factor domain similar to a KS domain with a conserved glutamine instead of 
an active site cysteine (Bisang et al., 1999). 
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The proposed minimal sim gene cluster consists of 49 putative open reading 
frames, all transcribed in the same direction with exception of simR (Figure 
1.6). It was proposed that 13 enzymes contribute to the biosynthesis of the 
angucyclinone (SimA1-13), the first detectable intermediate during 
simocyclinone biosynthesis. The polyketide skeleton is generated by a 
minimal PKS, including a ketosynthase (KS; SimA1), a ketosynthase-chain 
length factor (KS-CLF; SimA2) and an acyl carrier protein (ACP; SimA3).  
This minimal PKS resembles iterative type II PKS enzymes together with two 
cyclases (SimA4-5) and one ketoreductase (SimA6). Additional oxygenases 
(SimA7-8 and SimA13), ketoreductases (SimA9-10), and one decarboxylase 
(SimA12) were predicted to be involved in oxygenation, reduction and 
decarboxylation steps, respectively. Finally, the phosphopantetheinyl 
transferase SimA11 was predicted to modify the minimal PKS (Trefzer et al., 
2002). 
The biosynthesis of the tetraene linker was predicted to involve 9 
biosynthetic enzymes including the largest enzyme, the modular type I PKS 
(SimC1A-C). The arrangement of protein domains from SimC1A to SimC1C 
seems to be co-linear with the predicted pentaketide product, but note that 
simC1A, the gene encoding the first subunit of the modular PKS, is located 
downstream of simC1B and simC1C (Figure 1.6). Two additional enzymes 
(SimC6 and SimC7) were predicted to complement the missing 
ketoreductase and dehydratase functions of the type I PKS in trans to 
generate a system of four conjugated double bounds. SimC8 was proposed 
to be the phosphopantetheinyl transferase that post-translationally modifies 
the type I PKS (SimC1A-C). The octatetraene monocarboxylate intermediate 
would then be attached by an unknown enzyme to the 3’-hydroxyl group of 
D-olivose to form a carboxylic ester. A second terminal carboxylic acid would 
then be introduced into the tetraene linker by a dioxygenase (SimC4) and an 
aldehyde dehydrogenase (SimC5) (Trefzer et al., 2002). The last step in 
simocyclinone biosynthesis is the assembly of the aminocoumarin. The 
genes involved (simD1-6) are conserved in all known aminocoumarin gene 
clusters, as mentioned earlier. The aminocoumarin is chlorinated at position 
8 by the regio-specific halogenase SimD4 (Trefzer et al., 2002).  
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Finally, the four structural units of SD8 are linked together in three enzymatic 
steps, carried out by a glycosyl-transferase (simB7), an unknown enzyme 
that connects the tetraene precursor to the deoxysugar, and an 
aminocoumarin ligase (SimD5, also named SimL) (Galm et al., 2002; Trefzer 
et al., 2002).  
Despite the unique structure of SD8 and its complex biosynthesis, only two 
transcriptional regulators (SimR1 and SimR2) (Le et al., 2009; Le et al., 
2011a; Le et al., 2011b; Horbal et al., 2012) and one biosynthetic enzyme 
(SimD5) have been characterized experimentally (Luft et al., 2005; Pacholec 
et al., 2005; Anderle et al., 2007). SimD5 (SimL) is an aminocoumarin ligase 
that catalyses the formation of an amide bond between the aminocoumarin 
and the tetraene linker. SimD5 was a promising tool to develop and engineer 
novel antimicrobials. The narrow substrate specificity of SimD5 homologs 
(namely NovL, CloL, and CouL) for benzoic acid and pyrrole-carboxylic acid 
substrates limits the ability to generate novel aminocoumarin antibiotics 
(Galm et al., 2004a; Galm et al., 2004b). In contrast, SimD5 has a broad 
substrate specificity and accepts structurally diverse carboxylated acyl 
substrates, including polyunsaturated and saturated acyl chains and benzoic 
acid derivatives (Luft et al., 2005; Pacholec et al., 2005). Using different 
approaches, SimD5 turned out to be very efficient in product formation. The 
aminocoumarin ring from novobiocin, which is methylated at position 8, was 
successfully linked to simocyclinone C4, both chemo-enzymatically and 
through mutasynthesis (Luft et al., 2005). In addition, a novel novobiocin 
analogue was generated in vitro using four enzymes. SimD5, NovM, NovP, 
and NovN catalysed the conversion of the aminocoumarin ring and TDP-L-
noviose from novobiocin and decatetraenoic acid into a novel novobiocin 
analogue (Pacholec et al., 2005). Finally, by combining SimD5, NovL and 
CouL, novel hybrid aminocoumarin antibiotics were created in a two-step 
mutasynthesis procedure. These analogues had antibacterial activity against 
Gram-positive bacteria but not against Gram-negative bacteria 
(Pseudomonas aeruginosa). The low activity of some of these analogues 
might be caused by a polar side chain or by the absence of a substituent at 
position 8 of the aminocoumarin ring system (Anderle et al., 2007).   
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Figure 1.6  
Genomic arrangement of the simocyclinone (sim) gene cluster in 
S. antibioticus Tü6040.  
Genes are colour-coded according to their previously proposed involvement 
in the biosynthesis of the four structural units of simocyclinone D8 (see 
Figure 1.5) (Trefzer et al., 2002). 
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1.4.2 Biological activity of simocyclinones 
SD8 is active against Gram-positive bacteria and has cytostatic effects on 
different human tumour cell lines. In contrast, SD8 has no activity against 
Gram-negative bacteria, yeasts, or filamentous fungi at concentrations of up 
to 100 μg/mL (Schimana et al., 2000). Although SD8 is a potent inhibitor of 
DNA gyrase, like the structurally and biosynthetically related ‘classic’ 
aminocoumarins, it has a completely different mode of action. SD8 is 
bifunctional, with an angucyclinone and an aminocoumarin at either end 
binding to two distinct pockets of the DNA-binding surface of GyrA (Figure 
1.7 and Figure 1.8) (Edwards et al., 2009; Hearnshaw et al., 2014). 
Biochemical and structural studies on the N-terminal domain of the E. coli 
GyrA revealed that SD8 binds to GyrA in a 1:1 stoichiometry (Flatman et al., 
2005). The interaction with GyrA shows positive cooperativity, with the high-
affinity angucyclinone initiating binding, followed by binding of the low-affinity 
aminocoumarin, which might be facilitated by conformational changes in the 
protein after binding of the angucyclinone (configurational cooperativity) 
(Edwards et al., 2011). Because of the bifunctional nature of SD8, removal of 
either the angucyclinone or the aminocoumarin decreases its potency as a 
DNA gyrase inhibitor by about 100-fold compared to SD8, which inhibits DNA 
supercoiling at sub-micromolar concentrations (IC50 ~ 0.1-0.6 μM) (Edwards 
et al., 2009; Edwards et al., 2011). This shows that both ends of SD8, and 
their covalent linkage, are important for effective inhibition of DNA gyrase. 
Amino acid substitutions in GyrA that conferred resistance to SD8 were 
identified by direct mutagenesis based on the GyrA-SD8 crystal structure, 
and through the isolation and sequencing of spontaneous SD8-resistant 
mutants of E. coli (Figure 1.8) (Edwards et al., 2009). Five amino acid 
substitutions that conferred resistance in vivo were identified: V44G, H45Y, 
H45Q, G81S, and D87Y. These mutations reduced the inhibitory activity of 
SD8 by up to two orders of magnitude (Figure 1.8). The substituted amino 
acid residues lie close to the binding site of SD8 seen in the crystal structure, 
confirming this site represents the true binding site of SD8 (Hearnshaw et al., 
2014). The binding sites of SD8 and ciprofloxacin on GyrA lie close to each 
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other, but the two antibiotics interact with different amino acid residues 
(Edwards et al., 2009).  
The potent inhibitory activity of SD8 against DNA gyrase is due to its 
interaction with GyrA. SD8 also binds weakly to the C-terminal domain of 
GyrB, but this is most likely a consequence of non-specific hydrophobic 
interactions and it has no effect on the ATPase activity of GyrB up to a 7:1 
molar ratio of SD8 to enzyme (Flatman et al., 2005; Sissi et al., 2010). 
Despite the high structural similarity between DNA gyrase and Topo IV, SD8 
is only a weak inhibitor of Topo IV with an IC50 of ~ 50 μM, compared to an 
IC50 of ~ 0.1-0.6 μM for DNA gyrase (Flatman et al., 2005). Finally, SD8 has 
weak activity against eukaryotic topoisomerase II (IC50 ~ 5 μM), consistent 
with the inhibitory effect of SD8 on human tumour cell lines (Schimana et al., 
2000; Flatman et al., 2005). 
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Figure 1.7  
Comparison of DNA gyrase inhibition by novobiocin and SD8.  
Novobiocin (red) binds to the ATPase domain of GyrB and interferes with 
ATP binding (blue), whereas SD8 (pink) interferes with binding of DNA 
(orange) to GyrA at the dimer interface. Subunits of the GyrA dimer are 
shown in yellow and blue. The close-up view below shows overlays with a 
non-hydrolysable ATP analog (ADPNP, phosphoaminophosphonic acid 
adenylate ester) from the ATP-GyrB complex and DNA from the DNA-GyrA 
complex (PDB accession numbers: 1AJ6, 1EI1, 4CKL, 2XCR). 
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Figure 1.8  
Schematic representation of the SD8 binding site at the DNA gyrase 
subunit A (GyrA) dimer interface.  
Mutations are indicated for the E. coli DNA gyrase that occur spontaneously 
in vivo (red) or that were created and tested in vitro (blue) with fold-changes 
in the half-maximal inhibitory concentration (IC50) indicated (Edwards et al., 
2009). Hydrogen bonds are shown as dashed lines and water molecules as 
spheres. Hydrogens have been omitted for clarity. Figure modified from 
Hearnshaw et al. (2014) (SD8-GyrA55 complex; PDB accession number: 
4CKL). 
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1.4.3 Resistance mechanism against simocyclinones 
In contrast to the biosynthetic gene clusters of ‘classic’ aminocoumarins, 
which contain genes encoding a resistant GyrB (and Topo IV) subunit, the 
simocyclinone cluster contains no resistance genes related to DNA gyrase or 
Topo IV. Instead, the sim cluster has two genes encoding putative 
transmembrane efflux pumps, simEx1 and simEx2 (Trefzer et al., 2002). 
Heterologous expression of SimEx1 and SimEx2 in Streptomyces lividans 
showed that SimEx2 had no effect on resistance to SD8, whereas SimEx1 
(also named SimX) increased resistance up to 30-fold when coupled to the 
strong consecutive ermE* promoter (ermEp*). The biosynthesis and export of 
simocyclinone are coupled through the action of a transcriptional repressor 
called SimR (Le et al., 2009). Transcription of the gene encoding the SimX 
efflux pump is repressed by SimR in the absence of simocyclinone. 
However, simocyclinone binds to SimR and abolishes its ability to bind DNA 
and through this mechanism simocyclinone induces its own export (Le et al., 
2011a; Le et al., 2011b). 
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1.5 Aims of this project 
The complex biosynthesis of simocyclinones remains largely unexplored 
experimentally due to the genetic intractability of the natural producer 
S. antibioticus Tü6040. The aim of this thesis is to investigate simocyclinone 
biosynthesis in a heterologous system to facilitate mutagensis of the sim 
gene cluster and the analysis of the resulting simocyclinones. The principal 
focus of the thesis is the enzymatic function, structure and catalytic 
mechanism of SimC7.  
In summary, the following keypoints are addressed in this thesis: 
● Establishment of a heterologous system to facilitate mutagenesis of the 
sim gene cluster and analysis of the resulting simocyclinones, to investigate 
the simocyclinone biosynthetic pathway. 
● Investigation of the true function of SimC7, a previously predicted 
dehydratase. 
● Investigation of the catalytic mechanism of SimC7 by solving the crystal 
structure of the enzyme in complex with its cofactor and substrate. 
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2.1 Enzymes 
Commercially available enzymes, DNA purification kits, and size standards 
for DNA and protein work used in this study are listed in Table 2.1. 
Table 2.1  
DNA-modifying enzymes and DNA purification kits. 
Supplier Enzymes and kits 
Roche,  
Burgess Hill, UK 
Taq DNA polymerase 
Pfu DNA polymerase 
High Fidelity (HiFi) expand DNA 
polymerase 
dNTPs 
 Lysozyme 
Restriction endonucleases 
T4 DNA Ligase 
New England Biolabs, 
Ipswich, UK 
Restriction endonucleases 
Q5 High Fidelity (HiFi) DNA polymerase 
100 bp DNA ladder 
1 kb DNA ladder 
Prestained protein marker (7-175 kDa) 
Qiagen,  
Hilden, Germany 
Taq DNA polymerase 
Plasmid purification kit 
PCR/ Gel purification kit 
Inspiralis Ltd., Norwich, UK DNA gyrase (A2B2) 
 
  
49 
2.2 Bacterial strains, plasmids, and oligonucleotides 
2.2.1 Bacterial strains 
Bacterial organisms used in this study are listed in Table 2.2 (E. coli) and 
Table 2.3 (Streptomyces spp.). 
Table 2.2  
Strains of Escherichia coli and their genomic characteristics. 
Strain Characteristics Reference 
E. coli (B derivatives)  
Rosetta(DE3) 
pLysS 
F-, ompT, gal, dcm, hsdSB(rB
- mB-), 
λ(DE3 [lacI lacUV5-T7 gene1 ind1 
sam7 nin5]), pLysSRARE6 (CmlR) 
Novagen (Merck, 
Nottingham, UK) 
E. coli (K12 derivatives)  
BT340 E. coli DH5α carrying pCP20 (Datsenko and 
Wanner, 2000) 
DH5α  F’, supE44, lacU169, (Φ80lacZΔM15), 
ΔhsdR17, recA1, endA1, gyrA96, thi-1, 
relA1 
(Hanahan, 1983) 
DH10B F-, araD139, Δ(ara, leu)7697, ΔlacX74, 
galU, galK, rpsL, deoR, 
Φ80dlacZΔM15, endA1, nupG, recA1, 
mcrA, Δ(mrr, hsdRMS, mcrBC), λ- 
(Grant et al., 
1990) 
 
BW25113 Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), 
lacIp-4000(lacIQ), λ-, rpoS369(Am), 
rph-1, Δ(rhaD-rhaB)568, hsdR514 
(Datsenko and 
Wanner, 2000) 
ET12567 F’, dam-13::Tn9 (CmlR), dcm-6, hsdM, 
hsdR, recF143, zij-202::Tn10 (TetR), 
galK2, galT22, ara-14, lacY1, xyl-5, 
leuB6, thi-1, tonA31, rpsL136, hisG4, 
tsx-78, mtl-1, glnV44 
(MacNeil et al., 
1992) 
TOP10 F-, mcrA, Δ(mrr-hsdRMSmcrBC), 
Φ80lacZΔM15, ΔlacΧ74, recA1, 
araD139, Δ(ara-leu)7697, galU, galK, 
rpsL, galE15, galK16, λ-endA1, nupG 
(StrR) 
Invitrogen, 
Paisley, UK 
NR698 MC4100 (F- araD139 Δ(argF- 
lac)U169, rpsL150, relA1, flbB5301, 
deoC1, ptsF25, rbsR), imp4213 
(Ruiz et al., 
2005) 
E. coli ATCC 
25922™ 
wild type ATCC, USA 
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Table 2.3  
Strains of Streptomyces spp. and their genomic characteristics. 
Strain Characteristics Reference 
Streptomyces albus 
J1074 (R- M-) 
S. albus G mutant defective in 
SalGI-mediated restriction (R-) and 
modification (M-) 
(Chater and 
Wilde, 1976; 
Zaburannyi et 
al., 2014) 
Streptomyces 
antibioticus Tü6040 
Natural producer of simocyclinone 
D8 
(Schimana et al., 
2000) 
Streptomyces 
coelicolor M145 
SCP1-, SCP2- (wild type derivative 
without plasmids) 
(Kieser et al., 
2000) 
Streptomyces 
coelicolor M600 
SCP1-, SCP2- (wild type derivative 
without plasmids) 
(Kieser et al., 
2000) 
Streptomyces 
coelicolor M1152 
SCP1-, SCP2- derivative of 
S. coelicolor M145 with Δact, Δred, 
Δcpk, Δcda, rpoB[C1298T] 
(Gomez-
Escribano and 
Bibb, 2011) 
Streptomyces 
coelicolor 
M1152ex1 
S. coelicolor M1152 with 
genomically integrated pIJ10480 
(ermEp*-simEx1) 
this study 
Streptomyces 
lividans 1326 
wild type (SLP2+, SLP3+) (Kessler et al., 
1989) 
Streptomyces 
lividans TK24 
SLP2-, SLP3-, str-6 (StrepR) (Hopwood et al., 
1983; Ruckert et 
al., 2015) 
Streptomyces 
venezuelae ATCC 
10712™ 
wild type, natural producer of 
chloramphenicol 
ATCC, USA 
 
 
2.2.2 Spontaneous resistant mutants of S. coelicolor M1152 
Spores of Streptomyces strains were plated on SMMS agar (5×105 per plate) 
and paper discs (6 mm diameter; GE Healthcare, Amersham, UK) were 
placed on top of the distributed spores. Each paper disc was prepared with 
20 μL DMSO containing different amounts of SD8. Bacterial growth was 
monitored for 6 days by keeping the plates upright at 30 °C. Putative SD8-
resistant colonies of S. coelicolor M1152, which grew within the inhibition 
zone were picked and re-grown for single colonies. Liquid cultures (5 mL of 
YEME and 5 mL of TSB medium) of respective putative resistant colonies 
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were grown for 3-4 days and were screened again for increased SD8 
resistance. The screening was carried out on SMMS medium with one paper 
disc per plate containing larger amounts of SD8 (30 μg or 60 μg per paper 
disc). Resistant strains, which grew without or minimal inhibition towards the 
paper disc, were selected and analysed for mutations in the GyrA subunit. 
Therefore, a region in the gyrA gene was sequenced corresponding to amino 
acid residues Leu18 to Ile187, which covers the known binding site of SD8 in 
the homologous GyrA from E. coli (Edwards et al., 2009; Hearnshaw et al., 
2014). 
 
2.2.3 Plasmids and PAC clones 
Plasmids and PAC clones used in this study are listed in Table 2.4. 
Table 2.4  
Vectors and their genetic characteristics used in this study. 
Vector Characteristics Reference 
1K3 Cosmid pKC505 (SCP2 (fertility, 
replication), ori , aac(3)IV (AprR)) with 
~25kb genomic region with part of the 
simocyclinone gene cluster from 
S. antibioticus Tü6040 (AprR) 
(Trefzer et al., 
2002) 
1K3neo 1K3 with aac(3)IV replaced by neo 
(KanR) 
(T. Le, 
unpublished) 
1K3neoΔC7::Apr 1K3neo with simC7 replaced by Apr-
cassette (KanR, AprR) 
this study 
pCP20 FLP+, λ cI857+, λ pR rep
ts, bla, cat 
(CarbR, CmlR) 
(Cherepanov 
and 
Wackernagel, 
1995; 
Datsenko and 
Wanner, 2000) 
PAC-12I pESAC13 with 85 kb BamHI genomic 
region of the sim gene cluster from 
S. antibioticus Tü6040 (KanR, ThioR) 
Bio S&T, 
Montreal, 
Canada 
PAC-12IΔB6 PAC-12I with in frame deletion of simB6 this study 
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Vector Characteristics Reference 
PAC-12IΔC1C-
TE 
PAC-12I with in frame deletion of the 
thioesterase domain of simC1C, flanked 
with SnaBI sites 
this study 
PAC-12IΔC2 PAC-12I with in frame deletion of 
simC2, flanked with PmeI sites 
this study 
PAC-12IΔC3 PAC-12I with in frame deletion of 
simC3, flanked with XbaI sites 
this study 
PAC-12IΔC4 PAC-12I with in frame deletion of simC4 this study 
PAC-12IΔC5 PAC-12I with in frame deletion of simC5 this study 
PAC-12IΔC6 PAC-12I with in frame deletion of simC6 (T. Le and 
O. Shorinola, 
unpublished) 
PAC-12IΔC7 PAC-12I with in frame deletion of simC7 (T. Le and 
O. Shorinola, 
unpublished) 
PAC-12IΔC1C PAC-12I with in frame deletion of 
simC1C 
this study 
PAC-12IΔC1ABC PAC-12I with in frame deletion of 
simC1ABC 
(T. Le and 
O. Shorinola, 
unpublished) 
PAC-12IΔD6 PAC-12I with in frame deletion of 
simD6, flanked by SwaI sites 
this study 
PAC-12IΔLeft PAC-12I with in frame deletion of 'left' 
flanking site upstream to promoter of 
simB7, flanked with XbaI sites 
this study 
PAC-12IΔRight PAC-12I with in frame deletion of 'right' 
flanking site downstream to simB2, 
flanked with PmeI sites 
this study 
PAC-12IΔX7 PAC-12I with in frame deletion of simX7 this study 
PAC-12Isim PAC-12I with ~85 kb BamHI deletion of 
the whole sim gene cluster and flanking 
regions 
this study 
pESAC13 ΦC31, attP-int, sacB, oriT, P1 replicon 
(KanR, ThioR) (derivative of pPAC-S1) 
Bio S&T, 
Montreal, 
Canada (Sosio 
et al., 2000) 
pET15b Overexpression vector; T7 promoter, T7 
transcription start, His-tag coding 
sequence (N-terminal thrombin 
cleavage site), MCS (NdeI-BamHI), T7 
terminator, lacI, rep (pBR322), bla 
(CarbR) 
 
Novagen 
(Merck, 
Nottingham, 
UK) 
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Vector Characteristics Reference 
pET15b-NB-C7 pET15b with 855 bp NdeI-BamHI 
fragment of simC7 (ptipA::simC7) 
(CarbR) 
this study 
pET15b-NB-C7-
S95A 
SimC7 with point mutation S95A this study 
pET15b-NB-C7-
S95T 
SimC7 with point mutation S95T this study 
pET15b-NB-C7-
S95C 
SimC7 with point mutation S95C this study 
pET15b-NB-C7-
I108A 
SimC7 with point mutation I108A this study 
pET15b-NB-C7-
I108D 
SimC7 with point mutation I108D this study 
pET15b-NB-C7-
H112A 
SimC7 with point mutation H112A this study 
pET15b-NB-C7-
H112N 
SimC7 with point mutation H112N this study 
pET15b-NB-C7-
H112Q 
SimC7 with point mutation H112Q this study 
pET15b-NB-C7-
H112K 
SimC7 with point mutation H112K this study 
pET15b-NB-C7-
H112R 
SimC7 with point mutation H112R this study 
pET15b-NB-C7-
E132D 
SimC7 with point mutation E132D this study 
pET15b-NB-C7-
N137A 
SimC7 with point mutation N137A this study 
pET15b-NB-C7-
N137Q 
SimC7 with point mutation N137Q this study 
pET15b-NB-C7-
Y155F 
SimC7 with point mutation Y155F this study 
pET15b-NB-C7-
Y229F 
SimC7 with point mutation Y229F this study 
pGM1190 tsr, aac(3)IV, oriT, to terminator, tipAp, 
RBS, fd terminator (AprR) 
(Muth et al., 
1989) 
pGM1190-NB-C7 pGM1190 with 855 bp NdeI-BamHI 
fragment of simC7 (ptipA::simC7) 
this study 
pGM1190-pB7-
NB-C7 
pGM1190 carrying simC7 expressed 
from the simB7 promoter (pB7::simC7) 
this study 
pGM1190-Kan-
oriT 
pGM1190 with aac(3)IV replaced by 
neo gene (KanR) 
(N. Holmes, 
unpublished) 
pGM1190-Kan-
oriT-H-ΔC7::Apr 
pGM1190-Kan-oriT with ~5.2 kb 
fragment of sim gene cluster with simC7 
replaced by Apr-cassette 
 
 
this study 
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Vector Characteristics Reference 
pIJ773 pBluescript KS (+) with the apramycin 
resistance gene aac(3)IV and oriT from 
plasmid RP4, flanked by FRT sites (P1-
FRT-oriT-aac(3)IV-FRT-P2), (AprR) 
(Gust et al., 
2003) 
pIJ773_del_oriT pIJ773 without oriT (AprR) T. Le., 
unpublished 
pIJ775 P1-(SwaI, I-SceI)-oriT-aac(3)VI-(I-SceI, 
SwaI)-P2, lacZ, bla (AprR, CarbR) 
(Gust et al., 
2004) 
pIJ790 λ-RED (gam, bet, exo), cat, araC, 
rep101ts (CmlR) (modified lambda-RED 
recombination plasmid pKD20) 
(Gust et al., 
2003) 
pIJ10257 ΦBT1-based integrative vector 
containing the strong, constitutive 
ermE* promoter (ermEp*) (HygR) 
(Hong et al., 
2005) 
pIJ10257-NH-C7 pIJ10257 with simC7 cloned into NdeI-
HindIII site (HygR) 
this study 
pIJ10480 pIJ10257 with ermEp*-simEx1 (HygR) (Le et al., 
2009) 
pJET1.2/blunt rep (pMB1), eco47IR, PlacUV5, T7 
promoter, MCS, bla (CmlR) (blunt end 
insertion site) 
Fisher 
Scientific, 
Loughborough, 
UK 
pKC505 SCP2 (fertility, replication), ori, aac(3)IV 
(AprR) 
(Richardson et 
al., 1987) 
pR9406 self-transmissible helper plasmid 
derived from pUB307 (CarbR) 
A. Siddique 
and D. 
Figurski, 
unpublished 
pSET152 rep (pMB1), int fC31 (ΦC31 att-int locus 
from E. coli), oriT (RK2), ori (pUC18), 
lacZα, aac(3)IV (AprR) 
(Bierman et 
al., 1992) 
pSKB2 T7 promoter, T7 transcription start, N- 
and C-terminal His-tag coding 
sequence, N-terminal prescission pxx 
cleavage site, MCS (NcoI-XhoI), T7 
terminator, lacI, rep (pBR322) (KanR) 
unpublished 
pSKB2-NB-C7 N-terminal 6xHis tag fused to simC7; 
prescission protease cleavage site to 
remove N-terminal His-tag (KanR) 
this study 
pUB307 RP1 (= RK2) derivative with 5.5 kb 
deletion of AprR and Tn1; Tc-R, (oriT, 
oriV, Tra1, Tra2, rep, IS21, Par/Mrs) 
(KanR, TetR) 
(Bennett et al., 
1977) 
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Vector Characteristics Reference 
pUZ8002 tra, neo, RP4 (KanR) (Paget et al., 
1999) 
StH18 Supercos1 with ~42 kb chromosomal 
fragment from S. coelicolor (including 
gyrBA operon) 
(Bentley et al., 
2002) 
StH18-Apr-oriT StH18 derivative containing an AprR 
(aac(3)IV) and oriT cassette (from 
pIJ755) instead of KanR (neo) 
this study 
Supercos1 rep (pUC), bla, neo, S40 promoter, two 
adjacent cos sites and recognition 
sequences, T7 promoter, T3 promoter 
(CarbR, KanR) 
Agilent 
Technologies, 
Walbronn, 
Germany 
repts, temperature-sensitive origin of replication 
λ pR , bacteriophage λ rightward promoter 
cI857, gene encoding temperature-sensitive λ repressor from pMMC6 
ΦBT1 integrates intragenically into sco4848 
ΦC31 integrates intragenically into sco3798 
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2.2.4 Oligonucleotides 
DNA oligonucleotides used in this study are listed in Table 2.5. 
Table 2.5  
Oligonucleotides used for PCR amplification of DNA fragments.  
Intragenic regions (bold; start and stop codons in italics and underlined, overlapping start and stop codons of genes in red), 
recognition sites for restriction enzymes (upper case in bold and double underlined), and FRT-sites (upper case) or point mutations 
(upper case and underlined) are highlighted.  
Purpose Primer Sequence 
Extension PCR  
 P1 (FRT-site) ATTCCGGGGATCCGTCGACC 
 P2 (FRT-site) TGTAGGCTGGAGCTGCTTC 
Confirmation of positive PAC clones 
right wing right_wing_B2-F aacgagactgcccgtgtcttcacc 
 right_wing_B2-R aggaacccgatcaccgacaggatg 
left wing left_wing_B7-F tcaccgacgtcagcctgttcatcg 
 left_wing_B7-R gttcatcgaccgtgtgcccttcttg 
simC1A PKS-C1A-F caactgccacctcgtactcac 
 PKS-C1A-R gtacagcgtctcatccagcag 
ThioR gene thiostrepton-F ttatcggttggccgcgagattcc 
 thiostrepton-R 
 
atgactgagttggacaccatcg 
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Purpose Primer Sequence 
left wing left_wing_B7-new-F gtactcatgcgaatcctgttcgt 
 left_wing_B7-new-R cagacgtcgatgaagagctcc 
right wing right_wing_B2-new-F gtgcacatctccactgacgag 
 right_wing_B2-new-R gagtaccacgagatcgtctcc 
 
Confirmation of simEx1 in ΦBT1 integration site 
upstream check-simEx1-upstrm-F  ttggtaggatcgtctagaacaggag 
 check-simEx1-upstrm-R aatcaccaccatgccgatgac 
downstream check-simEx1-dwnstrm-
F 
ctcggtggacttgacgaactg 
 check-simEx1-dwnstrm-
R 
cctccaacgtcatctcgttctc 
Confirmation of deletions from PAC-12I 
simB6  check_del_B6-II-F gggaagtacttctccatcatcg 
 check_del_B6-II-R gacaacgggtagtagatcatcg 
simC1ABC  check-scar-simC1ABC-
F 
gcatgtcgtcgtacgcggcatgcag 
 check-scar-simC1ABC-
R 
gcgacctcgacccgtcgaaggcg 
simC1C (TE) check_del_C1CTE-F caccgatgtcctcaactatcc 
 check_del_C1CTE-R cataccttccacactcaacct 
simC1C check_scar_C1C-F tggacgagctctatgactttgtg 
 check_scar_C1C-R 
 
gcataccttccacactcaacct 
58 
Purpose Primer Sequence 
simC2 check_del_C2-F agaggatgaacagttgagtcgg 
 check_del_C2-R gtattcgctgaagatgcgttgg 
simC3 check_del_C3-F tctgtccttgaaggactgacca 
 check_del_C3-R ccgatgacatgggtgttggg 
simC4 check_del_C4-F cccacttctttcccttcctcc 
 check_del_C4-R ctcctccaggttctccaacag 
simC5 check_del_C5-F gagcgatctggtcattctgtcc 
 check_del_C5-R cagttcgtcaagtccaccgag 
simC6 check_del_C6-F caggcctgtccactggaaccttgc 
 check_del_C6-R gagggacgccgacctcgtgaagcg 
simC7 check_del_C7-F ggtgctggtcctcctgcccgaggtgc 
 check_del_C7-R tcccaccctgtacgccagaaaggtgc 
simD6 check_del_D6-F agcgagaccaacatcatcag 
 check_del_D6-R ggtgaagttcgtcttgtcct 
left wing check_scar_left-F ccgtcttcgtcgacttcaacc 
 check_scar_left-R gtgtagaagtcctggatcgtgag 
right wing check_scar_right-F gagttggtggacccatgactg 
 check_scar_right-R gagtggagtatccggttcctg 
Confirmation of strain identity 
S. coelicolor check_dagA-F gtgatctcatcaagtggagtg 
 check_dagA-R tagtagatgttgttgatgctgg 
S. antibioticus check_Santi-F tctccctctgaagtcgtatctg 
 check_Santi-R 
 
gtctacaccctcaccaacctc 
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Purpose Primer Sequence 
Confirmation of simC7 flanking site in 1K3neo 
 Check-C7-1K3-F gtaccagcgactcttcactc 
 Check-C7-1K3-R1 acaaagtagacgggcatcag 
 Check-C7-1K3-R2 gtcatagaggtcattggcgt 
Deletions in PAC-12I (PCR targeting) 
simB6 del_simB6-F gagcatgctgaccggcctgcacaccagctggtgacccacATTCCGGGGATCCGTCGACC 
 del_simB6-R gcgatggcacgaaaggcaggggtgccgtggtcaagttcaTGTAGGCTGGAGCTGCTTC 
simC1ABC del_simC1ABC_F aacgacgatgacaagcttcggcagtatctgaagaaggtgATTCCGGGGATCCGTCGACC 
 del_simC1ABC_R gactcaactgttcatcctctgaaccggatcgacgcgtcaTGTAGGCTGGAGCTGCTTC 
simC1C (TE 
domain) 
del_C1CTE-F-SnaBI tcccggctgacgacggggaccgccgggctgccgctggtgTACGTAATTCCGGGGATCCGTCGACC 
 del_C1CTE-R-SnaBI gaccgatgcgtaggaccggtaggactacagaacctcggcTACGTATGTAGGCTGGAGCTGCTTC 
simC1C del_simC1C-F cgcccttaccaagtcgatccctggaagcggtgccgtatgATTCCGGGGATCCGTCGACC 
 del_simC1C-R gacccgtacggcgaccgatgcgtaggaccggtaggactaTGTAGGCTGGAGCTGCTTC 
simC2 del_C2_F-PmeI ccagttgtccgctggttcgtcggccggtcctgaccagtgcGTTTAAACATTCCGGGGATCCGTCGAC
C 
 del_C2_R-PmeI tgccggtactcccccggcaggcgcagtatcggggaatcaGTTTAAACgTGTAGGCTGGAGCTGCTT
C 
simC3 del_C3_F-XbaI ccgcctgtccctctgtccttgaaggactgaccactcatgTCTAGAATTCCGGGGATCCGTCGACC 
 del_C3_RII-XbaI 1) gacgcctggtgctcatcggcttgctccgctcgtcgtgctTCTAGATGTAGGCTGGAGCTGCTTC 
simC4 del_simC4_F gacccggagcacgacgagcggagcaagccgatgagcaccATTCCGGGGATCCGTCGACC 
 del_simC4_R ggagcgggtacggggtgcatggaacctaccgttcagtcaTGTAGGCTGGAGCTGCTTC 
simC5 del_simC5_F ggatcgccgatccggcctgactgaacggtaggttccatgATTCCGGGGATCCGTCGACC 
 del_simC5_R tcggccgcatcggaacgtccagcactggcttgaggtggcTGTAGGCTGGAGCTGCTTC 
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Purpose Primer Sequence 
simC6 del_simC6-F ggatcgaccgggaatgacgatatccggagttgcgtgatgATTCCGGGGATCCGTCGACC 
 del_simC6-R tgaacaggtcggcccgcggcaggccgggtcagaccgtcaTGTAGGCTGGAGCTGCTTC 
simC7 del_simC7-F ccggcttcgcccagacgggatgagaggacctgaacgatgATTCCGGGGATCCGTCGACC 
 del_simC7-R cgctgaacacccagggctgactgaacggcgctgggactaTGTAGGCTGGAGCTGCTTC 
simD6 del_simD6_F-SwaI tgcgcgcggacgcgatggcgcgtcgggaggccacccatgcATTTAAATATTCCGGGGATCCGTCG
ACC 
 del_simD6_R-SwaI gcgagagcatcggtcgcgggttcatcatcgtccccttcaATTTAAATgTGTAGGCTGGAGCTGCTTC 
left flanking 
region 
del_left_side-F-XbaI gtcaggccgtcttcgtcgacttcaacccctcgccgggcaTCTAGAATTCCGGGGATCCGTCGACC 
 del_left_side-R-XbaI 
 
atgtcaggcccgcggctgatgcctgcccagaacgacgacTCTAGATGTAGGCTGGAGCTGCTTC 
right flanking 
region 
del_right_side-F-PmeI ttccacttccggggtgaggctgagcaaaggcgtggtcacGTTTAAACATTCCGGGGATCCGTCGAC
C 
 del_right_side-R-PmeI ggtaagcggttcggtgagtggagtatccggttcctgaacGTTTAAACTGTAGGCTGGAGCTGCTTC 
Cloning of DNA fragments 
simC7 gene simC7-NdeI-F GCAcatATGaagattcttgtgaccggagc 
 simC7-BamHI-R CAGAGGCTTctaaatgctctgagctgcc 
 simC7-HindIII-R GCAGGATCCctaaatgctctgagctgcc 
fragment with 
simC7 
Cloning-C7scar-HindIII-
F 
GCGAAGCTTgggctcgaccggatgcagtatgacc 
 
 Cloning-C7scar-HindIII-
R 
GCGAAGCTTcgcggtgatctcaccgaacgactgc 
simB7 promoter pB7-NdeI-F tgaCATATGtcgttctgggcaggcatcag 
 pB7-NdeI-R gcaCATATGtactccccattcagtggagg 
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Purpose Primer Sequence 
Sequencing 
cosmid  Seq-C7-1-F gggctcgaccggatgcagtatgac 
fragment  Seq-C7-2-F gcgatgttcgtggcgatcgg 
with simC7 Seq-C7-3-F cgcagtgggagagcgcctatcc 
 Seq-C7-4-F gtgcctgacggcccgatagc 
 Seq-C7-5-F gtttgtgactcaggtaatcg 
 Seq-C7-6-F ccgggaattcggctcgctcg 
 Seq-C7-1-R cgcggtgatctcaccgaacgactg 
 Seq-C7-2-R aagtcggcccgcgagatttgtttgg 
 Seq-C7-3-R tttcactaggttgcagcgcg 
 Seq-C7-4-R ctcgggcaggaggaccagca 
 Seq-C7-5-R gcgcagtcgaccaccgcgatcag 
 Seq-C7-6-R cgcctcccgcatcacctcga 
AprR gene Apr-F atgtcatcagcggtggagtgcaatg 
 Apr-R tcagccaatcgactggcgag 
gyrA fragment check_SCO3873-F ctcgagacggagatgcagcg 
 check_SCO3873-R gatgttggtcgccatgccga 
pESAC13 pESAC13-F cgagttgcatgataaagaagac 
 pESAC13-R cgaattgactagtgggtagg 
pET15b insert T7-promoter-F taatacgactcactataggg 
 T7-terminator-R gctagttattgctcagcgg 
pGM1190 pGM1190-F ctgaggtcattactggaccg 
 pGM1190-R tcgcaattcctttagttgttcc 
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Purpose Primer Sequence 
Recombineering of DNA gyrase in S. coelicolor  
 Recomb-GyrA-H45A-F  
(cac->gcc) 
gctgccggacgtccgcgacggcctcaagcccgtgGCCcgccgcgtgctgtacgccatgtacgacggcggc 
gyrA (sco3873) Recomb-GyrA-H45Y-F 
(cac->tac) 
gctgccggacgtccgcgacggcctcaagcccgtgTACcgccgcgtgctgtacgccatgtacgacggcggc 
 Recomb-GyrA-H45Q-F 
(cac->cag) 
gctgccggacgtccgcgacggcctcaagcccgtgCAGcgccgcgtgctgtacgccatgtacgacggcggc 
 Recomb-GyrA-H80A-F 
(cac->gcc) 
cgtcggcgacgtcatgggcaactaccacccgGCCggcgactcctccatctacgacgccctggtccgcctc 
 Recomb-GyrA-G81S-F 
(ggc->tcg) 
cgtcggcgacgtcatgggcaactaccacccgcacTCGgactcctccatctacgacgccctggtccgcctc 
 RecGyrA-H80A-G81S-F 
(cacggc->gcctcg) 
cgtcggcgacgtcatgggcaactaccacccgGCCTCGgactcctccatctacgacgccctggtccgcctc 
Control for galK Oligo-100  
(tag->tat) 
aagtcgcggtcggaaccgtattgcagcagcttTATcatctgccgctggacggcgcacaaatcgcgcttaa 
Confirmation of mutations in DNA gyrase via recombineering 
 Check-gyrA-H45-F cggcctcaagcccgtgcac 
 Check-gyrA-H80-F cgacgccctggtccgcctc 
 Check-gyrA-H45A-F cggcctcaagcccgtgGCC 
 Check-gyrA-H45Y-F cggcctcaagcccgtgTAC 
 Check-gyrA-H45Q-F cggcctcaagcccgtgCAG 
 Check-gyrA-H80A-F ctacgacgccctggtcGCC 
 Check-gyrA-G81S-F 
 
cgacgccctggtccgcTCG 
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 Check-gyrA-H80A-
G81S-F 
cgacgccctggtcGCCTCG 
Targeting of neo in StH18 
 StH18-Apr-oriT-F tcaagatctgatcaagagacaggatgaggatcgtttcgcATTCCGGGGATCCGTCGACC 
 StH18-Apr-oriT-R gcgtcgcttggtcggtcatttcgaaccccagagtcccgcTGTAGGCTGGAGCTGCTTC 
SimC7 mutants 
S95A S95Anew-F tgctctccGCCatcgccgtgacctggc 
S95C S95C-F tgctctccTGCatcgccgtgacctggc 
S95T S95Tnew-F tgctctccACCatcgccgtgacctggc 
S95A/T/C S95AT-R gcaccacatgccggaccc 
I108A I108A-F gacccgGCGggccggatgcacctc 
I108D I108D-F gacccgGATggccggatgcacctc 
I108A/ D I108A-R ccggtccgcgtccggccaggtc 
H112A H112A-F ggatgGCCctcgccgtcga 
H112N H112N-F ggatgAACctcgccgtcgagcg 
H112Q H112Q-F ggatgCAGctcgccgtcgagcg 
H112K H112K-F ggatgAAActcgccgtcgagcg 
H112R H112R-F ggatgCGTctcgccgtcga 
H112A/N/Q/K/R H112R-R ggccgatcgggtcccgg 
E132D E132D-F ggcccGATgcgctcgccac 
 E132D-R ggacgaaggtccagccaagcccg 
N137A N137Anew-F gccaccGCCgcgctgggctgggctc 
N137Q N137Qnew-F gccaccCAGgcgctgggctgggctc 
N137A/ Q N137Q-R gagcgcctcgggccggac 
Y155F Y155F-F ctgcgccTTCccgggcgc 
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 Y155F-R cgcaccatgtcgccgccg 
Y229F Y229F-F ggctcTTCccggccgaggtg 
 Y229F-R cctccagcacggcgcggg 
1) Putative RBS of simC4 (GGAG) is underlined. 
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2.3 Culture media, buffers and solutions 
2.3.1 Culture media 
Respective liquid media were prepared without addition of agar. 
 
DNA medium (Difco nutrient agar) 
Difco™ Nutrient Agar (4.6 g) was added to 200 mL distilled water in 250 mL 
Erlenmeyer flasks before autoclaving.  
 
DNB medium (Difco nutrient broth) 
Difco™ Nutrient Broth (4.6 g) was added to 200 mL distilled water in 250 mL 
Erlenmeyer flasks before autoclaving.  
 
IMA agar (Instant Mashed Potato) 
Potato Smash™   20 g/L 
LabM agar    20 g/L 
 
L agar (Lennox broth) 
Agar     10 g/L 
Difco™ Bacto tryptone  10 g/L 
NaCl     5 g/L   85.6 mM 
Glucose    1 g/L   5.6 mM 
 
LB medium (Luria Bertani Broth) 
Agar     10 g/L 
Difco™ Bacto tryptone  10 g/L 
Difco™ yeast extract  5 g/L 
NaCl     5 g/L   85.6 mM 
Glucose    1 g/L   5.6 mM 
 
MacConkey galactose indicator agar 
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Difco™ MacConkey agar   40 g/L 
D-(+)-galactose   10 g/L  55.5 mM 
The medium was made fresh on the day of use. 
 
Müller Hinton Broth (M-H Broth) 
Beef infusion solids   2 g/L 
 
MYM medium (Maltose yeast malt) 
Difco™ Bacto Agar   18 g/L 
Maltose    4 g/L   11.7 mM 
Yeast extract    4 g/L 
Malt extract    10 g/L 
Prior inoculation, the solidified medium was melted and trace element 
solution (2 mL/L) was added. 
 
R2 medium (Okanishi et al., 1974; Hopwood and Wright, 1978) 
The medium was used to select and grow Streptomyces strains after 
conjugation. 
Sucrose    103 g/L  300 mM 
K2SO4     0.25 g/L  1.4 mM 
MgCl2 × 6H2O   10.1 g/L  49.8 mM 
Glucose    10 g/L  5.6 mM 
Difco™ casaminoacids  0.1 g/L 
Components for 1 litre medium were dissolved in 800 mL distilled water and 
the solution was autoclaved in 250 mL Erlenmeyer flasks (80 mL each) 
containing 2.2 g Difco Bacto agar. Prior inoculation, the solidified medium 
was melted and following autoclaved or sterile-filtrated solutions were added 
per flask: 
KH2PO4 (0.5% w/v in dH2O)   1 mL 
CaCl2 × 2H2O (3.68% w/v)    8 mL 
L-proline (20% w/v)     1.5 mL 
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TES buffer (5.73% w/v, pH 7.2)   10 mL 
Trace element solution    0.2 mL 
NaOH (1 M) (unsterile)    0.5 mL 
Required growth factors for auxotrophs  0.75 mL 
 
R5 medium (Kieser et al., 2000) 
Sucrose    103 g/L  300 mM 
K2SO4     0.25 g/L  1.4 mM 
MgCl2 × 6H2O   10.1 g/L  49.8 mM 
Glucose    10 g/L  5.6 mM 
TES buffer    5.7 g/L 25 mM 
Difco™ yeast extract  5 g/L 
Difco™ casaminoacids  0.1 g/L 
Trace element solution  2 mL/L 
The solution was autoclaved in 250 mL Erlenmeyer flasks (100 mL each) 
containing 2.2 g Difco Bacto agar. Prior inoculation, the solidified medium 
was melted and following autoclaved or sterile-filtrated solutions were added 
per flask: 
KH2PO4 (0.5% w/v in dH2O)   1 mL 
CaCl2 × 2H2O (5 M)     0.4 mL 
L-proline (20% w/v)     1.5 mL 
NaOH (1 M) (unsterile)    0.7 mL 
Required growth factors for auxotrophs  0.75 mL 
 
SFM medium (Soya flour mannitol) 
The medium was used to prepare spores of Streptomyces strains. 
Agar     20 g/L 
Mannitol    20 g/L  109.8 mM 
Soya flour    20 g/L 
 
SOC medium (Super optimal catabolite repression) 
Tryptone    20 g/L 
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Yeast extract    5 g/L 
Glucose    3.6 g/L  20 mM 
MgSO4 x7H2O   1.2 g/L  4.9 mM 
MgCl2 x6H2O   952 mg/L  4.7 mM 
NaCl     584 mg/L  10 mM 
KCl     186 mg/L  2.5 mM 
 
Supplemented minimal medium, solid (SMMS) 
The medium was used for antibiotic assays with Streptomyces strains. 
Agar     15 g/L 
Dicfo casaminoacids  2 g/L 
TES buffer    5.7 g/L  25 mM 
The solution except agar was adjusted to pH 7.2 with 5N NaOH and 200 mL 
was poured into 250 mL Erlenmeyer flasks containing 3 g of Lab M agar. At 
time of use, following compounds were added: 
NaH2PO4 (50 mM)     2 mL  
K2HPO4 (50 mM)     2 mL  
MgSO4 (1 M)     1 mL  
Glucose (50% w/v)     3.6 mL  
Trace element solution    0.2 mL 
Growth factors for auxotrophs   1.5 mL 
 
TSB (Tryptone soya broth) 
Oxoid tryptone soya broth powder (CM129)  30 g/L 
 
YEME (Yeast extract-malt extract medium) 
Difco™ Bacto peptone  5 g/L 
Difco™ yeast extract  3 g/L 
Oxoid malt extract   3 g/L 
Glucose    10 g/L  55.5 mM 
Sucrose    340 g/L  993.3 mM 
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After autoclaving, magnesium chloride was added: 
MgCl2 × 6 H2O (2.5 M)   1.02 g/ L  5 mM 
 
2x YT medium (double concentrated yeast terrific broth medium) 
Difco Bacto tryptone  16 g/L 
Difco Bacto yeast extract  10 g/L 
NaCl     5 g/L 
 
2.3.2 Buffers and solutions 
Gyrase assay dilution buffer (pH 7.5) 
Tris/HCl (pH 7.5)   6.1 g/L 50 mM 
KCl     7.5 g/L 100 mM 
DTT     309 mg/L  2 mM 
EDTA (250 mM, pH 8.0)  292 mg/L 1 mM 
Glycerol    500 g/L 50% (v/v) 
 
Gyrase assay relaxation buffer (pH 7.5) 
Tris/HCl (pH 7.5)   4.2 g/L 35 mM 
KCl     1.8 g/L 24 mM 
MgCl2 x6H2O   813 mg/L 4 mM 
DTT     309 mg/L 2 mM 
Spermidine    261 mg/L 1.8 mM 
Glycerol (50%)   65 g/L  6.5% (v/v) 
Albumin    0.1 g/L 
 
Gyrase assay supercoiling buffer (pH 7.5) 
Tris/HCl (pH 7.5)   4.2 g/L 35 mM 
KCl     1.8 g/L 24 mM 
MgCl2 x6H2O   813 mg/L 4 mM 
DTT     309 mg/L 2 mM 
Spermidine    261 mg/L 1.8 mM 
ATP     507 mg/L 1 mM 
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Glycerol (50%)   65 g/L  6.5% (v/v) 
Albumin    0.1 g/L 
 
Elution buffer I (protein extraction) (pH 8.0) 
Tris/HCl (1 M, pH 8.0)   6.1 g/L 50 mM  
NaCl (5 M)     14.6 g/L 250 mM 
Glycerol (50%)   50 g/L  5% v/v  
Imidazole (1 M, pH 8.0)  23.8 g/L 350 mM 
 
Elution buffer III (protein extraction for crystallography) (pH 8.0) 
HEPES (1 M, pH 8.0)  4.8 g/L 20 mM 
NaCl (5 M)    2.9 g/L 50 mM 
Glycerol (50%)   200 g/L  20% v/v 
Imidazole (1 M, pH 8.0)  20.4 g/L 300 mM 
 
HSB-EP+ (pH 7.4) 
HEPES (pH 7.4)   2.4 g/L 10 mM 
NaCl (5 M)    8.8 g/L 150 mM 
EDTA (250 mM, pH 8.0)   877 g/L  3 mM 
Surfactant P-20   0.5 mL/L 0.05% (v/v) 
 
Loading dye for DNA samples (6-fold concentrated) 
Bromophenol blue   2.5 g/L 3.7 mM 
Xylene cyanol FF   2.5 g/L 4.6 mM 
Glycerol (50%)   330 mL/L 33% (v/v) 
 
Loading dye for protein samples (4-fold concentrated)  
Glycerol    400 mL/L 40% (v/v) 
Tris/HCl (1 M, pH 8.0)  29.1 g/L 240 mM 
SDS (25%)    80 g/L  8% (w/v) 
Bromophenol blue    0.4 g/L 0.04% (w/v) 
β-mercaptoethanol    40 mL/L 4% (v/v) 
EDTA (250 mM, pH 8.0  14.6 g/L 50 mM 
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Lysis buffer I (protein extraction) (pH 8.0) 
NaCl (5 M)     8.8 g/L 150 mM 
Triton X100    1 g/L  0.1% (w/v) 
Lysozyme    1 g/L  0.1% (w/v) 
Protease inhibitor (EDTA-free, Roche)  1 tablet per 10 mL 
 
Lysis buffer IV (protein extraction for crystallography) (pH 8.0) 
HEPES (1 M)    4.8 g/L 20 mM 
NaCl (5 M)    2.9 g/L 50 mM 
Glycerol (50%)   100 mL/L 10% (v/v) 
Imidazole (1 M, pH 8.0)  681 mg/L 10 mM 
Protease inhibitor (EDTA-free, Roche)  1 tablet per 10 mL 
 
Running buffer (1x concentrated) (SDS-PAGE) (pH 8.4 adj. with HCl) 
Tris/HCl (1 M, pH 8.0)  3 g/L  25 mM 
Glycine    14.4 g/L 192 mM 
SDS      1 g/L  0.1 % (w/v) 
 
Running buffer III (pH 8.0) 
HEPES (1 M)   4.8 g/L 20 mM 
NaCl (5 M)    8.8 g/L 150 mM 
Glycerol (50%)   50 g/L  5% (v/v) 
 
SET buffer with lysozyme (pH 8.0) 
Sucrose (103 g/L)   1.4 g/L 4.1 mM 
EDTA (250 mM, pH 8.0)    7.3 g/L 25 mM 
Tris/HCl (1 M, pH 8.0)    3 g/L  25 mM 
Lysozyme (from chicken egg) 2 g/ L  0.2% (w/v) 
 
Solution 2 (NaOH-SDS) 
NaOH     2 g/L   50 mM 
SDS     10 g/L  1% (w/v) 
72 
 
STEB buffer (pH 8.0) 
Sucrose    400 g/L 1.17 M 
Tris/HCl (1 M, pH 8.0)   12.1 g/L  100 mM 
EDTA (250 mM, pH 8.0)   29.2 g/L 100 mM 
Bromophenol blue   0.5 g/L 0.3 mM 
 
Storage buffer I (protein extraction) (pH 8.0) 
Tris/HCl (1 M, pH 8.0)  2.4 g/L 20 mM 
NaCl (5 M)    8.8 g/L 150 mM 
Glycerol (50%)   50 g/L  5% (v/v) 
MgCl2 x6H2O    2 g/L  10 mM 
EDTA (250 mM, pH 8.0)  584 mg/L 2 mM 
DTT      154 mg/L 1 mM 
 
Storage buffer X (protein extraction for crystallography) (pH 8.0) 
HEPES (1 M, pH 8.0)  4.8 g/L 20 mM 
Glycerol (50%)   100 g/L 10% (v/v) 
TCEP (0.5 M, pH 7.0)  625 mg/L 5 mM 
 
TBE buffer (Tris-Borate-EDTA buffer, pH 8.3) 
Trizma base    10.8 g/L 89.2 mM 
Boric acid    5.5 g/L 89 mM 
EDTA     930 mg/L 3.2 mM  
 
TE buffer (Tris-EDTA buffer, pH 8.0) 
Tris/HCl (1 M, pH 8.0)  1.2 g/L 10 mM 
EDTA (250 mM, pH 8.0)  292 mg/L 1 mM 
 
Trace element solution  
ZnCl2     40 mg/L 0.29 mM 
FeCl3 × 6 H2O   200 mg/L 0.74 mM 
CuCl2 × 2 H2O   10 mg/L 0.06 mM 
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MnCl2 × 4 H2O   10 mg/L 0.05 mM 
Na2B4O7 × 10 H2O   10 mg/L 0.03 mM 
(NH4)6Mo7O24 × 4 H2O  10 mg/L 0.01 mM 
 
Washing buffer I (protein extraction) (pH 8.0) 
NaCl (5 M)     14.61 g/L 250 mM 
Tris/HCl (1 M, pH 8.0)   6.1 g/L 50 mM 
Glycerol (50% v/v)   50 mL/L  5% (v/v) 
 
Washing buffer III (protein extraction for crystallography) (pH 8.0) 
HEPES (1 M, pH 8.0)  4.8 g/L 20 mM 
NaCl (5 M)    2.9 g/L 50 mM 
Glycerol (50% v/v)   100 g/L  10% (v/v) 
Imidazole (1 M, pH 8.0)  146.9 g/L 10 mM 
 
2.3.3 Antibiotic stock concentrations 
The antibiotics used in this study are listed in Table 2.6. For growth in liquid 
medium, the concentration of respective antibiotics was reduced by 50%.  
 
Table 2.6  
Antibiotics and their applications as used in this study. 
Antibiotic Stock (mg/mL) Final concentration (μg/mL) 
  Streptomyces 
spp. 
E. coli 
  DNA, MYM, R2, 
R5, SFM, Tu2 
L, LB 
Carbenicillin 100 - 100 
Chloramphenicol 25 1) - 25 
Kanamycin 50 - 50 
Nalidixic acid 50 2) 25 - 
Apramycin 50 50 50 
Hygromycin 40 (54) 50 25 4) 
Thiostrepton 50 3) 50 50 
1) in ethanol; 2) in 0.3M NaOH; 3) in DMSO; 4) on DNA medium. 
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2.3.4 Minimum inhibitory concentration (MIC) assays 
The minimum inhibitory concentration (MIC) was determined for 
simocyclinones against bacterial strains on microtiter plates as described 
previously (Wiegand et al., 2008). Culture medium (200 μL) was applied on a 
flat-bottom 96-well microtiter plate (Fisher Scientific, Loughborough, UK) and 
was mixed with 1% (v/v) of HPLC-purified simocyclinones in DMSO to a final 
concentration of up to 100 μg/mL. Müller Hinton broth was inoculated to 
5×105 colony forming units (CFU) per mL with an E. coli reference strain for 
antibiotic susceptibility testing (ATCC 25922™) or an E. coli strain with 
increased membrane permeability (NR689) and bacterial growth was 
analysed by measuring the OD600 after 16-20 hours at 37 °C with an EON™ 
microplate spectrophotometer (BioTek Instruments, Winooski, USA) and 
evaluated with the Gen5™ data analysis software. The assay was modified 
for Streptomyces species by inoculating SMMS medium with 1×105 spores 
per well, incubation for 6 days at 30 °C, and manual inspection of bacterial 
growth. The MIC was defined as the minimum concentration of a compound 
required for inhibiting bacterial growth.  
 
 
2.4 DNA manipulations in vivo (Genetic manipulations) 
2.4.1 Preparation of electro-competent cells of E. coli 
A single colony or glycerol stock of the respective E. coli strain was used to 
inoculate 10 mL of LB medium with respective antibiotics. Pre-cultures were 
grown overnight at 37 °C while shaking (250 rpm) and 1% inoculum was 
used for 50 mL of LB medium. The main culture was grown at 37 °C while 
shaking to an OD600 of 0.3-0.6. Cultures with temperature-sensitive plasmids 
were incubated at 30 °C throughout. The cultures were cooled on ice for 10-
30 min and were then continuously kept on ice. The cells were harvested 
and washed twice by repeated centrifugation (5 min at 1,825g and 4 °C) and 
carefully dissolved in 10 mL of ice-cold 10% (v/v) glycerol. After a final 
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centrifugation (5 min at 1,825g and 4 °C), the cells were dissolved in about 
500 μL of the remaining liquid.  
 
2.4.2 Transformation of E. coli 
Cultures of E. coli were transformed with isolated vector DNA or PCR-
amplified fragments of DNA via heat-shock or electroporation. For heat-
shock transformation, respective isolated DNA was added to 100 μL of 
chemically competent cells. The cells were incubated on ice for 30 min, heat-
shocked for 45 seconds, and kept on ice for 2 min before addition of 800 μL 
of SOC medium. For electroporation, cultures were made electro-competent 
as described (see chapter 2.4.1) and 200-300 μL of competent cells were 
carefully mixed with 2-5 μL of DNA solution (about 300 ng purified PCR 
product or 2-5 μg total nucleic acids from DNA isolation). The cell solution 
was transferred to pre-cooled 2 mm electroporation cuvettes (Isogen Life 
Science, De Meern, Netherlands) and electroporation was carried out using 
a Bio-Rad Gene Pulser I (Bio-Rad, Hertfordshire, UK) with a resistance of 
200 Ω, a capacitance of 25 μF, an electrical potential of 2.5 kV, and an 
expected time constant of 4.5-4.9 ms. Immediately after electro-
transformation, 750 μL of liquid SOC medium was added. All cultures were 
allowed to recover for 1 hour at 37 °C or 2 hours at 30 °C while shaking 
(250 rpm) before selection of transformed cells on LB agar medium 
containing respective antibiotics. Transformed cells were transferred onto 
new LB agar medium with respective antibiotics and clones were verified via 
PCR and DNA restriction digests. 
 
2.4.3 Conjugation between E. coli and Streptomyces spp. 
Because some Streptomyces have evolved a highly efficient system to 
detect and degrade foreign methylated DNA, a methylation-deficient E. coli 
strain was used to introduce DNA into Streptomyces strains.  
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Respective DNA constructs were first conjugated from E. coli DH5α or 
DH10B (donor) to the methylation-deficient E. coli strain ET12567 (recipient) 
via triparental conjugation using E. coli TOP10/pR9406 (self-transmissible 
helper plasmid). Cultures were grown shaking at 37 °C in 50 mL LB medium 
with respective antibiotics till OD600 ~0.6 using 1% inoculum from a 10 mL 
overnight pre-culture. Cultures were washed twice with 10 mL LB medium to 
remove antibiotics from the medium and were dissolved in 0.5 mL LB 
medium. The cultures were mixed by adding 10 μL of each culture on the 
same spot on LB agar. After triparental mating overnight at 37 °C, the mixed 
cultures were collected and transferred on LB agar with respective antibiotics 
to select for exconjugants of E. coli ET12567 carrying the respective vector 
construct and the helper plasmid. Successful conjugational transfer of DNA 
was confirmed via PCR. 
One single exconjugant colony of E. coli ET12567 with helper plasmid and 
confirmed DNA construct was grown overnight in 10 mL LB medium with 
respective antibiotics and 1% inoculum was used to grow 50 mL of main 
culture till OD600 ~0.6. Cells were harvested by centrifugation (5 min at 
1,026g), washed twice with 10 mL of LB to remove antibiotics from the 
medium, and dissolved in 0.5 mL LB medium. Meanwhile, about 1×107 
spores were heat-shocked for 10 min at 50 °C in 10 μL dH2O. The spores 
were dissolved in 0.5 mL 2xYT medium and were mixed with the washed 
E. coli colony. Cells and spores were pelleted by centrifugation (1 min at 
13,200g) and dissolved in 100 μL remaining liquid. A 10-fold dilution series 
was prepared with 100 μL of dH2O and plated on R2-S medium for 
conjugation of PAC clones or SFM medium with 10 mM MgCl2. After 16-22 
hours incubation at 30 °C, the plates were overlaid with 1 mL dH2O 
containing nalidixic acid and respective antibiotics to inhibit growth of E. coli 
colonies and to select for the integrated DNA construct, respectively. Single 
Streptomyces exconjugants were transferred at least twice on new medium 
with nalidixic acid and respective antibiotics to avoid contamination with 
E. coli colonies. Exconjugants were confirmed via PCR for presence of 
respective DNA constructs. 
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2.5 DNA manipulations and in vitro (Cloning) 
2.5.1 Isolation of plasmid DNA from E. coli 
Phage artificial chromosome (PAC) derivatives were isolated from E. coli by 
growing single colonies overnight at 37 °C in 10 mL LB medium in closed 
25 mL glass flasks. Cells were harvested by centrifugation (5 min at 1,026g), 
resuspended in 300 μL of solution I (50 mM Tris/HCl; 10 mM EDTA; pH 8.0). 
Cells were lysed and proteins were denatured by immediately adding 450 μL 
of solution II (200 mM NaOH; 1% SDS) and mixing the solution by inverting 
the tubes 10 times. The alkaline lysis was immediately stopped by addition of 
450 μL solution III (3 M potassium acetate; pH 5.5) and inverting the tubes 
10 times. Lysed cells and denatured proteins were pelleted by centrifugation 
(5 min at 13,200g) and the supernatant was immediately extracted with 
400 μL of PCI (phenol : chloroform : isoamyl alcohol, 25:24:1, v/v, saturated 
with 10 mM Tris/HCl; pH 8.0). The extraction was repeated with 400 μL 
chloroform to remove phenol residues. The upper aqueous phase was mixed 
with 600 μL of isopropanol and was incubated on ice for 10-20 min to 
precipitate the DNA, followed by centrifugation (1 min at 13,200g). The DNA 
pellets were washed with 300 μL of 70% ethanol, dried, and dissolved 
overnight in 50 μL of TE buffer (10 mM Tris/HCl; 1 mM EDTA; pH 8.0). For 
isolation of plasmid DNA, the silicon-based column system QIAprep Spin 
Miniprep kit (Qiagen, Manchester, United Kingdom) was used according to 
the manufacturer’s manual.  
 
2.5.2 Isolation of chromosomal DNA from Streptomyces spp. 
Cultures of Streptomyces strains were grown in a mixture of 5 mL YEME 
containing 34% (w/v) sucrose and 5 mL TSB. After 1-6 days, mycelial 
cultures from 1-2 mL medium were harvested by centrifugation (1 min at 
13,200g), washed with 1 mL dH2O, resuspended in 0.5 mL lysozyme buffer, 
and incubated for about 30 min at 37 °C to weaken the bacterial cell wall. 
Proteins were denatured by adding 250 μL of 2% (w/v) SDS solution and 
vigorous mixing for 1-2 min until the viscosity of the solution decreased 
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noticeably. Total DNA was extracted with 250 μL of PCI 
(phenol : chloroform : isoamylalcohol, 25:25:1, v/v, saturated with 10 mM 
Tris/HCl; pH 8.0). The solution was mixed vigorously for 1-2 min, phases 
were separated by centrifugation (2 min at 13,200g), and the upper aqueous 
phase was transferred to new 1.5 mL vials. The solution was mixed with 
0.1 volume of 3 M sodium acetate solution (pH 4.8) and then with 1 volume 
of isopropanol. The DNA was alcohol-precipitated for 5 min at room 
temperature and then pelleted by centrifugation (5 min at 13,200g). The DNA 
was washed in 500 μL of 70% ethanol, dried, and dissolved in 100 μL of TE 
buffer (10 mM Tris/HCl; 1 mM EDTA; pH 8.0). 
 
2.5.3 Agarose gel electrophoresis 
DNA fragments were analysed via agarose gel electrophoresis. Samples 
were mixed with 0.1 volume of 6-fold concentrated loading dye prior loading 
and were separated in 1-1.5% agarose gels using an electric potential of 80-
120 Volt. The gel was subsequently stained in ethidium bromide solution 
(about 1-5 μg/L EtBr final concentration). The DNA was visualised on a UV 
table and documented with an attached camera. 
For high molecular weight DNA, samples were prepared as described and 
separated by pulsed-field gel electrophoresis (PFGE) using a CHEF DR II 
pulse field gel apparatus (Bio-Rad). DNA fragments were separated in 1% 
agarose gels using an alternating electrical field of 6 V/cm for 16 hours.  
 
2.5.4 Purification of size-separated DNA fragments 
DNA fragments of respective length were cut out from agarose gels with a 
razor blade. The gel slice was cut into small fragments, 300 μL of PCI was 
added, and the mix was frozen in liquid nitrogen for 30 seconds. The vial was 
centrifuged (15 min at 13,200g), 300 μL of TE buffer was added, and the vial 
was centrifuged again. The aqueous phase was transferred into a new 
1.5 mL vial and purified from phenol residues by addition of 300 μL of 
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chloroform. After centrifugation (10 min at 13,200g), the upper phase was 
transferred to a new vial and the DNA was precipitated on ice for 10 min after 
addition of 0.1 volume of 3 M potassium acetate solution (pH 5.5), 1 volume 
isopropanol, and 1 μL of glycogen. The DNA was pelleted (10 min at 13,200g 
and 4 °C) and washed in 300 μL of 70% ethanol before dissolving in 25 μL of 
water or TE buffer.  
 
2.5.5 Polymerase chain reaction 
DNA fragments were amplified via polymerase chain reaction (PCR). 
Components were mixed as listed in Table 2.7 and PCR cycling was carried 
out as shown in Table 2.8. 
 
Table 2.7  
Components used for PCR amplifications.  
Standard DNA polymerase (Taq) was used for verification of DNA fragment 
lengths, high-fidelity DNA polymerases were used for sequencing (Pfu and 
Q5) and extension PCR (Expand HiFi or Q5 ). High GC-enhancer (5-fold; 
5 μL) was added instead of DMSO for Q5 DNA polymerase. 
 
Compound Volume Final concentration 
Forward/ reverse primer (25 μM) 1 μL (each) 25 pmol (each) 
dNTPs (10 mM) 0.5 μL  50 μM (each) 
DMSO 1.25 μL 5 % 
Polymerase buffer (5-/10-fold) 5 μL/ 2.5 μL 1-fold 
DNA Polymerase 1) 
   Taq (Qiagen, 5 U/μL) or 
   Pfu (Roche, 3.5 U/μL) or 
   Q5 HiFi (NEB, 2 U/μL) or 
   Expand HiFi (Roche, 3.5 U/μL) 
 
0.125 μL 
(1 μL) 
(1 μL) 
(1 μL) 
 
0.625 U 
(3.5 U) 
(2 U) 
(3.5 U) 
Template DNA 1 μL ~100 ng 
dH2O up to 25 μL  
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Table 2.8  
PCR cycling conditions.  
PCR conditions for Taq and Pfu DNA polymerases (A), extension PCR using 
Expand HiFi DNA polymerase (B), and high-fidelity Q5 DNA polymerase (C). 
Conditions to proof gene deletions are given in parenthesis. Elongation time 
was 1 min per 1 kb DNA template or 30 seconds for Q5 DNA polymerase. 
A) 
Cycle Temperature Time Repeat 
Initial denaturation 94 °C  4 min 1x 
Denaturation 94 °C 45 s  
Annealing 55-60 °C 45 s 30x 
Elongation 72 °C 25 s to 2 min  
Final elongation 72 °C 5 min 1x 
Cooling 4 °C 1 min 1x 
 
B) 
Cycle Temperature Time Repeat 
Initial denaturation 94 °C  4 min 1x 
Denaturation 94 °C 45 s  
Annealing 52 °C 45 s 10x 
Elongation 72 °C 90 s  
Denaturation 94 °C 45 s  
Annealing 56 °C 45 s 15x 
Elongation 72 °C 90 s  
Final elongation 72 °C 5 min 1x 
Cooling 15 °C 1 min 1x 
 
C) 
Cycle Temperature Time Repeat 
Initial denaturation 98 °C  30 s 1x 
Denaturation 98 °C 30 s  
Annealing 55-60 °C 45 s 30x 
Elongation 72 °C 15 s to 2 min  
Final elongation 72 °C 5 min 1x 
Cooling 4 °C 1 min 1x 
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2.5.6 Cloning of DNA fragments 
Vector DNA or PCR amplified DNA fragments were cut by respective 
restriction endonucleases according to the manufacturer’s manual. 
Restriction digestion mixes of 20 or 50 μL volume were incubated overnight 
at 37 °C. The DNA was extracted by addition of 200 μL TE-buffer and 300 μL 
of PCI followed by centrifugation (10 min at 13,200g) and precipitation with 
600 μL isopropanol. After centrifugation, the DNA pellet was washed with 
300 μL of 70% ethanol and dissolved in 15 μL TE-buffer. The cut and purified 
DNA fragments were ligated overnight at 4 °C. The ligation mix was prepared 
by mixing in order 3 μL of dH2O, 1 μL of 10x ligase buffer (Roche, Burgess 
Hill, UK), 5 μL digested DNA, and 1 μL T4 DNA ligase (Roche, Burgess Hill, 
UK). The ligated DNA was directly used for transformation of 
electrocompetent E. coli cells. 
 
2.5.7 PAC library construction 
Genomic DNA from S. antibioticus Tü6040 was used for construction of a 
genomic library by Bio S&T Inc. (Montreal, Canada) as described previously 
(Jones et al., 2013). Isolated genomic DNA was cloned into pESAC13, an 
integrative phage P1-derived artificial chromosome (PAC) vector derived 
from pPAC-S1, by replacing the carbenicillin resistance gene (BamHI 
fragment). Selection for pESAC13 was achieved by kanamycin resistance in 
E. coli and thiostrepton resistance in Streptomyces. The genomic library 
consisted of 2,688 individual PAC clones with an average insert size of 
110 kb and more than 20-fold genome coverage. PAC clones containing the 
complete sim gene cluster were identified by PCR screening of the genomic 
library using two primer pairs (Table 2.4) for amplification of fragments 
flanking the sim gene cluster on both sides. Six double-positive clones with 
amplification of both PCR products were identified. Sequencing of one 
double-positive clone (PAC-12I; Table 2.4) by Illumina sequencing 
(University of Cambridge, Cambridge, UK) revealed a total insert size of 
95 kb, containing the minimal 72-kb sim gene cluster flanked by genomic 
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regions of ~19 kb and 4 kb on either side. Thus, PAC-12I was chosen for 
heterologous expression studies. 
 
2.5.8 Deletion of genes via PCR targeting and complementation 
Genes were deleted by PCR targeting as described previously (Gust et al., 
2003; Gust et al., 2004), leaving an 81-bp in-frame scar. PCR targeting has 
been developed to improve genetic manipulation with linear DNA and 
deletion of DNA fragments from the genome of Streptomyces species. The 
strategy is based on λ-RED recombination with a disruption cassette 
mediated by λ-RED genes (exo, bet, gam), which encode a 5’-exonuclease 
(Exo), a single stranded DNA binding protein (Bet) and a polypeptide (Gam) 
that confers protection against nuclease attack of linear double-stranded 
DNA (Muniyappa and Radding, 1986). The introduced disruption cassette is 
flanked by FLP recognition target (FRT) sites, which are recognised and 
removed by the FLP-recombinase to leave an 81-bp “scar” sequence in the 
preferred reading frame.  
The strategy of PCR targeting was adapted in this study for mutagenesis of 
the heterologously expressed simocyclinone gene cluster as described 
recently (Jones et al., 2013). The sim gene cluster was isolated on a phage 
artificial chromosome (PAC) vector from a genomic library of S. antibioticus 
Tü6040 (see chapter 2.5.7). The presence of an origin of transfer (oriT) on 
the PAC vector backbone allowed conjugational transfer into Streptomyces 
strains, which is not only more efficient than protoplast transformation but 
also facilitates mutagenesis of the cluster in E. coli before conjugating 
respective scar mutants into Streptomyces strains (Figure 2.1). The 
introduction of large DNA constructs such as PACs into bacteria is 
particularly challenging and highly sensitive to disruptions. Therefore, E. coli 
strains were transformed by electroporation with purified and concentrated 
PAC clones and conjugational transfer was carried out overnight with careful 
handling of the conjugation plate. 
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For deletion of DNA fragments, an apramycin resistance cassette flanked by 
FRT sites was PCR amplified from pIJ773_del_oriT using extended primers 
with 39 nucleotide homology (5’-ends) to the flanking sites of the DNA region 
to be deleted (Figure 2.1). The PAC clone was transformed into E. coli 
BW25113 carrying the temperature-sensitive λ-RED recombination plasmid 
pIJ790 (gam, bet, exo). Recombination was carried out by induction of λ-
RED genes with 10 mM L-arabinose for 3-4 hours, followed by 
transformation of the respective extended PCR construct and a temperature 
shift from 30 °C to 37 °C for 16-20 hours. Successful PCR targeting was 
confirmed by PCR amplification and restriction digestion with EcoRI from 
Apramycin resistant colonies. Mutated DNA constructs were transformed 
twice into E. coli DH5α or DH10B and confirmed again as described to avoid 
transfer of mixed DNA constructs, which cannot be detected after removal of 
the resistance marker. The apramycin resistance cassette was removed from 
the DNA construct by transformation into E. coli BT340 carrying the 
temperature sensitive FLP-recombination plasmid pCP20, followed by 
overnight growth after a temperature shift from 30 to 43 °C (Figure 2.1). 
Excision of the apramycin resistance cassette left an 81-bp in frame scar, 
which was analysed by PCR amplification and restriction digestion with 
EcoRI from apramycin sensitive colonies.  
For mobilisation of PAC clones, the DNA constructs were conjugated from 
E. coli DH5α into the methylation-deficient E. coli strain ET12567 by 
triparental mating, using E. coli TOP10 cells carrying the self-transmissible 
driver plasmid pR9604 (Jones et al., 2013). PAC clones were conjugated 
from E. coli ET12567/pR9406 into Streptomyces strains as previously 
described (Kieser et al., 2000). After 16-20 hours of incubation on R2 
medium without sucrose to reduce the osmotic pressure for the impaired 
E. coli ET12567, plates were overlaid with thiostrepton and nalidixic acid. 
Exconjugants were streaked on SFM agar with thiostrepton and nalidixic acid 
and confirmed by PCR amplification and restriction digestion with EcoRI. For 
spore preparation, strains were grown on Instant Mashed Potato agar (2 g/L 
Smash® instant mashed potato and 2 g/L LabM agar, made up with tap 
water).  
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Figure 2.1   
Modified strategy for 
PCR targeting. 
The strategy was 
developed for 
mutagenesis of the 
simocyclinone (sim) 
biosynthetic gene cluster 
cloned into a phage 
artificial chromosome 
(PAC) vector. Modified 
from Gust et al. (2003). . 
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For complementation of SimC7, the respective gene was cloned into 
pGM1190 (ptipA::simC7) to generate pGM1190-NB-C7. Alternatively, simC7 
was fused to the simB7 promoter (pB7::simC7) to generate pGM1190-pB7-
NB-C7. Successful complementation was confirmed by PCR and product 
analysis was confirmed by liquid chromatography-mass spectrometry (LC-
MS). 
 
2.5.9 Site-directed mutagenesis of SimC7 
The PCR-based Q5® site-directed mutagenesis kit (New England Biolabs, 
Ipswich, UK) was used to generate simC7 point mutants, using plasmid 
pET15b-NB-C7 as the template. Pairs of oligonucleotides were designed to 
amplify linearized plasmid DNA with one oligonucleotide containing the 
desired mutation (Table 2.5). The template plasmid was degraded with DpnI 
and the linear PCR product was self-ligated in presence of kinase and DNA 
ligase before transformation into E. coli DH5α. Mutations were verified by 
sequencing. Protein purifications were carried out as described for native 
SimC7. 
 
2.5.10 Recombineering with single-stranded DNA oligonucleotides 
Recombineering is homologous recombination-mediated genetic 
engineering. Single-stranded linear DNA in form of ~70 base 
oligonucleotides are sufficient to introduce point mutations or deletions up to 
10 kb (Sawitzke et al., 2013). The recombineering efficiency can be 
visualised by using a control oligonucleotide that introduces a mutation in 
galK. The mutation corrects a TAG stop codon to a TAT tyrosine codon 
(galKTYR145UAG). Successful recombineering gives red colonies on 
MacConkey galactose indicator agar (Costantino and Court, 2003). 
Electrocompetent, recombineering-proficient cells of E. coli HME68 were 
prepared by adding 0.1% inoculum of an overnight culture to 50 mL of LB 
medium with appropriate selection. Cultures were grown at 30 °C while 
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shaking (250 rpm) till OD600 of 0.4-0.5. To induce the genes needed for 
recombineering, cultures were grown for 15 min at 42 °C and then cooled on 
ice for 5-10 min. Cells were washed twice in 10 mL of ice-cold 10% (v/v) 
glycerol (5 min at 1,825g and 4 °C) and were resuspended in the remaining 
liquid. Freshly prepared electrocompetent, recombineering-proficient cells 
(200 μL) were mixed with the desired oligonucleotides for single amino acid 
substitutions and a control oligo (~2,310 ng per oligo; 1 μL of 100 μM oligo). 
Cells were electroporated as described (see chapter 2.4.2). Cultures were 
grown shaking for 2 hours at 30 °C. Dilutions of 10-4 to 10-5 were plated on 
MacConkey agar with respective antibiotics and kept at 30 °C for 2 days. 
Single colonies were plated on selective LB plates and used for PCR 
screening with various primers and restriction digests. 
 
2.5.11 Clone library from genomic DNA 
A clone library was made from genomic DNA of S. antibioticus Tü6040. 
Genomic DNA (~10 μg) was partially digested for 1 hour at 37 °C with 0.05 U 
of Sau3AI and separated by agarose gel electrophoresis. Fragments of 10-
30 kb were purified and ligated into the BamHI-linearized and 
dephosphorylated plasmid pSET152. The ligation mix was transformed into 
library-efficient electrocompetent E. coli DH10B (Invitrogen) and the cells 
were grown overnight at 37 °C on 10 selective LB agar medium. Clones from 
each plate were pooled and used for triparental mating with E. coli DH5α/ 
pUB307 and S. lividans TK24 as described (see chapter 2.4.3). 
Exconjugants were replica-plated on SFM agar and spores were harvested 
by pooling spores from each plate. The spores were kept at -20 °C. 
 
2.5.12 Sequencing 
Genomic regions of interest were PCR-amplified using a proof-reading DNA 
polymerase (Pfu) under conditions described in chapter 2.5.5. Amplified 
DNA fragments were purified via PCR purification kit (Qiagen, Hilden, 
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Germany) and were sent for sequencing (MWG Eurofins, Ebersberg, 
Germany). 
For genome sequencing, genomic DNA was isolated from 
S. antibioticus Tü6040 grown in 50 mL DNB for 1 week shaking at 30 °C and 
sample quality was analysed by pulsed-field gel electrophoresis (PFGE) and 
a NanoDrop spectrophotometer (NanoDrop products, Wilmington, USA). The 
genome was sequenced and assembled at the Earlham Institute (Norwich, 
UK) using Pacific Biosciences (PacBio, Menlo Park, Canada) sequencing.  
 
2.6 Expression and purification of recombinant proteins 
2.6.1 Protein expression and purification (His-tagged) 
The recombinant SimC7 protein had 20 additional amino acids at the N-
terminus compared to the native sequence (MGSSHHHHHHSSGLVPRGSH) 
and a molecular weight of 32,235 Da.  
For overexpression of His-tagged recombinant proteins, two 400 mL LB 
cultures were grown shaking (250 rpm) at 28 °C with 1% inoculum from an 
overnight culture. The cultures were induced at early-growth phase 
(OD600 ~0.3) with 0.5 mM IPTG and were grown for about 16-18 hours at 
18 °C. The cells were harvested by centrifugation (F12 rotor with 3,032g for 
10 min at 4 °C) using one centrifugation tube per 400 mL culture. The cell 
pellets were re-dissolved in 20 mL of lysis buffer I and lysed for 5-10 min at 
room temperature and for 30 min on ice. The solution was sonicated twice 
for 40 seconds to separate DNA from proteins and the cell debris was 
separated by centrifugation (SS34 rotor with 38,724g for 30 min at 4 °C). The 
protein solution was mixed with 0.5 mL of Ni-NTA-Agarose beads (Qiagen) 
and was loaded on a 5 mL polypropylene column (Qiagen). His-tagged 
proteins were separated from the remaining lysate by applying 700 mL of 
washing buffer I and the tagged proteins were eluted from the Ni-NTA-
Agarose beads by addition of 1 mL protein elution buffer I. The solution was 
dialysed in a dialysis tube overnight at 4 °C in 2-3 L of storage buffer I and 
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stored at -80 °C. Isolated proteins were quantified via Bradford protein assay 
and purity was analysed by SDS-PAGE (Figure 2.2). 
For protein crystallography and mutant proteins, I established from a number 
of expression and purification trials that the presence of sodium chloride had 
a tendency to induce aggregation of protein derived from this construct. For 
this reason, sodium chloride was either excluded or kept at low 
concentrations in the buffers used thereafter. 10 mL overnight culture was 
used to inoculate 1 L of LB medium without sodium chloride containing 
40 mg carbenicillin and 10 mg chloramphenicol. The culture was grown at 
37 °C to OD600 ~0.3, cooled to 18 °C, and protein expression was induced by 
addition of IPTG to a final concentration of 0.5 mM. The culture was 
incubated for 16 hours shaking at 18 °C. Harvested cells were resuspended 
in lysis buffer IV, and lysed in an Avestin EmulsiFlex®-B15 high pressure 
homogeniser (three cycles with 16,000 psi pressure) (Avestin, Mannheim, 
Germany). Cell debris was removed by centrifugation (SS34 rotor with 
38,724g for 30 min at 4 °C). His-tagged protein was purified by Ni-affinity 
chromatography using 700 mL of washing buffer III and 15 mL of elution 
buffer III. Isolated proteins were analysed as described above (Figure 2.2), 
buffer exchanged against storage buffer X and concentrated to 4 mg/mL 
using VivaSpin 15 columns (Vivaproducts, Littleton, USA), and frozen at -
80 °C. The CD spectra of all the mutant SimC7 proteins were collected and 
found to be unchanged relative to that of the wild-type enzyme. 
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Figure 2.2   
Purification of recombinant SimC7 protein from E. coli. 
SimC7 was overexpressed and purified for enzyme activity assays (A) and 
for protein crystallography (B) as described in this chapter. Lanes: M, pre-
stained broad-range protein marker (NEB); IPTG, culture supernatant before 
(-) and after (+) induction with 0.5 mM IPTG; Lysate, lysate pellet (p) and 
supernatant (s); R, remaining supernatant after removal of protein-bound Ni-
NTA agarose; FT, flow-through before (1) and after (2) addition of washing 
buffer; Elution, elution fractions; D, dialysed SimC7 protein.   
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2.6.2 Protein quantification via Bradford assay 
The Bradford assay is a colorimetric method for quantification of proteins. 
The assay is based on the absorbance shift of Coomassie Brilliant Blue 
G-250 from a red colour under acidic conditions to a blue dye when bound to 
cationic or non-polar, hydrophobic amino acid residues. Consequently, the 
amino acid composition determines the intensity for staining (Bradford, 
1976). Bovine serum albumin (BSA) was used for calibration in 1-20 μg/mL 
final concentration. Aliquots (2 μL) of protein samples or dilutions of BSA in 
800 μL water were mixed with 200 μL dye reagent concentrate (Bio-Rad) 
and were incubated for 5 min in the dark. The absorption at 595 nm 
wavelength was determined against a protein-free control (blank). Protein 
concentrations were calculated using the linear equation from BSA 
standards, taking respective dilutions into account (Equation 1). 
 
Equation 1  
Calculation of protein concentrations via Bradford assay. 
 
(𝐴 595 𝑛𝑚) = 0.1592 × (𝑃𝑟𝑜𝑡𝑒𝑖𝑛 [
𝜇𝑔
𝑚𝐿
]) + 0.0152 
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 [
𝜇𝑔
𝑚𝐿
] = (
𝐴595 𝑛𝑚 − 0.0152
0.1592
)  
 
 
2.6.3 Discontinuous polyacrylamide gene electrophoresis (SDS-PAGE) 
Proteins were separated under denaturing conditions with sodium dodecyl 
sulphate using discontinuous polyacrylamide gel electrophoresis (SDS-
PAGE). Polyacrylamide gels were composed of a lower 12% separating gel 
(pH 8.8) and an upper 5% stacking gel (pH 6.8) as listed in Table 2.9. 
Protein samples (1-5 μL) were mixed with protein loading buffer (1-2-fold 
final concentration) and heat-denatured (95 °C for 5-10 min) before loading 
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them into the gel. The electrophoresis was performed at 80-150 Volts in 
SDS-PAGE running buffer for about 1-1.5 hours using prestained broad 
range protein marker (7-175 kDa) (New England Biolabs, Ipswich, UK) for 
identification of respective protein bands. 
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Table 2.9  
Composition of stacking gel (5%) and separating gel (12%) for SDS-
PAGE. 
Compound Stacking gel Separating gel 
Tris 125 mM 375 mM 
Acrylamide/Bisacrylamide 
(30:0.75, v/v) 
5 % 12 % 
SDS (w/v) 0.1 % 0.1 % 
Ammonium persulphate (w/v) 0.1 % 0.1 % 
TEMED (v/v) 0.1 % 0.04% 
adjusted with HCl to pH 6.8 pH 8.8 
 
 
2.6.4 Staining and immobilisation of proteins in SDS-PAGE gels 
Most commonly Coomassie Brilliant Blue (CBB) is used that reversibly binds 
to cationic and non-polar, hydrophobic amino acid residues. SDS-PAGE gels 
were stained in a Coomassie Brilliant Blue-based staining solution (Instant 
Blue, Expedeon, Harston, UK) overnight at room temperature under 
continuous agitation. The background staining was reduced by incubating 
the gel for 30 min in distilled water. 
 
 
2.7 Protein crystallography 
2.7.1 Protein crystallisation and cryoprotection 
All crystallisation experiments were performed with N-terminally His-tagged 
SimC7 at a concentration of approximately 4 mg/mL and at a temperature of 
20 °C. Screening was conducted by sitting-drop vapour diffusion in MRC 96-
well crystallisation plates (Molecular Dimensions) with a mixture of 0.3 μL 
well solution from both commercial and in-house screens (Qiagen: PEG 
suite, AmSO4 suite; Molecular Dimensions: PACT premier™, JCSG-plus™, 
structure, Morpheus™, MIDAS™, SG1™; in house: KISS) and 0.3 μL protein 
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solution with 40 μL of respective mother liquor using an OryxNano 
crystallisation robot (Doublas Instruments Ltd, Berkshire, UK). Images of 
screening conditions were taken daily by a Ministrel DT plate imager 
(Rigaku, Ettlingen, Germany) using visible light and UV light to distinguish 
between protein and salt crystals. Conditions with small protein crystals 
required manual optimisation. Promising conditions were optimised manually 
in 24-well hanging-drop vapour diffusion format using XRL plates (Molecular 
Dimensions) with drops consisting of 1 µL protein and 1 µL precipitant 
applied on microscope cover slips and positioned upside down above a well 
with 1 mL of respective mother liquor sealed with high vacuum grease (Dow 
Corning, Auburn, USA). Crystal formation was followed manually using a 
stereoscopic microscope (SMZ800, Nikon, Badhoevedorp, Netherlands) of 
10- to 63-fold magnification with an attached digital camera. 
Tetragonal crystals of the SimC7 complex with NADP+ were obtained from 
16% (w/v) PEG-8000 and 20% (v/v) glycerol (native SimC7) or 1.3 M DL-
malic acid (pH 7) supplemented with 1% (v/v) DMSO and 2.5 mM EDTA in 
the drop (SeMet-labelled SimC7). The native crystals did not require further 
cryoprotection, while the SeMet crystals were cryoprotected by 
supplementing the crystallisation solution with 25% (v/v) glycerol. Crystals of 
apo-SimC7 that were isomorphous with those of the complex with NADP+ 
(apo form 1) grew from 25% (w/v) PEG-6000, 20% (v/v) glycerol in 0.1 M 
MES (pH 6.5), while monoclinic apo-SimC7 crystals (apo form 2) were 
obtained from 16% (w/v) PEG-8000, 18% (v/v) glycerol with 10 mM 
dithiothreitol (DTT) added to the drop; neither form required further 
cryoprotection. 7-oxo-SD8 was isolated from S. antibioticus Tü6040 as 
described (see chapter 2.9.1), and was dissolved in DMSO to a 
concentration of 50 mM prior to mixing with protein. The cofactor NADP+ 
(Sigma-Aldrich, Dorset, UK) was dissolved in water to a concentration of 
100 mM without adjusting the pH, which was crucial for obtaining crystals. 
SimC7 was first mixed with NADP+ and then with 7-oxo-SD8, giving a final 
protein concentration of 0.12 mM (3.8 mg/mL) protein, 1.5 mM of 7-oxo-SD8, 
and 3.5 mM of NADP+. The final concentration of DMSO did not exceed 3% 
(v/v). Orthorhombic crystals of the ternary complex of SimC7 bound to 
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NADP+ and 7-oxo-SD8 grew from 20-25% (w/v) PEG-8000, 20-25% (v/v) 
glycerol in 0.1 M sodium acetate (pH 4.8), and did not require further 
cryoprotection. 
 
2.7.2 Selenomethionine labelling of recombinant protein 
For de novo structure determination, recombinant protein was labelled with 
selenomethionine (SeMet) by metabolic inhibition (Doublie, 1997). This 
technique is based on the inhibition of methionine biosynthesis and does not 
require a methionine-auxotroph strain and therefore no further 
transformation. Cells were grown in two times 0.5 L M9 minimal medium at 
37 °C to OD600 ~0.1, amino acids were added (100 mg/L each of threonine, 
lysine and phenylalanine; 50 mg/L each of leucine, isoleucine and valine; 
60 mg/L SeMet), and the cultures were further incubated for 90 min. Protein 
overexpression was induced with 0.5 mM IPTG overnight at 18 °C. Labelled 
protein was purified as described above (see chapter 2.6.1).  
 
2.7.3 X-ray data collection, structure determination and structure 
refinement 
Crystals were harvested and flash-cooled in liquid nitrogen using LithoLoops 
(Molecular Dimensions). The mounted crystals were stored in Unipuck 
cassettes (MiTeGen) prior to transport to the Diamond Light Source 
(Oxfordshire, UK), where they were transferred robotically to the goniostat on 
either beamline I03, I04 or I04-1 and maintained at -173 °C with a Cryojet 
cryocooler (Oxford Instruments). X-ray diffraction data were recorded using a 
Pilatus 6M hybrid photon counting detector (Dectris), then integrated using 
XDS (Kabsch, 2010), and scaled and merged using AIMLESS (Evans and 
Murshudov, 2013) via the XIA2 expert system (Winter, 2010). 
Native data from the complex with NADP+ were collected to 1.95 Å and 
processed in space group P41212 with an estimated solvent content of 
49.3%, based on one copy of the protein chain in the ASU. A SeMet-labelled 
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SimC7 crystal was used to collect a single-wavelength anomalous dispersion 
data set at the selenium K X-ray absorption edge (wavelength 0.9796 Å). 
The data were processed to 2.05 Å resolution in space group P41212 and 
were isomorphous with the native set. Experimental phases were determined 
by analysing the SeMet and native data using the SHELX suite (Sheldrick, 
2008). SHELXD located 4 selenium sites and, after phasing with SHELXE 
(which revealed that P41212 was the correct enantiomorph), the figure-of-
merit was 0.589 to 1.95 Å resolution. These phases were improved by 
density modification with PARROT (Cowtan, 2010) and used as input to 
automated building with BUCCANEER (Cowtan, 2006), which was able to fit 
233 residues (82% of the native sequence). After combining phases 
calculated from this model with the original experimental phases using 
SIGMAA (Read, 1986), PARROT and BUCCANEER were re-run. This time 
277 residues (98% of the native sequence) were fitted giving Rwork and Rfree 
values of 0.263 and 0.298, respectively, at 1.95 Å resolution. The model of 
the complex with NADP+ was completed by several iterations of manual 
rebuilding in COOT (Emsley and Cowtan, 2004) and restrained refinement in 
REFMAC5 (Murshudov et al., 1997) using isotropic thermal parameters and 
TLS group definitions obtained from the TLSMD server (Painter and Merritt, 
2006). 
A dataset was collected to 1.60 Å resolution from apo-SimC7 crystallised in 
the same form as in complex with NADP+. This was used to generate the 
model of apo form 1 starting from the model of the complex with NADP+ from 
which the coordinates of the cofactor had been removed. Model building and 
refinement were completed as above. Crystals of apo form 2 yielded a 
dataset to 1.90 Å resolution after processing in space group C2, with an 
estimated solvent content of 48.3% based on two copies of the protein in the 
ASU. The structure was solved by molecular replacement with PHASER 
(McCoy et al., 2007) using the protein component of NADP+ complex 
structure as the template, and then refined as above.  
Data for the ternary complex of SimC7 with NADP+ and 7-oxo-SD8 were 
processed to 1.20 Å resolution in space group P212121, giving an estimated 
solvent content of 45.3% based on one copy of the protein in the ASU. The 
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latter was located using PHASER with the same template as before. For this 
structure it was possible to use anisotropic thermal parameter refinement in 
REFMAC5.  
Model geometries were validated with MOLPROBITY (Davis et al., 2007) 
before submission to the Protein Data Bank. 
A simulated annealing omit electron density map was calculated for the 
substrate in the ternary complex. For this, the 7-oxo-SD8 was deleted from 
the coordinates of the final model. The resultant PDB file was used as input 
to simulated annealing refinement with PHENIX (Adams et al., 2010) from a 
starting temperature of 5000 K after applying small random shifts to the 
model (‘shake’ term set to 0.3). 
 
 
2.8 Enzyme assays in vitro 
2.8.1 DNA gyrase inhibition assays 
Assays were performed as described previously (Flatman et al., 2005; 
Hearnshaw et al., 2014). DNA gyrase from E. coli (A2B2 complex, Inspiralis 
Ltd., Norwich, UK) was diluted in gyrase dilution buffer (Inspiralis Ltd., 
Norwich, UK) as needed. Purified simocyclinones were dissolved in DMSO. 
Ciprofloxacin (Sigma-Aldrich, Dorset, UK) was dissolved in water. MGD8N2A 
was made by Axel Zeeck (Edwards et al., 2009). 
DNA supercoiling assays were carried out in 30 μL reaction volumes, 
containing DNA gyrase (22 nM), relaxed pBR322 DNA (0.5 μg; 6 nM) in 
presence of ATP (1 mM) using gyrase supercoiling buffer (Inspiralis Ltd., 
Norwich, UK). Reactions were initiated by the addition of DNA gyrase, 
followed by incubation at 37 °C for 30 min. The reactions were stopped by 
the addition of 30 μL chloroform-isoamylalcohol (24:1) and 15 μL of STEB 
solution, followed by brief vortexing and centrifugation (16,100g for 5 min). 
The upper phase was analysed on 1% (w/v) agarose gels.  
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DNA cleavage assays were carried out in presence of 1 μM ciprofloxacin 
under the conditions described above in relaxation buffer (Inspiralis Ltd., 
Norwich, UK). The reaction was either carried out in forward direction 
(0.5 μg; 6 nM relaxed pBR322 DNA in presence of 1 mM ATP) or reverse 
reaction (0.3 μg; 3.6 nM supercoiled pBR322 DNA in absence of ATP). After 
initial incubation for 30 min at 37 °C, the protein-DNA complex was 
separated by addition of proteinase K (0.2 μg/mL) and SDS (0.2%, v/v). The 
mixture was incubated for further 30 min at 37 °C before the reaction was 
stopped.  
 
2.8.2 Surface plasmon resonance (SPR) 
The binding of simocyclinones to DNA gyrase was analysed by surface 
plasmon resonance (SPR) at 25 °C on a BiacoreT100 instrument (GE 
Healthcare, Amersham, UK). Purified GyrA55 protein was immobilised on a 
CM5 sensor chip. The surface carboxyl groups on the chip were activated by 
addition of 35 μL of a mixture of N-hydroxysuccinimide (50 mM) and 1-ethyl-
3-(3-diaminopropyl)carbodiimide (0.2 M) from the Biacore amine coupling kit. 
The protein was diluted in HBS-EP+ buffer (10 mM Na-HEPES; 150 mM 
NaCl; 3 mM EDTA; 0.05% (v/v) surfactant P20; pH 7.4) and immobilised on 
the chip (10 μL/min) until a response of 3000 resonance units was reached. 
The remaining ester groups on the chip were deactivated by addition of 
35 μL of ethanolamine. The system was equilibrated with HBS-EP+ running 
buffer with 1% (v/v) DMSO and a flow rate of 30 μL/min. Defined 
concentrations of compounds were added, previously diluted in HBS-EP+ 
running buffer with a final DMSO concentration of 1% (v/v). Protein-ligand 
interactions were analysed with a binding time of 2 min followed by a 
dissociation time of 2 min at a flow rate of 5 μL/min. The protein was 
regenerated by washing the chip twice with 1 M NaCl for 1 min at a flow rate 
of 30 μL/min. The maximum binding response (Rmax) was calculated from the 
molecular weight ratio of compound (MW analyte) and protein (MW ligand) 
multiplied by the response of protein bound to the chip and the binding 
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stoichiometry (S) (Equation 2). Data were analysed using single kinetics 
with a 1:1 binding stoichiometry. 
 
Equation 2  
Calculation of the maximum binding response (Rmax). 
 
𝑅𝑚𝑎𝑥 =  (𝑀𝑊𝑎𝑛𝑎𝑙𝑦𝑡𝑒 / 𝑀𝑊𝑙𝑖𝑔𝑎𝑛𝑑)  × 𝑅𝑙𝑖𝑔𝑎𝑛𝑑 × 𝑆 
 
 
2.8.3 Circular dichroism (CD) spectroscopy 
Circular dichroism (CD) spectroscopy experiments were performed using a 
Chirascan-Plus CD spectrophotometer (Applied Photophysics, Surrey, UK). 
Concentrated proteins in storage buffer X were buffer exchanged against 
20 mM potassium phosphate buffer (pH 7.2) with 5% (v/v) glycerol and 
diluted to 0.2 mg/mL (6.25 μM). CD analysis was carried out at 20 °C using a 
quartz glass cuvette with a 0.5 mm path length. CD spectra were averaged 
from four scans collected between 190 nm and 260 nm wavelength, using a 
bandwidth of 2.0 nm, a step size of 0.5 nm, and one time point per second.  
 
2.8.4 SimC7 oligomeric state determination by size exclusion 
chromatography (SEC) 
Size exclusion chromatography (SEC) was used to determine the oligomeric 
state of SimC7. Concentrated protein samples (4 mg/mL) were prepared by 
exchanging storage buffer X with running buffer III using VivaSpin 500 
columns (Vivaproducts, Littleton, USA). A Superdex 75 10/300 GL column 
attached to an AKTA protein crystallography machine (GE Healthcare, 
Amersham, UK) was equilibrated with 2 column volumes (60 mL) of running 
buffer III before analysis of protein samples (100 μL) using a constant flow 
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rate of 0.5 mL/min. Absorption was recorded at 280 nm wavelength for 
1.25 column volumes.  
 
2.8.5 Ketoreductase activity assays  
Ketoreductase assays were performed in reaction mixtures consisting of the 
substrate 7-oxo-SD8 (25-200 μM), cofactor NAD(P)H (0.3 mM) or NAD+ 
(300 mM), HEPES (50 mM, pH 7.2), and enzyme (24.18 μg/mL, 500 nM). 
Reactions were initiated with SimC7 and quenched at specific time points 
with equal volumes of methanol. Stopped reactions were incubated for 
10 min at 100 °C and centrifuged (13,000g for 10 min at 4 °C) to remove 
precipitated protein. SD8 formation was quantified by analytical reversed-
phase HPLC using a linear gradient of 25-95% methanol over 20 min (see 
chapter 2.9.4). SD8 concentrations were calculated by comparison with a 
standard curve (7.5-2,100 pmol, Figure 2.3a and Figure 2.4), which was 
calculated from a serial dilution of SD8 prepared in methanol (0.25-70 μM) 
under the conditions described above. Samples were analysed in duplicates 
and SD8 standards were analysed in triplicates. Product formation was 
confirmed by SD8 and 7-oxo-SD8 standards as well as LC-MS.  
SimC7 variants were assayed as described above using 16.12 μg/mL 
(500 nM) enzyme, 0.3 mM NADH, 0.2 mM 7-oxo-SD8, and HEPES (50 mM, 
pH 7.2). Each mutant protein was analysed in three independent 
experiments. Data were averaged from two technical replicates for each 
SimC7 variant using a shortened linear gradient of 70-95% methanol over 
10 min (see chapter 2.9.4). Substrate conversion was determined by 
quantification of the peak area for the reaction product SD8 based on a 
standard curve (7.5-9,000 pmol, Figure 2.3b and Figure 2.4) calculated from 
a serial dilution of SD8 (0.25-300 μM) prepared in methanol. 
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Figure 2.3   
SD8 standard curve for determination of product conversion by (A) 
SimC7 and (B) SimC7 variants.  
Standards (A: 7.5-2,100 pmol; B: 7.5-9,000 pmol) were analysed by HPLC in 
triplicate and the average peak area was determined. Error bars indicate the 
standard deviation between results of three sampling repeats. The coefficient 
of determination (R2) was (A) 0.9998 and (B) 0.9992. 
  
A 
 
 
 
 
 
 
B 
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Figure 2.4   
Detection limit for determination of product conversion by (A) SimC7 
and (B) SimC7 variants. 
HPLC chromatograms at 360 nm wavelength are show for the most dilute 
(7.5 pmol) and most concentrated (2,100 pmol for SimC7 wildtype and 
9,000 pmol for SimC7 variants) SD8 standards used for calibration (see 
Figure 2.3).  
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2.9 Extraction and analysis of simocyclinones 
2.9.1 Extraction of simocyclinones 
For simocyclinone extraction, Streptomyces strains were grown for 6 days 
shaking at 30 °C in 50 mL Tu2 medium. For large-scale extraction of 
7oxoSD8, four 1 L cultures of S. coelicolor M1152ex1::12IΔC7 were grown in 
Tu2 medium. Cultures were adjusted to pH 4.0 with 10% HCl solution and 
simocyclinones were extracted twice using ethyl acetate (1 volume for small 
cultures and 0.2 volumes for large cultures) while shanking for about 30 min 
at room temperature. The phases were separated by centrifugation (1,026g 
for 10 min) and the organic phase was vacuum-concentrated and kept at -20 
or -80 °C.  
Alternatively, the adsorptive hydrophobic resin Diaion® HP20 (Sigma-Aldrich, 
Dorset, UK) was used to absorb simocyclinones from the production 
medium. The resin was activated overnight in 3-4 volumes of methanol. The 
methanol was removed by washing the resin 2-3 times in dH2O using a 
vacuum filter and was then kept in a semi-dry state before adding 50 g/L 
(5% w/v) to the culture medium. For simocyclinone extraction, cultures were 
centrifuged and methanol was added to the pellet (resin and mycelium) to 
dissolve simocyclinones from the resin. The liquid was vacuum-concentrated 
and samples were kept at -20 °C. 
 
2.9.2 13C-enrichment of simocyclinones 
For stable isotope labelling with carbon 13 (13C), cultures were grown as 
described (see chapter 2.9.1). One 1 L culture of S. coelicolor 
M1152ex1::12IΔC7 was grown in Tu2 medium shaking at 30 °C and spiked 
with a total of 10 mL of 1 M sterile-filtered [1,2-13C2] acetate over 6 days. 
Aliquots of 1.5 mL were added on days 0, 1, and 3, and two times 0.75 mL 
on days 4, 5, and 6 with a final concentration of 0.75-1.5 mM of [1,2-13C2] 
acetate at each time of addition. 
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2.9.3 Liquid chromatography-mass spectrometry (LC-MS) 
Simocyclinone extracts were analysed via liquid chromatography-mass 
spectrometry (LC-MS). Simocyclinone extracts were dissolved in methanol 
and samples (10 μL) were injected onto an HPLC column (Phenomenex 
Luna-C18 3μ C18(2) 100A, 100 mm × 2 mm) with a Phenomenex 
SecurityGuard Prep Cardridge Holder Kit (2 mm) attached to a Thermo ion-
trap LC-MS (LCQ DECA XPplus) equipped with a Surveyor HPLC system 
(Thermo Fisher, Loughborough, UK). Samples were separated using a linear 
gradient with 0.1% formic acid as mobile phase A and methanol as mobile 
phase B at a flow rate of 1 mL/min. Mobile phase B was kept at 25% for 
1 min followed by a gradient of 25-95% over 20 min, then 95% for 4 min, and 
25% for 6 min. Samples were analysed by positive electrospray ionisation 
(ESI) MS and UV-vis chromatography. The PDA collected spectra from 
200 nm to 600 nm at 1 Hz, additionally fixed wavelengths were collected at 
210, 340, and 365 nm (9 nm bandwidth) at 10 Hz. Data were collected from 
fragments with a mass-to-charge (m/z) ratio of 150-2000 and data-
dependent tandem mass spectrometry (MS2) was carried out for the most 
abundant ions above m/z 400 at an isolation width of m/z 4.0 and 30% 
collision energy. For quantification of SD8, an external calibration was used 
based on UV absorbance at 360±5 nm obtained from LC-MS. The spray 
chamber conditions were 350 °C capillary temperature, 50 units sheath gas, 
5 units aux gas, and a source voltage of 3.8 kV using a steel needle kit. The 
column was maintained at 30 °C and the autosampler maintained the 
samples at 10 °C. 
Later samples were analysed on a Shimadzu liquid chromatography mass 
spectrometry ion trap time-of-flight (LC-MS IT-TOF) (Shimadzu Scientific 
Instruments, Columbia, USA) using a shortened gradient and a flow rate of 
0.5 mL/min. Mobile phase B was kept at 25% for 1 min followed by a 
gradient of 25-95% over 7 min, then 95% for 6 min, and 25% for 2 min. 
Samples were analysed by positive electrospray MS and UV-vis 
chromatography. The PDA collected spectra from 200 nm to 600 nm at 
4.167 Hz with a time constant of 0.16 s. Data were collected from fragments 
104 
with a mass-to-charge (m/z) ratio of 180-1500 with a maximum ion 
accumulation time of 20 ms and automatic sensitivity control set to a target of 
70% optimum base peak intensity. Tandem mass spectrometry (MS2) was 
carried out for the most abundant precursor ions with isolation width of m/z 
3.0, 50% collision energy and 50% collision gas. The spray chamber 
conditions were 250 °C curved desorbation line, 300 °C heat block, 1.5 L/min 
nebulizer gas, and drying gas “on”. The instrument was calibrated with 
sodium trifluoroacetate cluster ions according to the manufacturer’s 
instructions. 
 
2.9.4 High-pressure liquid chromatography (HPLC) 
For purification of simocyclinones, dried culture extracts were dissolved in a 
minimal amount of methanol or a 10:1 methanol-acetone mixture and were 
separated by high-pressure liquid chromatography (HPLC).  
For preparative HPLC, samples (350 μL) were injected onto an HPLC 
column (Phenomenex Gemini-NX 5μ C18 110A AXIA Packed, 150 mm × 
21.20 mm) with a Phenomenex SecurityGuard Prep Cartridge Holder Kit 
(21.20 mm) attached to a Dionex UltiMate 3000 HPLC machine. Separation 
was performed using a linear gradient with 0.1%formic acid as mobile phase 
A and methanol as mobile phase B. The gradient was 75-95% mobile phase 
B over 20 min followed by 95% mobile phase B for 5 min at a flow rate of 
21 mL/min, and absorbance was recorded at 360 nm.  
For analytical HPLC, samples (30 μL) were separated on an HPLC column 
(Phenomenex Gemini-NX 3μ C18 110A, 150 mm × 4.6 mm) attached to an 
Agilent 1200 series HPLC machine using a linear gradient with 0.1% formic 
acid as mobile phase A and methanol as mobile phase B. The gradient was 
either 25-95% or 75-95% solvent B over 20 min at a flow rate of 1 mL/min. 
Absorbance was recorded with a diode array detector at 210 nm, 230 nm, 
and 360 nm for simocyclinones and 535 nm as reference. The gradient was 
shortened for enzyme activity assays with SimC7 variants to 70-95% 
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methanol against 0.1% formic acid over 10 min, followed by 95% methanol 
for 5 min (see chapter 2.8.5).  
 
2.9.5 Normal phase liquid chromatography (LC) 
Crude extracts of simocyclinones were separated by normal phase liquid 
chromatography (LC) on a Biotage chromatography machine (Biotage, 
Uppsala, Sweden). Samples were purified on a pre-packed silica column 
(Biotage® SNAP cartridge KP-SIL 50 g, 40- to 65-μm particle size, 39 mm × 
81 mm; Biotage, Uppsala, Sweden) using a gradient elution from CH2Cl2-
MeOH (95:5) to CH2Cl2-MeOH (70:30) over 4 hours at a flow rate of 50 mL/h 
(Holzenkampfer et al., 2002). A methanol gradient (5-30% methanol) against 
dichloromethane was performed at a flow rate of 10 mL/min for 2 hours. 
Fractions of 10 mL were collected and the presence of simocyclinones was 
verified by thin layer chromatography, HPLC, and LC-MS.  
 
2.9.6 Thin layer chromatography (TLC) 
Thin layer chromatography (TLC) is a fast and simple way to identify 
chemical compounds present in a mixture and to determine their purity 
based on their distinct chemical properties. Samples were spotted (1 μL) on 
normal phase (silica coated aluminium) TLC plates (GE Healthcare, 
Amersham, UK), dried, and separated by placing in a glass chamber filled 
with ~1 cm of solvent. The solvent mixture was optimized so that the 
retention factor value (Rf value), which is the distance travelled by the 
component relative to the distance travelled by the solvent, was ~0.3. The 
presence of simocyclinones was confirmed under UV-light. 
 
2.9.7 Small molecule size exclusion chromatography (SEC) 
Size exclusion chromatography (SEC) separates molecules in solution 
according to their size. Simocyclinone samples were dissolved in methanol 
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and loaded on a column packed with 30 g of Sephadex LH-20 (18- to 
111-μm particle size) (Sigma-Aldrich, Dorset, UK) using a mobile phase of 
10% acetone, 80% methanol, and 10% water. Fractions of 10-15 mL were 
collected and presence of simocyclinones was confirmed by HPLC and 
LC-MS. Respective fractions were combined and dried in vacuo. 
 
2.9.8 Nuclear magnetic resonance (NMR) spectroscopy  
The structure of simocyclinones were analysed by nuclear magnetic 
resonance (NMR) spectroscopy. HPLC-purified compounds were dissolved 
in DMSO-d6 and then analysed on Bruker AVANCE-DRX 700 and Avance III 
400 spectrometers at 298 K. Data were processed and analysed using 
TopSpin v3.2 software (Bruker). Proton (1H) coupling constants were 
determined using experiments from the Avance III 400 spectrometer. All 
other assignments were made using experiments from the DRX 700 
spectrometer.  
For proton (1H) NMR spectroscopy, a high number of scans was chosen to 
amplify the signal for simocyclinones (160 scans). The proton (1H) NMR 
experiment was repeated after addition of 5 μL deuterated water (D2O) to 
confirm the signals of hydroxyl groups. For carbon (13C) NMR spectroscopy, 
an attached proton test (APT) experiment was used to facilitate the 
assignment of protons attached to each carbon. Whereas carbons in 
methane (CH) and methyl (CH3) groups yield positive signals, carbons in 
quaternary (C) and methylene (CH2) groups yield negative signals.  
Beside proton (1H) and carbon (13C) NMR spectroscopy, several two-
dimensional NMR techniques were applied to confirm the structure of 
7-oxo-SD8. Correlation spectroscopy (COSY) and total correlation 
spectroscopy (TOCSY) were used to determine neighbouring hydrogen 
atoms, heteronuclear single quantum coherence spectroscopy (HSQC) was 
used to assign hydrogens to respective carbon atoms, and heteronuclear 
multiple-bond correlation spectroscopy (HMBC) was used to detect 
107 
heteronuclear correlations between hydrogens and carbons over longer 
ranges of about 2-4 bonds. 
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2.10 Software for in silico analysis 
Software programs used for in silico analyses are listed in Table 2.10. 
Table 2.10  
List of software used for bioinformatics. 
Software Purpose Reference 
antiSMASH (v2.0-3.0) 
(http://antismash.secondary
metabolites.org/) 
Genome mining of 
biosynthetic gene 
clusters 
(Weber et al., 
2015) 
BioEdit (v7.1.11) 
(http://www.mbio.ncsu.edu/b
ioedit/bioedit.html) 
Alignment of DNA and 
protein sequences 
(Hall, 1999) 
BLAST 
(http://blast.ncbi.nlm.nih.gov
/Blast.cgi) 
Homology searches of 
DNA and protein 
sequences 
(Altschul et al., 
1990; Camacho et 
al., 2009)  
Buccaneer (ccp4i) Automated structure 
building  
(Cowtan, 2006) 
CCP4i (v6.5.019) 
(http://www.ccp4.ac.uk/ccp4i
_main.php) 
Macromolecular 
crystallography suite 
(Potterton et al., 
2003) 
ChemDraw (v13) 
(http://www.cambridgesoft.c
om) 
Property prediction of 
chemicals 
Cambridgesoft 
(Cambridge, USA) 
DNAPlotter (v1.11) 
(http://www.sanger.ac.uk/sci
ence/tools/dnaplotter) 
Genome visualisation (Carver et al., 
2009) 
EBI-PISA  
(http://www.ebi.ac.uk/pdbe/p
isa/) 
Protein, interfaces, 
structures, and 
assemblies server 
(Krissinel and 
Henrick, 2007) 
ESPript (v3.0) 
(http://espript.ibcp.fr/ESPript
/ESPript/) 
Protein sequence 
alignment and 
secondary structure 
information server 
(Robert and 
Gouet, 2014) 
Gepard (v1.30) 
(http://mips.gsf.de/services/
analysis/gepard) 
Dotplot calculation of 
DNA sequences 
(Krumsiek et al., 
2007) 
Mega (v5.05) 
(http://www.megasoftware.n
et/) 
Alignment of DNA and 
protein sequences 
(Tamura et al., 
2011) 
MolProbity 
(http://molprobity.biochem.d
uke.edu/) 
Protein X-ray structure 
validation server 
(Davis et al., 
2007; Chen et al., 
2010) 
Parrot (ccp4i) 
 
Density modification  
(Cowtan, 2010) 
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Software Purpose Reference 
PerlPrimer (v1.1.21) 
(http://perlprimer.sourceforg
e.net) 
Oligonucleotide design 
for PCR 
(Marshall, 2004)  
Phaser (ccp4i) Molecular replacement (McCoy et al., 
2007) 
Phenix 
(https://www.phenix-
online.org/) 
Automated structure 
determination; simulated 
annealing refinement 
(Adams et al., 
2010) 
Phyre2 (v2.0) 
(http://www.sbg.bio.ic.ac.uk/
phyre2) 
Protein folding 
recognition server 
(Kelley and 
Sternberg, 2009; 
Kelley et al., 2015) 
Pfam (v26.0; Nov. 2011) 
(http://pfam.sanger.ac.uk/) 
Annotation of protein 
domains 
(Finn et al., 2010)  
Prodigal (v1.20) 
(http://prodigal.ornl.gov/) 
ORF prediction for 
Streptomyces DNA 
(Hyatt et al., 2010)  
PyMOL (v1.7.1) 
(http://sourceforge.net/proje
cts/pymol/) 
Visualisation of protein 
structures 
The PyMOL 
Molecular 
Graphics System, 
Schrödinger, LLC. 
RAST (v2.0) 
(http://rast.nmpdr.org/) 
Prokaryotic genome 
annotation server 
(Aziz et al., 2008) 
Refmac5 Restrained refinement  (Murshudov et al., 
1997) 
ShelX suite 
(http://shelx.uni-
ac.gwdg.de/SHELX/) 
Experimental phasing of 
macromolecules 
(Sheldrick, 2008) 
SigmaA (ccp4i) Combining of model and 
experimental phases 
(Read, 1986) 
Smart (v6.0 and v7.0) 
(http://smart.embl-
heidelberg.de/) 
Protein domain 
annotation server 
(Schultz et al., 
1998; Letunic et 
al., 2012)  
WinCoot (v0.7),  
Coot (v0.8.2) 
(http://www.ysbl.york.ac.uk/
~emsley/coot) 
Structural alignment of 
proteins 
(Emsley and 
Cowtan, 2004; 
Emsley et al., 
2010)  
wwPDB 
(http://wwpdb-
validation.wwpdb.org/valids
ervice/)  
Protein X-ray structure 
validation server 
(Berman et al., 
2003) 
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3.1 Introduction 
Understanding the complex biosynthesis of secondary metabolites such as 
the simocyclinones requires the genetic manipulation of the corresponding 
biosynthetic gene clusters. However, the natural producer of the 
simocyclinones, S. antibioticus Tü6040, grows very slowly and is particularly 
challenging to manipulate genetically. Although there are a few reports of 
successful directed mutations of the sim gene cluster in S. antibioticus 
Tü6040 (Galm et al., 2002; Trefzer et al., 2002; Galm, 2003), the procedures 
used had low and inconsistent success rates. Therefore, heterologous 
expression and manipulation of the sim cluster was desirable.  
The sim gene cluster was initially isolated on four overlapping cosmids 
(Trefzer et al., 2002). This was sufficient for sequencing of the ~72-kb sim 
cluster but did not permit straightforward reconstruction of the cluster as a 
single contiguous clone. A newly developed approach allows cloning and 
manipulation of genomic fragments of up to 150 kb in phage artificial 
chromosomes (PACs) (Jones et al., 2013), enabling heterologous expression 
of large gene clusters such as the sim gene cluster. 
Here I show that the sim gene cluster can be cloned on a single PAC, which 
facilitates genetic manipulations and product analysis by using a 
heterologous system. I show that S. coelicolor M1152 is able to produce 
simocyclinones heterologously and that overexpression of the 
simocyclinone-specific efflux pump SimEx1 improves growth and survival of 
M1152, most likely by increased export of simocyclinones.  
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3.2 Isolation of the simocyclinone (sim) biosynthetic gene 
cluster 
The entire sim gene cluster was isolated on a single phage artificial 
chromosome (PAC) clone (PAC-12I) after PCR screening of a genomic 
library generated in E. coli according to a recently developed protocol for 
working with large gene clusters (Jones et al., 2013). The genomic library 
was generated and screened by Bio S&T (Montreal, Canada). Subsequent 
sequencing of the 95-kb insert revealed the presence of the whole 72-kb 
minimal sim gene cluster consisting of 49 genes, flanked by genomic regions 
of ~19 kb and 4 kb on either side (Figure 1.6 and Figure 3.1).  
Comparison of the sequencing results obtained from PAC-12I with previously 
published sequences of the sim cluster (Galm et al., 2002; Trefzer et al., 
2002) revealed no significant differences (i.e. no frameshifts or premature 
stop codons in biosynthetic genes). 
 
113 
Figure 3.1   
Comparison of sequenced 
simocyclinone (sim) gene 
cluster fragments.  
The sim gene cluster has been 
sequenced independently by 
two research groups (Galm et 
al., 2002; Trefzer et al., 2002). 
The newly sequenced 
genomic DNA fragment in 
PAC-12I covers the entire 
minimal sim gene cluster as 
well as ~19 kb and 4 kb 
sequence on either side (grey 
open reading frames). For 
gene annotations see Figure 
1.6. 
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3.3 Optimisation of the heterologous system 
Clone PAC-12I was conjugated into the heterologous host S. coelicolor 
M1152 using the methylation-deficient E. coli strain ET12567 carrying the 
self-transmissible helper plasmid pR9406. S. coelicolor M1152 was chosen 
as heterologous host because it is a fast growing strain specifically 
engineered for improved heterologous production and analysis of secondary 
metabolites. The strain has no antimicrobial activity and a simplified 
extracellular metabolite profile for high-performance liquid chromatography 
(HPLC) and mass spectrometry analyses due to the deletion of four 
endogenous secondary metabolite gene clusters (Gomez-Escribano and 
Bibb, 2011). Beside the deletion of its endogenous gene clusters, a point 
mutation in the rpoB gene encoding for the RNA polymerase β-subunit 
further contributes to a pleiotropic increase in expression levels of secondary 
metabolite gene clusters (Gomez-Escribano and Bibb, 2011).  
Unexpectedly, introduction of PAC-12I dramatically reduced growth and 
sporulation of S. coelicolor M1152. Several attempts were made to improve 
the viability of the heterologous host and overcome the toxicity of 
simocyclinones (see chapter 6). The best results were achieved after 
overexpression of the simocyclinone export protein SimEx1. Overexpression 
of the simocyclinone efflux pump SimEx1 has been shown previously to 
confer resistance against externally added SD8. Resistance of S. lividans 
against SD8 increased from an MIC of 2 μg/mL to 65 μg/mL after 
introduction of an integrative plasmid (pIJ10480) carrying simEx1 expressed 
from the strong constitutive promoter ermEp* (ermEp*::simEx1) (Le et al., 
2009). Consequently, pIJ10480 was introduced into M1152, resulting in 
strain S. coelicolor M1152ex1, which improved resistance against externally 
added SD8 ~100-fold from 1 μg/mL to 100 μg/mL. Indeed, the modified 
heterologous host M1152ex1 showed improved growth and sporulation in the 
presence of the sim gene cluster (i.e. introduction of PAC-12I) compared to 
M1152 (Figure 3.2). Normal growth was observed for M1152ex1 and 
M1152ex1 with a control construct lacking the sim gene cluster (PAC-
12Isim) (Figure 3.2). Nevertheless, growth of M1152ex1 expressing the 
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sim gene cluster remained impaired, raising further questions about the basis 
of resistance in the native producer S. antibioticus Tü6040.  
Strain M1152ex1 with PAC-12I was grown in defined medium (Tu2 medium) 
optimised for SD8 production with L-glutamine as nitrogen source and 
glycerol as carbon source (Schimana et al., 2001). Production of SD8 was 
generally two- to five-fold higher in the heterologous host M1152ex1 
(24-56 mg/mL) compared to S. antibioticus Tü6040 (9-14 mg/L). As 
expected, no simocyclinones were detectable from M1152ex1 with a control 
construct lacking the sim gene cluster (PAC-12Isim). All cultures carrying 
the control construct PAC-12Isim were unimpaired in growth, showing that 
the sim gene cluster is responsible for the observed toxicity.  
Heterologous production of simocyclinones in M1152ex1 was monitored over 
14 days to determine the time range of maximum production. Optimum yield 
was achieved after 6 days of growth in production medium and correlated 
with the growth of the heterologous host (Figure 3.2 and Figure 3.3). In 
comparison, S. antibioticus Tü6040 produced simocyclinones much earlier 
and reached maximum production levels after only 3 days of growth, as 
shown previously (Schimana et al., 2000). Since strain M1152ex1 gave best 
results for heterologous expression of simocyclinones, this strain was used 
for all further experiments in this study.  
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Figure 3.2  
Growth of Streptomyces strains.  
Growth of the natural simocyclinone producer S. antibioticus Tü6040 in 
comparison with the heterologous host S. coelicolor M1152. Growth and 
sporulation of M1152 was strongly impaired in presence of the sim gene 
cluster, which could be partially restored by overexpression of the 
simocyclinone efflux pump SimEx1. Strains were grown on SFM agar for 
9 days at 30 °C. 
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Figure 3.3   
Growth and SD8 production of the heterologous host.  
Growth of S. coelicolor M1152, M1152ex1 and M1152ex1 carrying the sim 
gene cluster (PAC-12I) was monitored over 14 days. Biosynthesis of SD8 
(black line) by strain M1152ex1/ PAC-12I was quantified by LC/MS. 
Simocyclinones were isolated as described and SD8 was quantified by 
measuring the peak area from the UV-vis chromatogram from LC-MS 
analysis. Cultures were inoculated with 107 spores (M1152 and M1152ex1) 
or 108 spores (M1152ex1/ PAC-12I). 
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3.4 Discussion 
Heterologous expression is a convenient tool for structure–function analysis 
of secondary metabolites, and improved derivatives of S. coelicolor and 
Streptomyces avermitilis have recently been developed for this purpose 
(Komatsu et al., 2010; Gomez-Escribano and Bibb, 2011; Komatsu et al., 
2013). Here, I demonstrate the utility of this approach for the manipulation 
and functional analysis of simocyclinone, an antibiotic naturally made by 
S. antibioticus Tü6040, a strain that is particularly challenging for genetic 
manipulation. Despite the large size of the sim gene cluster (49 genes 
covering ~72 kb), it was straightforward to isolate a PAC clone carrying the 
entire cluster and to introduce it by conjugation into an engineered 
S. coelicolor host, where the clone integrated irreversibly and replicated 
stably as part of the chromosome. The same approach was recently used for 
the successful heterologous expression in S. coelicolor of the 83.5-kb FK506 
gene cluster from Streptomyces tsukubaensis (Jones et al., 2013). The 
engineered S. coelicolor host often gives a greater yield than the natural 
producer (Gomez-Escribano and Bibb, 2011; Jones et al., 2013), and this 
was also true for simocyclinone. A further advantage of this approach is that 
genetic modification of the target cluster can be carried out in E. coli, giving 
full access to the advanced recombineering tools available in this host. The 
explosion of whole genome sequencing has revealed tens of thousands of 
new secondary metabolic gene clusters (Medema et al., 2011; Cimermancic 
et al., 2014), many in rare and difficult-to-culture actinomycetes for which no 
genetic tools have been developed. As a consequence, the heterologous 
expression approach exemplified here is an attractive option for 
characterizing many of these clusters and is likely to be of increasing 
importance in the future. 
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4.1 Introduction 
The 49-gene simocyclinone (sim) biosynthetic cluster of S. antibioticus 
Tü6040 has been sequenced and a hypothetical biosynthetic pathway has 
been proposed (Galm et al., 2002; Trefzer et al., 2002). Although two sim 
cluster transcriptional regulators have been studied (Le et al., 2009; Le et al., 
2011a; Le et al., 2011b; Horbal et al., 2012), to date, only one biosynthetic 
enzyme has been characterised due to the genetic inaccessibility of the 
native producer and until recently limitations in available techniques to 
analyse large biosynthetic gene clusters heterologously. SimD5 (SimL) 
catalyses the presumed last step in the pathway, functioning as an amide-
bond-forming ligase that attaches the aminocoumarin to the tetraene linker 
(Luft et al., 2005; Pacholec et al., 2005; Anderle et al., 2007). 
Trefzer et al (2002) proposed that the tetraene linker in SD8 would be the 
product of a modular type I polyketide synthase, SimC1ABC, working in trans 
with two monofunctional enzymes, SimC6 and SimC7. One of these 
monofunctional enzymes, SimC7, a member of the short-chain 
dehydrogenase/reductase (SDR) superfamily, was proposed to supply the 
dehydratase activity missing from two modules of the polyketide synthase 
(Trefzer et al., 2002). 
Here I determine the true function of SimC7 experimentally and show that it 
is in fact an NAD(P)H-dependent ketoreductase that acts on the C-7 
carbonyl group of the angucyclinone during simocyclinone biosynthesis. I 
show that deletion of simC7 from the sim gene cluster results in production of 
7-oxo-SD8, a novel simocyclinone, with a non-reduced carbonyl group at 
position 7 of the angucyclinone of simocyclinones. I manually optimise the 
purification of 7-oxo-SD8 and verify its structure using nuclear magnetic 
resonance (NMR) spectroscopy and high-resolution mass spectrometry 
(MS). Furthermore, I show that the C-7 hydroxyl group generated by SimC7 
is essential for the antibiotic activity of simocyclinone and I propose that the 
inactivity of 7-oxo-SD8 arises from an intramolecular hydrogen bond 
between the non-reduced 7-carbonyl group and the neighbouring 8-hydroxyl 
group.  
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4.2 Structural analysis of the novel simocyclinone 7-oxo-SD8 
In order to determine the role of SimC7 in simocyclinone biosynthesis, I 
created an in-frame deletion in simC7 in PAC-12I using λ-Red-mediated 
PCR targeting, and introduced the resulting PAC clone (PAC-12IΔC7) into 
the optimised heterologous host S. coelicolor M1152ex1. Fermentation 
extracts of the resulting simC7 mutant strain were analysed by HPLC and the 
major biosynthetic product had a later retention time than that of SD8 
(Figure 4.1). The UV-vis spectrum of the new compound was similar to that 
of SD8 but with reduced absorbance at 275 nm and a slight shift in the 
absorbance maxima to 245 nm and 361 nm (Figure 4.2). Unexpectedly, the 
major biosynthetic product of the simC7 mutant had a mass 2 Da lighter than 
SD8. All of the A-, B- and C-group simocyclinone intermediates made by the 
simC7 mutant were also 2 Da lighter than the equivalent molecules made by 
the wild-type sim cluster, suggesting that the 2 Da difference lay in the 
angucyclic polyketide, and not the tetraene linker.  
This suggested that one of the five hydroxyl groups present in the angucyclic 
polyketide moiety of SD8 remained as a carbonyl group in this compound, 
and that SimC7 acts as a ketoreductase. To test this hypothesis, I purified 
the new simocyclinone intermediate from 4 L culture and determined its 
structure. I manually optimised the purification of the new compound by 
using organic extraction with acidified ethyl acetate (pH 4), several pre-
purification steps (filtering through glass wool, normal phase liquid 
chromatography, dissolving in acetone, size exclusion chromatography) 
followed by optimised preparative reverse-phase HPLC. For purification, the 
dried extract from 4 L culture medium (~1.5 g with ~15% compound) was 
dissolved in methanol, filtered through glass wool and purified by normal-
phase liquid chromatography as described (Holzenkampfer et al., 2002). The 
presence of the compound was verified by thin layer chromatography and 
LC-MS and selected fractions were pooled, dried in vacuo, and dissolved in 
acetone. The acetone-soluble fraction was dried and dissolved in methanol 
for size exclusion chromatography. Following elution using methanol, 
fractions were collected and the presence of the compound was confirmed 
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by LC-MS. Fractions containing the compound were combined, dried 
in vacuo, and the concentrate was dissolved in a methanol–acetone mix 
(1:1) and purified further by preparative HPLC, which I optimised for 
purification of the new compound using analytical HPLC. After freeze drying, 
I obtained ~63 mg of the new simocyclinone derivative 7-oxo-SD8 in a fine 
yellow powder (yield ~27%; purity >98%).  
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Figure 4.1  
Analysis of simocyclinones produced by the simC7 deletion mutant.  
LC-MS-UV analysis of simocyclinones was carried out using culture extracts 
from the heterologous host S. coelicolor M1152ex1 expressing the sim gene 
cluster. Chromatograms (200-700 nm) of culture extracts from clones 
carrying the simC7 mutant cluster on PAC-12IΔsimC7 (top) and the complete 
sim cluster on PAC-12I (middle), alongside an isolated standard of SD8 
(bottom), are shown on the left side. Molecular weights were confirmed by 
high-resolution mass spectrometry (parent peaks are indicated). Cultures 
were grown for 6 days at 30 °C in production medium. A close-up of the total 
ion chromatogram (TIC) for 7-oxo-SD8 (top) and SD8 (bottom) is shown on 
the right side. 
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Figure 4.2  
Absorbance spectra of simocyclinones.  
The absorbance spectra of (A) SD8 and (B) 7-oxo-SD8 are shown with 
indicated wavelength of absorbance maxima. Compounds were dissolved in 
methanol (50 μg/mL) and were analysed by HPLC-UV at pH 7 as described 
(see chapter 2.9.4). The absorbance spectra of both compounds were 
extracted and compared at respective retention times. The extinction 
coefficient (ε) at 340 nm was 52,400 M-1 cm-1 for SD8 and 56,600 M-1 cm-1 
for 7-oxo-SD8 using an Agilent 1200 series instrument with a cell path length 
of 10 mm at 50 μM sample concentration. In comparison, the extinction 
coefficient of NADH and NADPH is 6,220 M-1 cm-1 at 340 nm. 
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The molecular formula of the new compound was determined using high 
resolution mass spectrometry which confirmed it was missing two hydrogen 
atoms (m/z (ESI) for C46H40ClNO18: calculated 930.2006, observed 
930.2009, Δ = 0.3 ppm [M+H]+) compared to SD8 (m/z (ESI) for 
C46H42ClNO18: calculated 932.2163, observed 932.2156, Δ = -0.8 ppm 
[M+H]+) (Figure 4.1). MS/MS analysis revealed similar fragmentation 
patterns for the new compound and SD8, with all ion fragments containing 
the angucyclic polyketide moiety having m/z ratios reduced by 2 Da 
compared to SD8. Notably, the ion fragment for the angucyclinone itself, 
which was only detectable at low abundance in the SD8 spectra, was one of 
the most abundant peaks for the new compound (Figure 4.3). 
I analysed the structure of the new compound by one-dimensional (1H-NMR 
and 13C-NMR) and two-dimensional (COSY, TOCSY, HSQC and HMBC) 
NMR spectroscopy techniques. Signals from hydroxyl groups were 
determined by comparing the proton NMR spectra before and after addition 
of 5 μL deuterated water (D2O) to the sample, which sequesters the signals 
of exchangeable hydrogens. Full NMR spectra can be found at the end of 
this chapter (Figure 4.9-4.14). Examination of the NMR spectra suggested 
the new molecule was structurally similar to SD8. However, the signal for the 
H-6 proton was shifted downfield 0.4 ppm and no signal could be observed 
for the H-7 proton consistent with a structural change in the angucyclic 
polyketide (Figure 4.4, Figure 4.9 and Table 4.1). Further analysis of 
proton-proton and proton-carbon correlations from two-dimensional NMR 
data (COSY, TOCSY, HSQC and HMBC) enabled me to determine the 
position of the structural change in the new molecule (Figure 4.5 and Figure 
4.6 and Figure 4.10-4.13). I confirmed appropriate proton-proton correlations 
for H-5 and H-6 which were supported by relevant proton-carbon 
correlations. In addition, I identified a signal shifted downfield for C-7 in the 
13C spectrum from 63.5 ppm to 194.9 ppm typical for a carbonyl group 
(Figure 4.14 and Table 4.2) and cross-peaks to a C-7 resonance could be 
identified in the HMBC experiments (Figure 4.5 and Figure 4.12).  
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Figure 4.3  
High resolution tandem mass spectra for SD8 and 7-oxo-SD8.  
Fragmentation patterns are shown for the sodium adducts of (A) SD8 and (B) 
7-oxo-SD8. Selected fragments are highlighted, consistent with the mass 
difference of 2 Da being located in the angucyclinone. 
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B 
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Figure 4.4  
Numbering of carbon atoms in 7-oxo-SD8 for NMR spectroscopy.  
Numbering of atoms was adopted from structural determination of SD8 for 
comparison (see Table 4.1 and Table 4.2). The carbonyl group at position 7 
in the angucyclinone is highlighted in red (Holzenkampfer et al., 2002).  
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Table 4.1  
1H NMR data (700 MHz) for 7-oxo-SD8 in d6-DMSO.  
Data for SD8 were taken from (Holzenkampfer et al., 2002) for comparison. 
(1) Due to solvent overlap and poor resolution only a doublet observed. 
(2) Due to overlap with 4’-H signal could not extract J value. 
 
1H NMR SD8   7-oxo-SD8   
Proton(s) δH (ppm) δH (J in Hz) δH (ppm) δH (J in Hz) 
6’-CH3 1.16 d, 6.0 1.19 d, 6.02 
2’-CH2 (a) 1.55 ddd, 11.5, 11.5, 11.5 (ax) 1.59 dd, 11.73, 11.11 
13-CH3 1.81 s 1.86 s 
5-H (a) 1.91 ddd, 13.5, 7.5, 1.0 1.92 dd, 14.59, 5.09 
5-H (b) 1.98 m 2.08 m 
8’-CH3 2.01 s 2.03 s 
4-CH2 (a) 2.23 d, 19.0 2.38 d, 19.32 
2’-CH2 (b) 2.42 ddd, 1.0, 4.5, 11.5 (eq) 2.47 d, 5.65 
(1) 
4-CH2 (b) 2.70 d, 19.0 2.64 d, 19.32 
5’-H 3.78 dq, 6.0, 9.0 (ax) 3.87 dq, 6.09, 15.50 
6-H 4.42 dd, 7.5, 7.5 4.82 m (2) 
4’-H 4.74 dd, 9.0, 9.0 (ax) 4.77 dd, 9.41, 9.41 
OH (a) 4.82 --- --- --- 
1’-H 4.96 dd, <1, 11.5 (ax) 5.05 dd, 0.94, 11.48 
3’-H 5.18 ddd, 4.5, 9.0, 11.5 (ax) 5.23 m 
12b-OH 5.27 n/a 5.88 s 
6-OH 5.58 n/a 5.43 d, 7.78 
7-H 5.75 s --- --- 
2-H 5.90 s 5.93 q, 1.16 (2J) 
2’’-H 6.00 d, 15.0 6.03 d, 15.06 
9’’-H 6.59 d, 15.0 6.58 d, 15.18 
4’’-H 6.61-6.73 m 6.60-6.77 m 
7’’-H 6.61-6.73 m 6.60-6.77 m 
5’’-H 6.79-6.88 m 6.80-6.92 m 
6’’-H 6.79-6.88 m 6.80-6.92 m 
8’’-H 7.23 m/ dd, 15.0, 11.0 7.23 m 
14’’-H 7.23 m 7.23 m 
15’’-H 7.23 m 7.23 m 
3’’-H 7.26 dd, 15.0, 11.0 7.23 m 
11-H 7.33 d, 8.0 7.58 d, 7.91 
10-H 7.45 d, 8.0 7.93 d, 8.03 
OH (b) 9.58 n/a 9.81 s 
OH (c) 9.85 n/a 10.31 s 
NH 11.3 n/a 11.98 s 
13’’-OH 12.6 n/a 12.61 s 
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Table 4.2  
13C NMR data (700 MHz) for 7-oxo-SD8 in d6-DMSO.  
Data for SD8 were taken from (Holzenkampfer et al., 2002) for comparison. 
13C NMR   SD8 7-oxo-SD8 13C-labelled 7-oxo-SD8 
position carbon δC (ppm) δC (ppm) δC (ppm) δC (J in Hz) 13C-enrichment peak coupling * 
6’ CH3 17.70 18.21 17.73 --- --- -  
8’ CH3 20.50 21.07 20.60 29.75 yes - 7' 
13 CH3 23.10 23.78 23.31 16.81 yes - 3 
2’ CH2 36.50 36.74 36.28 --- --- +  
5 CH2 38.70 40.49 40.10 n/a --- - n/a 
(2) 
4 CH2 42.70 44.48 44.00 16.26 yes + 4a 
6 CH 62.60 61.66 61.19 15.40 yes - n/a (2) 
7 CH or C 63.50 194.87 194.40 27.10 yes + 6a 
6a C 65.40 64.20 63.72 27.18 yes + 7 
12a C 65.70 (1) 65.40 64.95 26.87 yes + 12 
1’ CH 70.60 70.50 71.38 --- --- -  
3’ CH 71.60 71.85 71.38 --- --- -  
4a C 72.00 72.73 72.25 16.30 yes + 4 
5’ CH 73.10 73.64 73.17 --- --- -  
4’ CH 74.10 74.43 73.95 --- --- -  
12b C 75.10 76.31 75.84 18.86 yes + 1 
12’’ C 105.30 105.47 104.67 n/a --- +  
17’’ C 114.40 113.77 114.96 --- --- +  
13a’’ C 115.30 115.85 115.43 --- --- +  
131 
13C NMR   SD8 7-oxo-SD8 13C-labelled 7-oxo-SD8 
position carbon δC (ppm) δC (ppm) δC (ppm) δC (J in Hz) 13C-enrichment peak coupling * 
15’’ CH 115.80 116.44 115.92 --- --- -  
11 CH 118.10 117.14 119.37 30.05 yes - 11a 
14’’ CH 119.60 119.85 n/a --- --- -  
2’’ CH 121.50 120.01 121.40 38.43 yes - 1'' 
2 CH 121.80 120.62 121.80 29.22 yes (3) - --- (3) 
9’’ CH 124.60 122.69 121.78 32.52 yes - 10'' 
7a C 124.80 125.69 125.39 32.23 yes - 8 
10 CH 125.80 130.44 129.96 29.22 yes + 9 
11a C 127.60 132.50 132.03 30.02 yes - 11 
4’’ CH 133.10 133.58 133.07 26.00 yes - 3'' 
9 C 134.20 134.54 136.96 29.22 yes + 10 
7’’ CH 134.40 135.10 134.67 26.74 yes - 8'' 
6’’ CH 139.00 137.43 138.93 25.64 yes + 5'' 
5’’ CH 140.20 139.51 140.83 25.64 yes - 6'' 
8’’ CH 141.10 140.96 140.48 26.74 yes - 7'' 
3’’ CH 144.40 141.40 144.69 26.00 yes - 4'' 
17a’’ C 145.60 145.14 145.84 --- --- +  
16’’ C 151.00 146.22 150.85 --- --- +  
8 C 152.60 151.41 156.73 32.23 yes + 7a 
3 C 157.70 157.74 158.68 16.97 yes + 14 
11’’ CO 158.70 159.15 159.05 --- --- +  
13’’ C 185.70 159.45 159.05 --- --- +  
1’’ CO 165.20 165.80 165.33 38.40 yes + 2’’ 
132 
13C NMR   SD8 7-oxo-SD8 13C-labelled 7-oxo-SD8 
position carbon δC (ppm) δC (ppm) δC (ppm) δC (J in Hz) 13C-enrichment peak coupling * 
10’’ CO 166.10 166.55 165.97 32.52 yes + 9’’ 
7’ CO 169.60 170.27 169.81 29.75 yes + 8’ 
12 CO 190.00 188.47 188.00 26.87 yes + 12a 
1 CO 196.00 195.52 195.06 18.86 yes + 12b 
* Coupling carbon atom. 
(1) Only visible by feeding of [1,3-13C2] malonic acid. 
(2) Overlap of solvent signal with signal for C-5. 
(3) 13C-enrichment but no coupling partner. 
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Figure 4.5  
Selected HMBC correlations for the angucyclic polyketide moiety of 
SD8 and of the new simocyclinone intermediate 7-oxo-SD8.  
Key correlations for the C-7 position are depicted in red. R includes the 
deoxysugar, tetraene linker and the aminocoumarin. 
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Figure 4.6  
Differences in 2D NMR spectra of SD8 and 7-oxo-SD8.  
Shifted peaks and cross-peaks are shown of SD8 (red) and 7-oxo-SD8 (blue) 
from 2D NMR experiments (correlated spectroscopy and heteronuclear 
single quantum coherence). Projections of proton and carbon signals of 
7-oxo-SD8 are indicated for each map. These are entirely consistent with the 
introduction of a carbonyl group at the C-7 position. 
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Because signals for ternary carbons without direct hydrogen contacts are 
generally very weak, I decided to confirm the C-7 carbonyl carbon by stable 
isotope labelling with carbon 13 (13C). Therefore, I grew the simC7 mutant 
strain in presence of [1,2-13C2] acetate for 6 days and isolated the new 
compound by extraction with ethyl acetate (~285 mg with ~12% compound), 
dissolving the dried extract in acetone, and purification of the acetone-
soluble fraction by preparative HPLC. After freeze-drying, I obtained 26 mg 
of the 13C-labelled 7-oxo-SD8 (yield ~78%; purity >99%). According to the 
proposed biosynthetic pathway and previous labelling experiments I 
expected incorporation of labelled acetate into 31 carbons of the 
angucyclinone, the tetraene, and the acetyl group attached to the 
deoxysugar (Holzenkampfer and Zeeck, 2002). The remaining 15 carbons of 
the aminocoumarin and the deoxysugar would not be labelled because their 
carbon skeletons originate from amino acid and sugar metabolism, 
respectively. Indeed, the feeding experiment resulted in ~30% incorporation 
of 13C-labelled acetate based on an observed average mass shift of ~10 m/z 
(detectable mass shift of up to 18-19 m/z) from LC-MS analysis (Figure 4.7). 
As expected, NMR analysis revealed incorporation of 13C-labelled acetate 
into the angucyclinone, the tetraene, and the acetyl group attached to the 
deoxysugar but no incorporation into the deoxysugar itself or the 
aminocoumarin (Figure 4.8a and Table 4.2). Importantly, the NMR data 
confirmed the presence of a carbonyl group at position 7 in the 
angucyclinone. Identical carbon-carbon coupling constants were observed 
for the shifted signal peak of C-7 and the signal peak for C-6a (Figure 4.8b, 
Figure 4.15 and Table 4.2). 
In conclusion, I have shown that the product of the simC7 mutant had a 
carbonyl group instead of a hydroxyl group at position C-7 in the 
angucyclinone. The new simocyclinone intermediate was named 
7-oxo-simocyclinone D8 (7-oxo-SD8) according to the structural change 
compared to SD8 (Figure 4.4 and Figure 4.5). 
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Figure 4.7  
Isotope patters of (A) purified 7-oxo-SD8 and (B) 13C-enriched 
7-oxo-SD8.  
Data were extracted from the total ion chromatogram at 20 min retention time 
after LC-MS analysis as described. The parent ion of proton and sodium 
adducts are indicated in red for unlabelled 7-oxo-SD8. 
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Figure 4.8  
Structural validation of 13C-labelled 7-oxo-SD8.  
(A) Incorporation pattern of [1,2-13C2] acetate (arrows) into 7-oxo-SD8. The 
coupling constant for the carbon at position 5 could not be identified due to 
signal overlap with the solvent DMSO-d6 (red circle). No coupling partner 
could be identified for the carbon at position 2. (B) 13C-NMR spectra of 
unlabelled (red) and labelled (blue) 7-oxo-SD8. The carbon signals of 
unlabelled and labelled 7-oxo-SD8 have identical chemical shifts. 
Incorporation of [1,2-13C2]-acetate as shown in (A) causes coupling of intact 
acetate units, resulting in identical coupling constants for the respective two 
neighbouring carbons. Identical coupling constants were observed for the 
carbonyl group at position 7 and the ternary carbon at position 6a (see Table 
4.2).  
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It is worth mentioning that the absence of a coupling partner for carbon C-2 
in the angucyclic polyketide supports a decarboxylation event at this position, 
which is most likely carried out by the predicted decarboxylase SimA12 
(Figure 4.8a, Figure 4.15 and Table 4.2). Although incorporation of 13C-
labelled precursors has been done for SD8, the use of [1,3-13C2] malonic 
acid and [2-13C] malonic acid did not allow any conclusion about the 
decarboxylation side due to missing information about carbon-carbon 
coupling and the direct use of acetate was not possible as it inhibited 
simocyclinone production in S. antibioticus Tü6040 (Holzenkampfer et al., 
2002). The incorporation pattern of 13C-labelled acetate into the 
angucyclinone of simocyclinones was identical to the incorporation pattern 
observed for landomycin A (Weber et al., 1994) and urdamycin A (Rohr et 
al., 1989) suggesting a common biosynthetic pathway for the formation of the 
benz[α]anthracene backbone. 
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Figure 4.9  
1H NMR spectrum of 7-oxo-SD8. 
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Figure 4.10  
Correlated spectroscopy (COSY) spectrum of 7-oxo-SD8. 
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Figure 4.11  
Total correlated spectroscopy (TOCSY) spectrum of 7-oxo-SD8. 
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Figure 4.12  
Heteronuclear multiple bond correlation (HMBC) spectrum of 
7-oxo-SD8. 
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Figure 4.13  
Heteronuclear single quantum coherence (HSQC) spectrum of 
7-oxo-SD8. 
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Figure 4.14  
Attached proton test (APT) 13C-NMR spectrum of 7-oxo-SD8. 
The boxes below the NMR spectrum show a close-up of (A) the region for 
the 7-carbonyl group in 7-oxo-SD8 and (B) the absence of a signal for the 
7-CH group present in SD8. 
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Figure 4.15  
Attached proton test (APT) 13C-NMR spectrum of 7-oxo-SD8 after 13C-
enrichment with [1,2-13C2]-acetate. 
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4.3 Complementation of simC7 mutant 
To determine if the simC7 phenotype was caused solely by loss of SimC7 
function, I complemented the mutant with an in trans copy of the gene. I 
cloned the simC7 gene into pGM1190 and introduced the construct into the 
simC7 mutant (S. coelicolor M1152ex1::12IΔC7). Although the 
complemented strain was able to produce SD8, the yield was very low 
(Figure 4.16), probably because the simC7 gene lacked a promoter to drive 
its expression. simC7 is the last gene in a putative seven-gene operon 
ranging from simB7 to simC7 suggests that the putative native promoter of 
simC7 is upstream to simB7 (Figure 3.1). Therefore, I created a second 
construct and drove expression of simC7 from its putative native promoter by 
fusing the simC7 gene directly to an ~400-bp fragment spanning the 
intergenic region upstream of simB7. I cloned this fusion into the vector 
pGM1190 and introduced this construct into the simC7 mutant, which 
restored SD8 production to the simC7 mutant (Figure 4.16).  
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Figure 4.16  
Complementation of simC7 deletion mutant.  
LC-MS-UV analysis of simocyclinones confirmed the complementation of 
simC7 in the heterologous host S. coelicolor M1152ex1 carrying the mutated 
sim cluster without simC7. Chromatograms (200-700 nm) are shown of 
culture extracts from complemented strains with simC7 under control of the 
tipA promoter (top) or its putative natural promoter (middle) compared to 
standards of SD8 and 7-oxo-SD8 (bottom). Molecular weights were 
confirmed by high-resolution mass spectrometry (not shown). Cultures were 
grown for 6 days at 30 °C in production medium. 
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4.4 SimC7 is an NAD(P)H-dependent ketoreductase that acts on 
the angucyclic polyketide 
The fact that the simC7 mutant produced 7-oxo-SD8 suggested that SimC7 
is a ketoreductase involved in biosynthesis of the angucyclic polyketide and 
is not a dehydratase that acts during formation of the tetraene linker as 
previously proposed (Trefzer et al., 2002). To test this hypothesis, I 
overexpressed an N-terminally His-tagged version of SimC7 in E. coli and 
assayed the purified recombinant protein for its ability to use 7-oxo-SD8 as a 
substrate. Both the substrate and the product of the reaction have strong 
chromophores with only minor differences in their absorbance spectra, and 
because their spectra also overlap those of NAD(P)+/NAD(P)H, it was not 
possible to assay SimC7 using spectrophotometric methods. Instead, I 
followed the reaction by HPLC-UV (with SD8 as a standard) and found that 
SimC7 readily converted 7-oxo-SD8 into SD8 (Figure 4.17b). SimC7 was 
able to use NADH or NADPH for the reduction (Figure 4.17b) but showed a 
preference for NADPH (data not shown). Although I tried to measure the 
substrate conversion in presence of NADPH, the reaction was almost 
completed after 30 seconds, which did not allow me to collect a sufficient 
amount of samples for kinetic analysis. Reduced concentrations of SimC7 
during the assays did not improve the measurements and the reaction was 
too slow below an enzyme concentration of 10 nM. It was also possible to 
assay the reaction in the reverse direction, following the oxidation of SD8 to 
7-oxo-SD8 by SimC7 (Figure 4.17c). This reaction was much slower and 
required a very high concentration of the NAD+ cofactor (300 mM). In all 
cases, the identity of the reaction product was confirmed by tandem mass 
spectrometry. 
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Figure 4.17  
Ketoreductase activity of SimC7.  
(A) SimC7 mediates conversion of the novel simocyclinone intermediate 
7-oxo-SD8 (1) into SD8 (2). (B) NAD(P)H-dependent conversion of 
7-oxo-SD8 into SD8 and (C) NAD(P)+-dependent conversion of SD8 into 
7-oxo-SD8, monitored by reversed-phase HPLC. Samples were incubated 
for 1 h at room temperature using the substrate 7-oxo-SD8 (100 μM), the 
cofactor NADH (0.3 mM) or NAD+ (300 mM) and the enzyme SimC7 
(500 nM) in HEPES buffer (50 mM, pH 7.2). Reactions (250 μL) were 
stopped by quenching in methanol (1:1) and heat denaturation for 10 min at 
100 °C. 
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4.5 The C-7 hydroxyl group is required for the antibiotic activity 
of simocyclinone 
The activity of 7-oxo-SD8 was tested in vivo and in vitro. Wild-type E. coli 
and other Gram-negative bacteria are resistant to simocyclinones because 
the compounds cannot penetrate the outer membrane (Schimana et al., 
2000). Therefore, I used an E. coli strain (NR698), which is sensitive to 
simocyclinones due to an in-frame deletion in the imp (increased membrane 
permeability) gene (Ruiz et al., 2005). The MIC for SD8 was 0.3 μM. In 
contrast, strain NR698 grew in presence of 7-oxo-SD8 at concentrations up 
to 17.5 μM, an ~60-fold increase in MIC. In comparison, a wild type E. coli 
strain (ATCC 25922™), which is naturally resistant against simocyclinones, 
had an increased MIC for SD8 of ~87.5 μM and grew unimpaired in the 
presence of high levels of 7-oxo-SD8 (MIC >100 μM). The contrasting 
antibiotic activities of SD8 and 7-oxo-SD8 against whole cells suggested that 
the oxidation state of the oxygen at the C-7 position might be important for its 
ability to block DNA supercoiling by DNA gyrase. To answer this question, I 
analysed the activity of SD8 and 7-oxo-SD8 as DNA gyrase inhibitors in vitro. 
In line with previous studies (Edwards et al., 2009; Oppegard et al., 2009; Alt 
et al., 2011), I found that SD8 inhibited supercoiling by DNA gyrase with 
IC50 = 0.1-0.5 μM (Figure 4.18a). In contrast, 7-oxo-SD8 was almost 3 
orders of magnitude less active (IC50 = 50-100 μM) (Figure 4.18a). The 
fluoroquinolone ciprofloxacin links DNA gyrase to its substrate by stabilizing 
the DNA-protein cleavage complex, leading to a characteristic “cleavage 
band” on gels (Figure 4.18b) (Collin et al., 2011). The presence of SD8 
prevents the enzyme from binding to its substrate and thereby blocks DNA 
cleavage by gyrase (Edwards et al., 2009). I tested the ability of 7-oxo-SD8 
to abrogate the ciprofloxacin-stimulated cleavage of DNA by gyrase, using 
SD8 as a control (Figure 4.18b) (Flatman et al., 2005). As shown previously 
(Edwards et al., 2009), SD8 prevented DNA cleavage at low concentrations 
(e.g., 0.5 μM). In contrast, much higher concentrations of 7-oxo-SD8 
(>10 μM) were required for inhibition of DNA cleavage by gyrase (Figure 
4.18b). 
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Figure 4.18  
Inhibition of DNA gyrase by 7-oxo-SD8.  
(A) Supercoiling and (B) cleavage relaxation assays with DNA gyrase in the 
presence of 7-oxo-SD8 or SD8. The reaction mixtures contained E. coli DNA 
gyrase and varying concentrations of either SD8 or 7-oxo-SD8. For 
relaxation assays, the mixtures were incubated without ATP and with 
ciprofloxacin (1 μM). 
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To investigate the binding of 7-oxo-SD8 to GyrA, I used surface plasmon 
resonance as described previously (Edwards et al., 2009). Therefore, the 
GyrA protein was immobilised on a CM5 sensor chip by amine coupling via 
reactive esters, which makes use of the N-terminus and ε-amino groups of 
lysine residues of the protein. I found that SD8 bound to the GyrA N-terminal 
domain with a similar affinity to that reported previously, but that only weak, 
non-specific binding could be seen for the 7-oxo analog (data not shown). 
Taken together, these data suggest that 7-oxo-SD8 binds gyrase 2-3 orders 
of magnitude more weakly than SD8. MGD8N2A is a simocyclinone analog 
(generated by chemical hydrolysis of SD8) that lacks the angucyclic 
polyketide and the deoxysugar (Figure 4.19). This analog has been tested 
previously and found to have greatly reduced activity against DNA gyrase 
(IC50 = 50 μM) in comparison to SD8 (IC50 = 0.1–0.6 μM) (Edwards et al., 
2009). I repeated these experiments with MGD8N2A and obtained a similar 
value (IC50 = 25 μM). Thus, comparing the IC50 values for 7-oxo-SD8 and 
MGD8N2A, it is clear that the presence of a carbonyl group at the C-7 
position has a similarly negative effect on the activity of simocyclinone as 
does complete loss of the angucyclinone. 
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Figure 4.19   
Chemical structures of SD8, 7-oxo-SD8 and MGD8N2A. 
The structural difference between SD8 and 7-oxo-SD8 at position C-7 is 
highlighted in red.   
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4.6 Discussion 
To examine the prediction that SimC7 is a dehydratase involved in the 
biosynthesis of the tetraene linker, the ~72-kb sim gene cluster was isolated 
on a single PAC clone and simocyclinones were expressed heterologously in 
an S. coelicolor strain engineered for improved antibiotic production. Deletion 
of simC7 from the PAC clone resulted in the production of a novel 
simocyclinone, 7-oxo-SD8, which unexpectedly carried a normal tetraene 
linker but was altered in the angucyclinone moiety. I went on to demonstrate 
that SimC7 is an NAD(P)H-dependent ketoreductase that converts 
7-oxo-SD8 into SD8 and that reduction of the keto group, catalysed by 
SimC7, is essential for the antibiotic activity of simocyclinone. 
The biochemical function of SimC7  
SimC7 was proposed to be a dehydratase involved in the biosynthesis of the 
tetraene linker (Trefzer et al., 2002), but I have demonstrated that SimC7 is 
actually an NAD(P)H-dependent ketoreductase that reduces a carbonyl 
group at the C-7 position of the angucyclinone moiety. The fermentation 
product of the simC7 mutant, 7-oxo-SD8, was almost inactive as a DNA 
gyrase inhibitor, showing that reduction of the 7-oxo functional group by the 
ketoreductase activity of SimC7 is essential for the biological function of 
simocyclinones. Although SimC7 readily converts 7-oxo-SD8 into SD8, 
synthesis of the angucyclic polyketide is normally completed before it is 
linked to the D-olivose sugar and the other moieties of simocyclinone 
(Schimana et al., 2001). This means that the natural substrate of SimC7 
would be an A-group intermediate (i.e., one having only the angucyclic 
polyketide moiety) carrying a C-7 carbonyl. This species was detected 
neither in the native producer S. antibioticus (Schimana et al., 2001; Galm et 
al., 2002; Trefzer et al., 2002) nor in the heterologous host carrying the wild-
type sim cluster, but as expected, a species with the appropriate mass was 
detected among the intermediates made by the simC7 mutant. Having 
155 
determined the true function of SimC7, it remains unclear how the tetraene 
linker of simocyclinone is assembled and how dehydration takes place.  
SimC7 (30 kDa; 284 amino acids) is a member of the SDR family, one of the 
largest protein superfamilies, having more than 120,000 representatives in 
the databases. SDR proteins are diverse, with low overall amino acid 
sequence identity (typically 20-30% in pairwise comparisons), and they are 
principally characterized by the presence of a predicted pyridine nucleotide-
binding Rossmann fold, comprising a parallel β-sheet flanked by three 
helices on each side. SDR proteins also have diverse biochemical activities, 
including acting as dehydratases, reductases, dehydrogenases, 
decarboxylases, and epimerases (Kallberg et al., 2010; Persson and 
Kallberg, 2013). Despite its function as an angucyclinone ketoreductase, 
based on sequence identity, SimC7 seems to be most similar to various SDR 
sugar epimerases, and SimC7 secondary and tertiary structure predictions 
using the Phyre2 server (Kelley and Sternberg, 2009; Kelley et al., 2015) 
also show highest similarity to sugar-modifying enzymes, such as 
epimerases, reductases, and dehydratases. No close homologs in the 
databases are known to function as ketoreductases. Although none is closely 
related to SimC7, several SDR ketoreductases have been identified that act 
on polyketides. These include SDR proteins that reduce the carbonyl group 
at position C-9 in the biosynthetic pathways for jadomycin (JadE), 
actinorhodin (ActKR), and hedamycin (HedKR) (Kulowski et al., 1999; 
Korman et al., 2008; Javidpour et al., 2011a) and SDR proteins that reduce 
the carbonyl group at position C-6 in the biosynthetic pathways for 
landomycins (LanV) and urdamycins (UrdMred) (Paananen et al., 2013; 
Patrikainen et al., 2014). Close homologs of these enzymes are encoded in 
the sim gene cluster, raising the possibility that SimA6 and SimA9 function to 
reduce the angucyclinone C-10 and C-6 carbonyl groups, respectively, 
during the biosynthesis of simocyclinone.  
SimC7 function is vital for producing simocyclinones with antibiotic 
activity 
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Why does such a small structural change render 7-oxo-SD8 effectively 
inactive as a DNA gyrase inhibitor? The crystal structure of the GyrA–SD8 
complex revealed how DNA gyrase binds the angucyclinone (Hearnshaw et 
al., 2014) (Figure 1.8 and Figure 4.20). The C-6 hydroxyl group makes a 
hydrogen bond to Met120, the C-7 hydroxyl group makes hydrogen bonds to 
Pro79 and Arg121 (via a water molecule), and the C-8 hydroxyl group makes 
hydrogen bonds to His80 and Arg121. One speculative possibility is that the 
presence of a C-7 carbonyl group in 7-oxo-SD8 leads to the formation of an 
intramolecular hydrogen bond with the neighbouring C-8 hydroxyl group, 
thus simultaneously breaking contacts with His80 and a highly coordinated 
water molecule held in place by Pro79 and Arg121 (Figure 4.20). His80 in 
particular seems to play a crucial role in binding simocyclinone, as the SD8 
IC50 is increased 230-fold when this residue is mutated to alanine (Edwards 
et al., 2009). In addition, the presence of a carbonyl group at C-7 will alter 
the conformation of the angucyclic polyketide, which may affect other 
bonding interactions with GyrA. Thus, the introduction of a carbonyl group at 
position C-7 is likely to break several hydrogen bonds that secure the 
angucyclic polyketide in its binding pocket in addition to the loss of the above 
mentioned hydrogen bond between the C-7 hydroxyl group and Pro79 and 
Arg121 via water molecule.  
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Figure 4.20  
The angucyclinone binding pocket in GyrA.  
SD8 is contacted by residues from both GyrA subunits; those from one 
subunit are shown in red and those from the other subunit are shown in blue. 
For clarity, all hydrogens have been omitted. Interactions were identified from 
the crystal structure of the GyrA–SD8 complex (PDB accession number 
4CKL) (Hearnshaw et al., 2014). 
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5.1 Introduction 
Angucyclin(on)es form the largest group of polycyclic aromatic polyketides, 
many with anticancer and antibacterial activities (Kharel et al., 2012). They 
share a polyketide-derived tetracyclic benz[α]anthracene carbon skeleton, 
but numerous structures are generated by a range of tailoring reactions, 
including O- or C-linked deoxysugar glycosylation to form angucyclines (Rohr 
and Thiericke, 1992). In general, these tailoring enzymes are not well 
understood. An important challenge, therefore, is to define the step catalysed 
by each enzyme, and to determine their reaction mechanisms. This 
knowledge is particularly relevant to the rational engineering of 
angucyclin(on)e biosynthetic pathways for novel therapeutics. 
The angucyclinone moiety of SD8 is synthesised by a type II polyketide 
synthase (PKS) (SimA1-3) and multiple tailoring enzymes (SimA4-13, 
SimC7) that catalyse cyclisation, aromatisation, oxidation and reduction 
reactions. In recent years, several ketoreductases of the short-chain 
dehydrogenase/reductase (SDR) family have been characterised that act on 
angucyclinones or related polyketides. The reduction of carbonyl groups at 
the C-6 and C-9 positions of polyketides have been functionally 
characterised and the crystal structures of the corresponding SDR 
ketoreductases (KRs) have revealed their catalytic reaction mechanisms 
(Figure 5.1) and the factors that determine their stereoselectivity. The 
ketoreductases LanV and UrdMred act on the C-6 carbonyl group of 
angucyclic polyketides from the landomycin and urdamycin pathways 
(Paananen et al., 2013; Patrikainen et al., 2014). In contrast, the 
ketoreductases ActKR and HedKR act on the C-9 carbonyl group of early 
intermediates in the actinorhodin and hedamycin polyketide pathways 
(Korman et al., 2004; Korman et al., 2008; Javidpour et al., 2011a; Javidpour 
et al., 2011b; Javidpour et al., 2013). The LanV, UrdMred, ActKR and HedKR 
structures revealed the catalytic Ser-Tyr-Lys triad characteristic of SDR 
enzymes, where the latter two residues form a YxxxK motif. In these 
classical SDR proteins the conserved active site tyrosine serves as central 
acid-base catalyst that donates a proton to the substrate (Figure 5.1). The 
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adjacent lysine residue lowers the pKa of the tyrosine hydroxyl group and 
often contributes directly to a proton relay mechanism, and the hydroxyl 
group of the serine stabilises and polarises the carbonyl group of the 
substrate (Kavanagh et al., 2008). 
At the sequence level, SimC7 shares little similarity with any characterised 
ketoreductase, even with functionally analogous polyketide ketoreductases. 
The striking differences between the amino acid sequence of SimC7 and 
those of the polyketide ketoreductases HedKR, ActKR, LanV and UrdMred 
suggested that SimC7 might have a novel catalytic mechanism. To 
investigate this possibility, I solved several crystal structures of SimC7. 
Here I present crystal structures of SimC7 alone (apo), in complex with 
NADP+, and in a ternary complex with both NADP+ and 7-oxo-SD8, 
determined to 1.6 Å, 1.95 Å and 1.2 Å resolution, respectively. My results 
show that SimC7 is structurally distinct from previously characterised 
polyketide ketoreductases and, importantly, lacks the canonical SDR Ser-
Tyr-Lys catalytic triad (Oppermann et al., 2003; Kavanagh et al., 2008; 
Kallberg et al., 2010; Persson and Kallberg, 2013). Based on the atomic-
resolution structure of the substrate-complex and active site mutations I 
propose that SimC7 catalyses a substrate-assisted, two-step reaction for 
reduction of the C-7 carbonyl group involving an unusual phenolate 
intermediate. 
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Figure 5.1  
Comparison of proposed proton relay mechanisms for classic SDR 
ketoreductases.  
The reduction of carbonyl groups by SDR ketoreductases follows a common 
mechanism that involves a characteristic catalytic triad (Ser-Tyr-Lys). The 
active site tyrosine (blue) acts as acid-base catalyst that transfers a proton to 
the substrate. The carbonyl group is reduced via direct hydride transfer from 
the cofactor NADPH followed by a proton relay system as indicated (black 
arrows). Hydrogen bonds are dashed lines. The proton of lysine is 
replenished by adjacent water molecules. 
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5.2 Optimisation of crystal conditions for SimC7 
Recombinant SimC7 crystallises preferentially in the presence of organic 
acids at a pH range below (pH 3.8-4.8) or above (pH 6.5-9) its predicted 
isoelectric point (pI = 5.96) (see Materials and Methods, chapter 2.7.1). 
Therefore, I tested the effect on crystal growth of various monobasic acids 
(formic acid, acetic acid, propionic acid, caproic acid), dibasic acids (oxalic 
acid, malic acid), and tribasic acids (citric acid). Best results were achieved in 
the presence of 0.1 M acetic acid (pH 4.8), followed by formic acid and 
propionic acid under equivalent conditions. Diffraction data for the trimeric 
complex of protein, cofactor and simocyclinone were of reproducibly high 
resolution in the presence of acetic acid (1.2-1.5 Å). Saturated solutions of 
neutralised citric acid (1.1-1.5 M, pH 6.5) or DL-malic acid (1.3-1.6 M, 
pH 7.0), which are structurally very similar, resulted in large crystals of 
bipyramid shape. Unfortunately, the diffraction data from crystals grown in 
the presence of citric or malic acid showed strongly increased mosaicity and 
co-crystallisations with SD8 and 7-oxo-SD8 were unsuccessful. Evaluation of 
the structural data from respective conditions revealed that the larger organic 
acids occupied the enzyme’s active site as indicated in several unrefined 
structures (data not shown), which most likely stabilized the enzyme and 
promoted crystal growth. Similar results were initially obtained for saturated 
ammonium sulphate (1.4-1.8 M) which was not considered for further 
optimisations due to the presence of salt molecules in the active site and the 
very irregular appearance of the crystals. 
In summary, low concentrations of short monobasic acids promote crystal 
growth and result in reproducibly high-resolution protein crystal structures 
(1.2-1.5 Å), whereas longer acids or high concentrations of di- or tribasic 
acids have adverse effects and occupy the substrate binding pocket of 
SimC7. 
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5.3 Overall structure of SimC7 
Several crystal structures of SimC7 were solved, including SimC7 alone 
(1.6 Å resolution), in complex with NADP+ (1.95 Å), and in a ternary complex 
with both NADP+ and 7-oxo-SD8 (1.2 Å) (Table 5.1 and Table 5.2). SimC7 is 
made up of two domains, the larger of these is the nucleotide binding domain 
that adopts a classic Rossmann fold (Rossmann et al., 1975), consisting of a 
seven-stranded parallel β-sheet (β1-6 and β9), which is flanked by three 
parallel α-helices on both sides (α1, α6, α10 and α2, α3, α4, respectively) 
(Figure 5.2a-b and Figure 5.3). The smaller substrate-binding domain, 
characteristic of the so-called ‘extended’ SDR subfamily (Kavanagh et al., 
2008), is mainly α-helical and is largely formed by two insertions in the 
nucleotide binding domain (between β6 and α6, and between β9 and α10). 
Notably, the latter insertion contains a ‘lid’ motif consisting of two anti-parallel 
α-helices (α8 and α9) that folds over the active site (Figure 5.2a-b and 
Figure 5.3). The substrate-binding domain is completed by a short helical 
segment at the C-terminus of the polypeptide chain. 
Overall all SimC7 structures are very similar (Table 5.3), with the notable 
exception of the lid motif, which displays a number of different conformations 
(Figure 5.2c and Table 5.3). Although the changes are not large (maximum 
Cα-Cα shift 5.35 Å; Table 5.3), there is a clear closure of the lid over the 
bound substrate (Figure 5.2c), suggesting a role in gating access to the 
active site and/or substrate capture. Moreover, in the ternary complex the 
underside of the lid contributes to the tight, highly hydrophobic substrate 
binding pocket (Figure 5.4 and Figure 5.5) that provides the necessary 
environment for catalysis (see below). 
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Table 5.1  
X-ray data collection and processing. 
a
 Values for the outer resolution shell are given in parentheses.  
b
 Rmerge = ∑hkl ∑i |Ii(hkl)  I(hkl)|/ ∑hkl ∑iIi(hkl).  
c 
Rmeas = ∑hkl [N/(N  1)]
1/2
 × ∑i |Ii(hkl)  I(hkl)|/ ∑hkl ∑iIi(hkl), where Ii(hkl) is the ith 
observation of reflection hkl, I(hkl) is the weighted average intensity for all observations i of 
reflection hkl and N is the number of observations of reflection hkl.  
d
 CC½ is the correlation coefficient between symmetry-related intensities taken from random 
halves of the dataset.  
Data set Binary 
SeMet 
Binary 
native 
Apo 
form 1 
Apo 
form 2 
Ternary 
complex 
Beamline I03 I03 I04-1 I04-1 I04 
Wavelength (Å) 0.9796 1.0052 0.9173 0.9173 0.9795 
Detector Pilatus 
6M 
Pilatus 
6M 
Pilatus 
6M 
Pilatus 
6M 
Pilatus  
6M 
Resolution 
range (Å)a 
51.48 – 
2.05 
(2.10 – 
2.05) 
50.74 – 
1.95 
(2.00 – 
1.95) 
53.40 – 
1.60 
(1.64 – 
1.60) 
54.88 – 
1.90 
(1.95 – 
1.90) 
47.52 – 
1.20 
(1.23 – 
1.20) 
Space Group P41212 P41212 P41212 C2 P212121 
a, b, c (Å) 51.5, 
51.5, 
213.2 
52.2, 
52.2, 
214.0 
52.4, 
52.4, 
213.6 
107.0, 
64.8, 
91.5 
51.9,  
53.7,  
102.3 
α, β, γ (°) 90.0, 
90.0, 
90.0 
90.0, 
90.0, 
90.0 
90.0, 
90.0, 
90.0 
90.0, 
105.5, 
90.0 
90.0,  
90.0,  
90.0 
Total 
observationsa 
457751 
(25343) 
563166 
(40131) 
435288 
(32092) 
336053 
(23051) 
1159483 
(81348) 
Unique 
reflectionsa 
19033 
(1335) 
22650 
(1625) 
40514 
(2936) 
47271 
(3433) 
90009 
(6590) 
Multiplicitya 24.1 
(19.0) 
24.9 
(24.7) 
10.7 
(10.9) 
7.1  
(6.7) 
12.9  
(12.3) 
Mean I/(I)a 16.5 (1.3) 18.4 (2.2) 20.0 (1.5) 13.6 (1.0) 17.5 (2.1) 
Completeness 
(%)a 
99.8 
(99.7) 
99.9 
(99.8) 
99.9 
(99.2) 
98.5 
(96.1) 
100.0 
(99.5) 
Rmerge
a,b 0.122 
(2.745) 
0.118 
(1.845) 
0.066 
(1.814) 
0.087 
(1.990) 
0.070 
(1.208) 
Rmeas
a,c 0.125 
(2.820) 
0.120 
(1.883) 
0.069 
(1.903) 
0.094 
(2.157) 
0.073 
(1.249) 
CC½
a,d 0.999 
(0.673) 
0.999 
(0.819) 
1.000 
(0.701) 
0.999 
(0.543) 
0.999 
(0.760) 
Wilson B value 
(Å2) 
45.3 34.0 21.6 34.2 11.9 
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Table 5.2  
Refinement of X-ray structures. 
Data set Binary 
native 
Apo 
form 1 
Apo 
form 2 
Ternary 
complex 
Resolution range 
(Å)a 
50.74 – 
1.95 
(2.00 – 
1.95) 
53.40 – 
1.60 
(1.64 – 
1.60) 
54.88 – 
1.90 
(1.95 – 
1.90) 
47.52 – 
1.20 
(1.23 – 
1.20) 
Reflections: 
working/freeb 
21479/1171 38504/2010 44913/2357 
85532/ 
4476 
Final Rwork
a,c 0.182 
(0.282) 
0.189 
(0.297) 
0.195 
(0.342) 
0.126 
(0.218) 
Final Rfree
a,c 0.217 
(0.316) 
0.218 
(0.303) 
0.229 
(0.348) 
0.149 
(0.230) 
Cruickshank DPI 
(Å)d 
0.139 0.087 0.150 0.032 
R.m.s. bond 
deviations (Å) 
0.010 0.010 0.009 0.010 
R.m.s. angle 
deviations () 
1.40 1.38 1.29 1.52 
No. of protein 
residues (ranges) 280 (1 to 
280) 
280 (1 to 
280) 
A chain:278 
(2-279); 
B chain 281 
(-1 to 279)* 
278 (2-279) 
No. of heterogen 
residues: cofactor/  
7-oxo/ water/ other 
1/0/104/0 0/0/167/0 0/0/202/2 1/1/324/1 
Mean B-factors: 
protein/ cofactor/  
7-oxo/ water/ other/ 
overall (Å2) 
47/46#/-
/46/-/47 
35/-/-/39/-
/35 
50/-/-
/49/58/50 
17/11/21/32
/28/19 
Ramachandran plot: 
favoured/ allowed/ 
disallowed (%)e 
98.6/1.4/0.0 99.3/0.7/0.0 98.4/1.2/0.4 99.1/0.9/0.0 
PDB code 5L3Z 5L40 5L45 5L4L 
a
 Values for the outer resolution shell are given in parentheses. 
b
 The data set was split into "working" and "free" sets consisting of 95 and 5% of the data, 
respectively. The free set was not used for refinement.  
c
 The R-factors Rwork and Rfree are calculated as follows: R = (| Fobs - Fcalc |)/| Fobs |, where 
Fobs and Fcalc are the observed and calculated structure factor amplitudes, respectively.  
d
 Diffraction precision indicator based on Rfree based as calculated by REFMAC5 
(Murshudov et al., 1997) 
e
 As calculated using MOLPROBITY (Davis et al., 2007) 
*
 Two residues were visible for the N-terminal His-tag in the B-chain. Since the numbering 
scheme was based on the wild-type sequence, these residues were labelled as “-1” and “0”. 
#
 Cofactor was refined with occupancy of 0.7.  
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Table 5.3  
Comparison of SimC7 structures. 
Pairwise superpositions of all protein structures determined herein; Root-
mean-square deviations (r.m.s.d.) were determined by LSQKAB (Kabsch, 
1976). For Apo form 2, the two molecules in the ASU were treated as 
separate models.  
* With the exception of this comparison, all the others showed the biggest 
shift in the lid region (residues 216-246 inclusive). Here the biggest shift was 
due to a trans/cis isomerisation of Pro37 (see main text for further 
explanation). The second largest shift (in the lid) is also shown. 
# N. B. Apo form 1 and Binary native SimC7 are isomorphous. 
Overall r.m.s.d. 
(Å)  
[max. Cα shift 
(Å)/ corresp. 
res.] 
Apo  
form 1 
Apo  
form 2:  
A-chain 
Apo  
form 2:  
B-chain 
Binary 
native 
Ternary 
complex 
Apo form 1 0.00 1.13 
[4.18/ 
P37]* 
[3.82/ 
A231] 
0.58 
[1.71/ 
P230] 
0.18# 
[0.40/ 
R222] 
0.84 
[3.67/ 
G227] 
Apo form 2:  
A-chain 
 0.00 0.88 
[3.15/ 
E232] 
1.10 
[3.92/A23
1] 
1.43 
[5.35/ 
G227] 
Apo form 2:  
B-chain 
  0.00 0.58 
[1.65/ 
P230] 
0.98 
[4.20/ 
G227] 
Binary native    0.00 0.83 
[3.67/ 
G227] 
Ternary 
complex 
    0.00 
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Figure 5.2  
Crystal structure of SimC7.  
S. antibioticus SimC7 displayed as (A) a molecular surface and (B) in 
cartoon representation where pale blue, beige and magenta colouration 
indicate the nucleotide binding domain, the substrate binding domain and the 
lid motif, respectively. Ligands are shown as van der Waals spheres, where 
green indicates the cofactor and yellow the 7-oxo-SD8 substrate. (C) Close-
up of the region highlighted in part (B) showing conformational changes in 
the lid between the apo (chain A, form 2; blue), the binary complex (salmon) 
and the ternary complex (magenta); only the core protein structure and 
ligands (stick representation) for the latter are shown. C-4 of the cofactor and 
C-7 of the substrate are highlighted by black spheres, showing C-7 of the 
substrate is positioned 3 Å from C-4 of the nicotinamide ring, poised for 
direct hydride transfer. (D) and (E) are orthogonal close-ups of the region 
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highlighted in part (C) showing the detail of the active site of the ternary 
complex including the Ser95-Ile108-His112 ‘catalytic triad’ residues, and 
Asn137, which is important in maintaining the syn-conformation of the 
cofactor. For clarity, the lid motif has been omitted and only the angucyclic 
polyketide moiety of the substrate is shown. Part (E) is also reproduced as a 
stereo image in Figure 5.8 (see chapter 5.7), which also shows a difference 
electron density map calculated from the final model after simulated 
annealing refinement with the substrate omitted. 
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Figure 5.3  
Structure-based sequence alignment of SimC7 with triphenylmethane 
reductase (TMR) from Citrobacter sp. and quinone oxidoreductase 
(QOR2) from E. coli.  
Conserved residues are shown in white on a red background and similar 
residues are shown in red font. Secondary structure for SimC7 is shown 
above the alignment (α for α-helix and β for β-strand, TT for β-turn and η for 
310 helix). The bars above the alignment indicate the cofactor binding domain 
(1a-c in blue) and the substrate binding domain (2a-c in orange) with black 
dots indicating residues that interact with the NADP+ cofactor. The conserved 
N-terminal cofactor-binding motif (TGxxGxxG, yellow with black frame) and 
the flexible lid (Met216 to Gly246, pink frame) are highlighted. Blue triangles 
indicate the positions equivalent to the active site triad residues in canonical 
SDR proteins. The active site residues of TMR and QOR2 are unknown. 
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Figure 5.4  
Schematic representation of the highly hydrophobic substrate binding 
pocket of SimC7.  
The substrate is bound by only one direct hydrogen bond between the C-7 
carbonyl group in the angucyclinone moiety and the side-chain hydroxyl of 
Ser95. Although Ser95 is positioned within hydrogen bonding distance to the 
C-7 carbonyl group (2.7 Å distance from oxygen to oxygen atom; ~1.7 Å 
estimated distance for the respective hydrogen bond), Ser95 is not required 
for the reaction (see chapter 5.9). This interaction may assist in positioning 
the substrate and to facilitate the reaction. Interacting residues are shown in 
black (side-chain interactions) or blue (backbone interactions). The 
hydrophobic residues shown in grey line the entrance to the substrate pocket 
but do not interact directly with the bound angucyclinone. One face of the 
pocket is formed by the cofactor itself (not shown). The electron density for 
the aminocoumarin and the adjacent part of the tetraene linker (grey), which 
protrude from the active site pocket, was not visible in the complex structure 
(see Figure 5.8a-b). 
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Figure 5.5  
SimC7 has a very constricted active site.  
Orthogonal cross-sections through a molecular surface centred on the active 
site revealing how tightly the cofactor (green) and the substrate (yellow) are 
bound in the active site pocket. For clarity, only the nicotinamide ribosyl 
moiety of the cofactor and the polyketide moiety of the substrate are shown. 
The surface of the protein is shown in pale blue and the interior of the protein 
is shown in grey. In (A) and (C) the view corresponds roughly to that shown 
in Figure 5.2d, whereas (B) and (D) show the view from above relative to 
Figure 5.2d. The ligands are depicted as van der Waals spheres in (A) and 
(B), and in stick representation in (C) and (D). In the lower panels, C-4 of the 
cofactor and C-7 of the substrate are highlighted by black spheres, showing 
C-7 of the substrate is exactly positioned 3 Å from C-4 of the nicotinamide 
ring, poised for direct hydride transfer. Active site residues that are out of the 
plane of view are not shown.   
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5.4 Oligomeric state of SimC7 
Three different crystal forms were obtained for SimC7. SimC7 alone (apo) 
crystallised in two crystal forms, form 1 [space group P41212; one molecule 
per asymmetric unit, (ASU)] and form 2 (space group C2; two molecules per 
ASU). The complex with NADP+ was isomorphous with apo form 1 (Table 
5.1). Crystal contacts within crystal form 1 and form 2 gave rise to two 
distinctly different two-fold symmetric putative dimers, both having 
substantial interfacial areas (1046 and 1246 Å2, respectively; Table 5.4). By 
contrast, SimC7 in complex with NADP+ and 7-oxo-SD8 produced a new 
crystal form (space group P212121) in which no substantial interfaces were 
present, the largest covering only 496 Å2, and this did not generate a two-
fold symmetric dimer. In parallel, size exclusion chromatography was used to 
ascertain the oligomeric states of the apo form and the binary complex in 
solution. In both cases, the protein was exclusively monomeric (Figure 5.6).  
The chromatographic and crystallographic results first appeared to be in 
conflict. Therefore, the characteristics of the potential SimC7 dimer interfaces 
were compared with the closest structural homolog of SimC7 where both 
crystallographic and experimental data supported the existence of a 
homodimer, namely triphenylmethane reductase (TMR) from Citrobacter sp. 
(PDB accession number 2VRB) (Kim et al., 2008c). Each structure was 
analysed using the PISA server (Krissinel, 2015), the ProFace server (Saha 
et al., 2006) and the Shape Complementarity program (Lawrence and 
Colman, 1993). From the various outputs, the most striking results were the 
hydrophobic P-values determined by PISA and the Residue Propensity 
Scores reported by ProFace (see legend to Table 5.4 for definitions). For the 
SimC7 structures, these results diminished the significance of both types of 
dimer, whereas for TMR, they were fully supportive of a dimer being 
biologically relevant, despite having a somewhat smaller dimer interface area 
than the values obtained for both interface types in SimC7. Indeed, 
assessing the biologically relevant assembly from interfacial area alone can 
lead to erroneous conclusions (Ponstingl et al., 2000; Bahadur et al., 2004; 
Krissinel, 2010).  
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Figure 5.6  
Size exclusion chromatography of SimC7 in the presence and absence 
of cofactor.  
The oligomeric state of SimC7 was analysed by size exclusion 
chromatography in the absence (top) or presence (middle) of cofactor. 
SimC7 eluted as monomer under all conditions tested with a retention time of 
11 min. The second peak seen at 16 min was caused by the absorbance of 
the cofactor (bottom). Conditions were equivalent to crystallisation screens 
with concentrated protein (4 mg/mL) and ten-fold molar excess of reduced 
(NADPH) or oxidised (NADP+) cofactor using a mobile phase of 20 mM 
potassium phosphate (pH 7.2) with 5% (v/v) glycerol. For analysis with 
cofactor, SimC7 was pre-incubated on ice for 4 hours. 
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Table 5.4  
Interfaces of crystallographically observed dimers.  
a
Values from the PISA server (http://www.ebi.ac.uk/pdbe/pisa/) (Krissinel, 2015).  
b 
Indicates the solvation free energy gain upon formation of the interface, in kcal mol
-1
. The value is calculated as the difference in total solvation energies of 
isolated and interfacing structures. Negative Δ
i
G corresponds to hydrophobic interfaces, or positive protein affinity. 
c 
The probability of finding a patch of the same area on the protein surface that would be more hydrophobic than the interface. Thus, lower values indicate 
specific hydrophobic patches, which are likely to be preferred in protein-protein interactions, while larger values (≥ 0.5) indicate interfaces that are non-
specific. 
d 
As calculated by the Proface server (http://resources.boseinst.ernet.in/resources/bioinfo/interface/) (Saha et al., 2006), where on average, the interfaces of 
functional homodimers (and protein-protein complexes in general) have positive values, and large crystal-packing interfaces have negative values. 
e 
Values calculated by the program SC (Lawrence and Colman, 1993), being a measure of the extent to which, on average, the normal vectors between 
closest-neighbour opposing points within the molecular interface are antiparallel. A value of 1.0 implies that the surfaces fit exactly because all such vectors 
are perfectly antiparallel, whereas values below 0.65 indicate relatively poor shape complementarity. 
* 
TMR also crystallises in another form (PDB accession number 2VRC) where the ASU contains four molecules arranged as two homodimers, both being 
equivalent to the dimer generated by the crystallographic symmetry in this crystal form. This dimer does not resemble either of the two putative SimC7 
dimers. 
‡ 
NCS = non-crystallographic symmetry. 
Structure  PDB 
code 
Space 
group 
Operator Interface 
area 
(Å2)a 
ΔiG 
(kcal/mol)a.b 
Hydrophobic 
P-valuea,c 
H-bonds/ 
salt bridgesa 
Residue 
Propensity 
Scored 
Shape 
comple-
mentaritye 
SimC7 Apo form 1  5L40 P41212 y+1,x-1,-z 1064 -9.0 0.266 10/4 -2.74 0.66 
SimC7 Apo form 2  5L45 C2 2-fold NCS‡ 1246 -11.4 0.422 5/3 -1.66 0.58 
SimC7 Binary  5L3Z P41212 y+1,x-1,-z 1032 -11.2 0.219 8/2 -3.54 0.70 
TMR Binary  2JL1* C2221 -x,y,-z+1/2 892 -13.9 0.041 6/8 1.40 0.75 
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Therefore, an oligomeric state inferred from a crystal structure should be 
treated as a hypothesis unless confirmed by experiment. Moreover, the fact 
that I observed both distinctly different dimers when the protein is in the apo 
form raises concerns about their relevance. Consequently, both of the 
dimeric assemblies observed for SimC7 are most likely crystallographic 
artefacts. 
 
5.5 Structural homologs of SimC7 
Structures annotated as SDR proteins (PFAM family PF00106) are prevalent 
in the Protein Data Bank with >600 entries (Finn et al., 2010; Berman et al., 
2014). To look for structural homologs of SimC7, I carried out a structure-
based similarity search using the DALI server (Holm and Sander, 1995) 
(Table 5.5). Strikingly, characterised angucyclinone ketoreductases ranked 
very low in the search, the closest match being LanV (Figure 5.7), which 
was the 166th ranked hit after filtering for sequence redundancy (Table 5.5). 
Instead, the two most structurally similar proteins to SimC7 were quinone 
oxidoreductase (QOR2) from Escherichia coli (PDB accession number 
2ZCV) (Kim et al., 2008b) (Figure 5.7) and triphenylmethane reductase 
(TMR) from Citrobacter sp. KCTC 18061P (PDB accession number 2VRB) 
(Kim et al., 2008c). QOR2 and TMR share with SimC7 the ability to reduce 
substrates with extensively conjugated pi-systems but have roles in the 
detoxification of xenobiotics rather than the biosynthesis of natural products. 
The majority of the closest structural homologs of known function are 
involved in sugar biosynthesis, many of them epimerases such as UDP-
hexose 4-epimerase from Thermatoga maritima (Shin et al., 2015). In 
addition, a handful of entries are annotated as non-catalytic regulatory 
proteins, such as human HSCARG (PDB accession number 2EXX) (Zheng 
et al., 2007), which is proposed to control gene expression in response to 
fluctuations in the intracellular NADP+:NADPH ratio. Also scoring highly were 
a number of reductases from plant sources, including cinnamoyl-CoA 
reductase (PDB accession number 4R1S) (Pan et al., 2014), a key enzyme 
in lignin biosynthesis.   
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Table 5.5  
Selected structural homologues of SimC7. 
Protein Source 
Biological 
unit
a
 
PDB 
code
b
 
Ligand 
bound
c
 
Resol. 
(Å) 
DALI output 
“Catalytic” 
triad 
Reference 
      Rank
d
 
Z-
score 
R.m.s.d. 
(Å) 
aligned 
residues 
Identity 
(%) 
  
SimC7 
Streptomyces 
antibioticus 
Tü6040 
Monomer 5L4L 
NADP
+
 & 
7oxo-SD8 
1.20 - - 0.00 278 100 
Ser95, Ile108, 
His112 
This work 
QOR2 
Escherichia 
coli 
Monomer 2ZCV NADP
+
 1.60 1 27.4 3.1 266 23 
Leu104, 
Leu114, His118 
(Kim et al., 
2008b) 
TMR 
Citrobacter 
sp. KCTC 
18061P 
Dimer 2JL1 NADP
+
 1.96 2 27.0 3.2 268 22 
Tyr107, 
Leu117, His121 
(Kim et al., 
2008c) 
HSCARG 
Homo 
sapiens 
Monomer/ 
Dimer 
2EXX NADP
+
 2.40 4 24.8 3.1 263 22 
Leu114, 
His129, Lys133 
(Zheng et 
al., 2007) 
UDP-
hexose 4-
epimerase 
Thermotoga 
maritima 
Dimer 4ZRM 
NADP
+
 & 
UDP-Glc 
2.00 6 22.9 2.5 247 20 
Thr117, Tyr143, 
Lys147 
(Shin et al., 
2015) 
Cinnamoyl-
CoA 
reductase 
Petunia 
hybrid 
(Monomer) 4R1S NADP
+
 1.60 8 22.4 3.0 246 22 
Ser123, Tyr157, 
Lys161 
(Pan et al., 
2014) 
LanV 
Streptomyces 
cyanogenus 
Dimer 4KWI 
NADP
+
 & 
Lando 
2.00 166 14.3 3.0 173 22 
Ser147, Tyr160, 
Lys164 
(Paananen 
et al., 2013) 
UrdMred 
Streptomyces 
fradiae 
(Tetramer) 4OSP 
NADP
+
 & 
rabelomycin 
2.25 167 14.3 3.2 177 20 
Ser147, Tyr160, 
Lys164 
(Patrikainen 
et al., 2014) 
HedKR 
Streptomyces 
griseoruber 
(Tetramer) 3SJU NADP
+
 2.40 N/A 15.5 4.0 185 19 
Ser142, Tyr155, 
Lys159 
(Javidpour 
et al., 
2011a) 
ActKR 
Streptomyces 
coelicolor 
Tetramer 2RHC 
NADP
+
 & 
Emodin 
2.10 N/A 15.1 3.9 185 18 
Ser144, Tyr157, 
Lys161 
(Korman et 
al., 2008) 
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a Experimentally determined (e.g. by size exclusion chromatography), unless shown in brackets, in which case it was inferred from the crystal 
structure alone. For HSCARG, the oligomeric state (as judged by dynamic light scattering) was dependent on the NADP+ concentration.  
b Results of a DALI search (http://ekhidna.biocenter.helsinki.fi/dali_server) (Holm and Sander, 1995) using the SimC7 ternary complex structure 
as the template. The hits were filtered for redundancy; where a relevant ligand bound structure exists for a particular enzyme, this is the one 
that is shown.  
c Lando = 11-deoxy-6-oxylandomycinone. Where the cofactor is underlined, this indicates that the nicotinamide ring adopts the syn 
configuration like SimC7; otherwise the configuration is anti.  
d Ranking of the DALI hit (after redundancy filtering at 90% sequence identity). For some classes of enzymes, e.g. the sugar epimerases, only 
the top hit is shown. The lower ranking hits LanV and UrdMred were also chosen as they were relevant to the discussion. For the same reason, 
ActKR and HedKR were included, despite not being picked up by a blind DALI search.  
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Figure 5.7  
Comparison of the ternary complexes of SimC7 and LanV and the 
binary complex of QOR2 and respective reaction mechanisms.  
(A) Structures are depicted in cartoon representation, where pale blue, beige 
and magenta colouration indicate the nucleotide binding domain, the 
substrate binding domain and the lid motif, respectively (N.B there is no 
distinct substrate binding domain or lid motif in LanV). The ligands are shown 
as van der Waals spheres, with the NADP+ cofactor shown in green and the 
substrate (where present) shown in yellow. See Table 5.5 for more extensive 
comparison of SimC7 structural homologues. (B) Reaction mechanism for 
SimC7 (only the angucyclinone is shown for 7-oxo-SD8 and SD8), QOR2 
and LanV.  
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In terms of their overall structures, the closest DALI hits, together with 
SimC7, fall into the extended SDR subfamily of proteins, which are 
characterised by having two distinct domains that together form a partially 
occluded active site pocket at their junction (Figure 5.7a-b). In contrast, the 
more distantly related angucyclinone ketoreductases belong to the classical 
SDR subfamily (Kavanagh et al., 2008), where three insertions within the 
core Rossmann fold motif delineate a more accessible active site cavity, but 
do not constitute a well-defined substrate binding domain (Figure 5.7c). 
 
5.6 Cofactor binding 
The NADP+ cofactor in the binary SimC7 complex is bound in an extended 
configuration on top of the Rossmann fold motif and held by a network of 
hydrogen bonds such that the nicotinamide moiety adopts the syn-
conformation relative to the adjacent ribose sugar, with the Si-face of the ring 
directed toward the substrate binding pocket (Figure 5.2d-e, Figure 5.5 and 
Figure 5.8). This conformation is coordinated by Asn137 and His112, which 
make hydrogen bonds with the carboxamide of the nicotinamide ring and the 
C-2′ hydroxyl group of the ribose sugar, respectively.  
SimC7 accepts NADH and NADPH as cofactor (see chapter 4.4). 
Nevertheless, SimC7 has a strong preference for NADPH, which is likely due 
to the additional favourable contacts with the 2′ phosphate, specifically salt 
bridges with the guanidinium groups of Arg9 and Arg32. Further hydrogen 
bonds are made by the side-chain of Asp49 and the backbone amide of 
Leu50 with the adenine moiety, and by the side-chain of Tyr69 and the 
backbone amides of Ser11 and Ile12 with the diphosphate group of the 
cofactor, where the latter two amino acids correspond to the second ‘xx’ 
dipeptide in the TGxxGxxG cofactor binding motif characteristic of the 
extended SDR subfamily (Kavanagh et al., 2008) (Figure 5.3). The 
functional significance of the first and second Gly residues of the motif is also 
apparent in this protein-cofactor complex, since side-chains at these 
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positions would result in steric clashes with the cofactor. In contrast, the 
previously identified polyketide ketoreductases LanV, UrdMred, HedKR and 
ActKR all belong to the classical SDR subfamily and therefore contain a 
different cofactor binding motif (TGxxxGxG) and the classic active site motif 
YxxxK. 
 
5.7 Substrate binding 
In the ternary complex with substrate, determined at 1.2 Å resolution, the 
angucyclic ring system of 7-oxo-SD8 binds adjacent and parallel to the 
nicotinamide ring of the cofactor (Figure 5.2d-e and Figure 5.8), where it 
adopts a relatively planar conformation differing from the conformations seen 
in the DNA gyrase-SD8 and SimR-SD8 complexes, in which the A-ring of the 
angucyclinone in SD8 is tilted upwards towards the epoxide (Le et al., 2011b; 
Hearnshaw et al., 2014) (Figure 5.9). This planar conformation is most likely 
enforced by the shape of the very constricted and highly hydrophobic 
substrate pocket created by residues Ile96, Trp100, Ile108, His112, Glu132, 
Ala133, Thr160, Tyr229, Ile237, Gln241, and Arg244 (Figure 5.4 and Figure 
5.5). Within this hydrophobic pocket, 7-oxo-SD8 is bound only by a single 
direct hydrogen bond between the side-chain of Ser95 and the C-7 carbonyl 
oxygen of the angucyclinone moiety, which may help to position the latter 
exactly above the C-4 position of the nicotinamide ring, where it is poised for 
direct hydride transfer (highlighted by black spheres in Figure 5.2c-e, Figure 
5.5 and Figure 5.8). As mentioned above, the natural substrate for SimC7 is 
likely to be a 7-oxo angucyclinone intermediate lacking the deoxysugar, the 
tetraene linker and the aminocoumarin. Consistent with this, only the 
angucyclinone moiety is buried in the active site of SimC7 in the ternary 
complex. Roughly half of the tetraene linker is visible in the electron density, 
projecting away from the protein surface, and the aminocoumarin ring is not 
resolved at all (Figure 5.8). 
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Figure 5.8  
Simulated annealing omit electron density maps.  
Parts (A) and (B) show orthogonal stereo views of the active site of the 
SimC7 ternary complex. Ligands are depicted in stick representation, where 
green indicates carbon atoms of the cofactor and yellow, carbons of the 
substrate; C-4 of the cofactor and C-7 of the substrate are specifically 
highlighted by small black spheres. Superposed upon the substrate in blue is 
a simulated annealing omit map calculated at 1.2 Å resolution (see Materials 
and Methods, chapter 2.7.3). Also shown are the catalytic triad residues, as 
well as Asn137, which is important in maintaining the syn conformation of the 
cofactor. The view in part (A) is equivalent to that in Figure 5.2e (again the 
lid motif has been removed for clarity). In part (B), the protein backbone 
encompassing the 5-4 loop and bearing the catalytic triad has been shown 
in transparent mode as it would otherwise obscure the detail of the active 
site; the lid is in magenta. Parts (C) and (D) show omit maps (red density) for 
just the active site residues in Apo form 1 (1.6 Å resolution) and the binary 
complex (1.95 Å resolution), respectively. In the latter panel a separate omit 
map is also shown (blue density), which was calculated from the final model 
lacking only the cofactor. The view in parts (C) and (D) is roughly equivalent 
to that used in Figure 5.2d. All omit maps were contoured at ~3.0 σ.  
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Figure 5.9  
Comparison of the 7-oxo-SD8 conformation in the ternary complex of 
SimC7 with SD8 conformations observed previously in other 
complexes.  
(A) Orthogonal views showing a least-squares superposition of the 
angucyclic polyketide moiety of 7-oxo-SD8 (based on the 6 carbon atoms of 
ring D) upon SD8 from the complex with GyrA55 and SD8 from the complex 
with SimR. (B) Chemical drawings of the angucyclinone moiety of SD8 and 
7-oxo-SD8 to visualise conformational differences between the three crystal 
structures. The C-7 position is highlighted in red.  
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5.8 A novel catalytic mechanism for an angucyclinone 
ketoreductase 
SimC7 lacks the canonical Ser-Tyr-Lys SDR catalytic triad (Table 5.5). While 
the serine is conserved (Ser95), the other two residues (i.e. the YxxxK motif) 
are not, being instead replaced by Ile108 and His112, respectively. This Ser-
Ile-His triad is unlike any described for the five subfamilies of SDRs defined 
by Kavanagh (Kavanagh et al., 2008). Particularly surprising is the absence 
of the tyrosine residue that acts as the acid/base catalyst in the classical 
SDR mechanism. Inspection of the structure of the ternary complex shows 
that none of the five tyrosine residues in SimC7 is sufficiently close to C-7 of 
the angucyclinone ring system of the substrate to play a direct role in 
catalysis. Further, the structure also shows that there is no alternative 
residue that could act as an acid/base catalyst. Consequently, SimC7 must 
perform ketoreduction of 7-oxo-SD8 via a novel mechanism.  
Based on the structure of the ternary complex of the enzyme with NADP+ 
and 7-oxo-SD8, I propose a simple two-step mechanism for SimC7 that does 
not depend on catalytic residues in the protein, but rather takes advantage of 
the specific properties of the substrate itself, and is thus a novel example of 
substrate-assisted catalysis (Dall'Acqua and Carter, 2000). In the first step, 
the hydrophobic environment of the substrate binding pocket and the 
juxtaposition of the quinone-like C-ring and the phenyl-like D-ring of the 
angucyclinone favour the formation of an intramolecular hydrogen bond 
between the proton on the C-8 hydroxyl group and the oxygen of the 
neighbouring C-7 carbonyl group (Figure 5.10). This enhances the 
polarisation of the latter such that the electrophilicity of C-7 is increased, 
making it a good acceptor for a direct hydride transfer from the 4-pro-S 
position of the nicotinamide ring. Crucially, the hydride donor and acceptor 
carbon atoms are only 3.0 Å apart in the crystal structure. The C-7 hydroxyl 
group is then formed by internal proton transfer from the neighbouring C-8 
hydroxyl group, generating a phenolate intermediate in which the negative 
charge on the C-8 oxygen atom is stabilised by the aromatic D-ring. In the 
second step of the reaction, the phenolate intermediate leaves the substrate 
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binding pocket and the proton required to reinstate the C-8 hydroxyl group is 
recovered by abstraction from bulk water, which is not possible within the 
confines of the active site (Figure 5.10). Exchange of the negatively charged 
reaction intermediate is most likely accelerated by repulsion from the 
hydrophobic active site cavity. Finally, the direct hydride attack from below 
the angucyclic polyketide unambiguously explains the 7-S-stereochemistry of 
simocyclinones. In support of this proposed mechanism, molecular modelling 
(Chem3D Pro v.13) predicts the existence of the key intramolecular 
hydrogen bond between the C-8 hydroxyl group and the C-7 carbonyl group 
of 7-oxo-SD8, and an equivalent intramolecular hydrogen bond is observed 
in the small molecule crystal structure of panglimycin, a closely related 
polyketide (Fotso et al., 2008). Furthermore, molecular modelling (Chem3D 
Pro v.13) also predicts that the C-8 hydroxyl group will have the most acidic 
and exchangeable proton in the angucyclic polyketide, with an estimated pKa 
of 6.9-7.7, and, therefore, could readily transfer to the neighbouring C-7 
oxygen at the end of step 1. Indeed, there is no other possible proton donor 
(neither protein nor water derived) sufficiently close to O-7 to perform this 
role. 
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Figure 5.10  
Proposed SimC7 reaction mechanism.  
SimC7 has an atypical catalytic triad comprised of Ser95, Ile108, and 
His112. In the first step of the proposed mechanism, the C-7 carbonyl group 
of the substrate (7-oxo-SD8) is reduced by transfer of the 4-pro-S hydride of 
the cofactor onto the C-7 carbon of the substrate. This transfer from below 
the C-ring results in the characteristic 7-S-stereochemistry of SD8. 
Ketoreduction at position C-7 is completed by an intramolecular proton 
transfer from the neighbouring C-8 hydroxyl group of the angucyclinone; the 
resultant negative charge on the latter is stabilised by the adjacent aromatic 
ring system (ring D). In the second step, the C-8 oxyanion intermediate 
regains a proton from bulk water after leaving the substrate binding pocket. 
Note that there are no water molecules in the active site pocket that could 
contribute to the reaction mechanism. In the ternary complex, the nearest 
water to O-7 of the angucyclic polyketide is ~5.5 Å away, and the nearest 
water to O-8 is ~4.9 Å away. Due to steric constraints within the pocket, 
neither could approach the substrate oxygen atoms without a repositioning of 
the substrate or a conformational change in the protein.   
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Figure 5.11  
Variations in the active site triad and substrates between SimC7, QOR2 
and TMR.  
Arrangement of the cofactor (yellow) and the protein residues (blue) that 
constitute the active site triad in SimC7, quinone oxidoreductase (QOR2, 
PDB accession number 2ZCV) from E. coli, and triphenylmethane reductase 
(TMR, PDB accession number 2JL1) from Citrobacter sp. The substrate of 
each enzyme is shown below. The natural substrate of TMR is not known. 
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5.9 Mutagenesis of the SimC7 active site 
To investigate the potential roles of the SimC7 ‘catalytic triad’ residues in the 
proposed reaction mechanism, I mutagenized Ser95, Ile108, and His112 
(Table 5.6). In the wild-type enzyme, the hydroxyl group of Ser95 could aid 
catalysis by helping to bind and correctly orient the substrate, and by 
providing additional polarisation to the C-7 carbonyl group via a hydrogen 
bond, the latter role being consistent with the function proposed for the 
structurally equivalent Ser/Thr residues in the classical SDR mechanism 
(Oppermann et al., 2003; Kavanagh et al., 2008; Korman et al., 2008; 
Kallberg et al., 2010; Persson and Kallberg, 2013). Despite the serine being 
within hydrogen bonding distance of the C-7 carbonyl group, the serine 
residue retains activity (86% substrate conversion relative to the wildtype 
enzyme), suggesting that this is not the proton donor and Ser95 is not crucial 
for activity (Table 5.6). Therefore, SimC7 must be able to orient 7-oxo-SD8 
for catalysis without the necessity for the hydrogen bond from Ser95, and 
this likely arises because the active site cavity of the complex with NADP+ 
closely matches the shape of the substrate (Figure 5.5).  
Ile108 contributes to the hydrophobic surface that forms one side of the 
active site cavity and appears to have a rather non-specific role in helping to 
trap the angucyclinone group against the nicotinamide ring of the cofactor 
(Figure 5.5). Unsurprisingly, an I108A substitution had almost no effect on 
the enzyme, whereas changing it to aspartate (I108D) abolished activity 
(Table 5.6). In the latter case, the introduction of a negative charge would 
interfere with the hydrophobic environment and could disrupt the 
intramolecular hydrogen bond in the substrate, both being necessary for 
catalysis.  
Finally, mutation of His112 (H112A, H112N, and H112Q) strongly reduced or 
abolished enzyme activity (Table 5.6), consistent with its key role in binding 
and positioning the cofactor via a hydrogen bond to the 2′-hydroxyl of the 
nicotinamide ribosyl moiety (Figure 5.2d-e and Figure 5.10). 
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To exclude that the reduced substrate conversion by certain SimC7 mutants 
(i.e. mutations I108D, H112A, H112N, and H112Q) was due to incorrect or 
incomplete protein folding, I recorded the far UV circular dichroism (CD) 
spectra of respective mutant enzymes (Figure 5.12). The CD spectral 
signatures of all tested SimC7 mutants were almost identical to the wild type 
protein, confirming that the above mentioned changes in substrate 
conversion were entirely caused by respective introduced point mutations. 
 
 
Table 5.6  
Enzymatic activities of SimC7 active site mutants.  
Substrate conversion was analysed using HPLC by quantifying the reaction 
product, SD8, against purified SD8 standards. Results and standard 
deviations are shown from three independent experiments. Specific activity is 
given as enzyme activity per milligram of protein (i.e. nanomoles of product 
formed per minute per milligram of protein).  
Mutant Conversion (%) Specific activity (nmol min-1 mg-1) 
Wildtype 100.0 ± 7.3 13.9 ± 1.0 
S95A 86.1 ± 7.1 11.9 ± 1.0 
I108A 91.5 ± 13.8 12.7 ± 1.9 
I108D 1.2 ± 0.8 0.2 ± 0.1 
H112A 12.5 ± 3.6 1.7 ± 0.5 
H112N 5.8 ± 2.5 0.8 ± 0.3 
H112Q 1.0 ± 1.4 0.1 ± 0.2 
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Figure 5.12  
Far UV circular dichroism (CD) spectra of inactive SimC7 mutants.  
The CD spectra of all inactive SimC7 mutants were nearly identical to the CD 
spectrum recorded for the wildtype enzyme. SimC7 has a secondary 
structure composition of 44% α-helix, 20% β-sheet, 10% β-turn, and 25% 
other. 
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5.10 Discussion 
Substrate-assisted catalysis refers to a functional group in a substrate that 
contributes to enzyme catalysis. This has been widely demonstrated for 
hydrolytic enzymes (serine proteases, GTPases, type II restriction 
endonucleases, lysozymes and chitinases) but there are few examples from 
other enzyme groups like the oxidoreductases. Substrate-assisted catalysis 
can occur by different mechanisms including general base catalysis and 
stabilisation of intermediates (Dall'Acqua and Carter, 2000). 
The sequence of SimC7 is distinct from previously characterised polyketide 
ketoreductases and the structural data reported in this study suggest that 
SimC7 catalyses a novel substrate-assisted, two-step reaction for the 
reduction of the C-7 carbonyl group. This mechanism involves the 
intramolecular transfer of a substrate-derived proton to generate a phenolate 
intermediate, obviating the need for proton transfer for a canonical SDR 
active site tyrosine. Like SimC7 (Ser-Ile-His), the two closest structural 
homologs, TMR (Tyr-Leu-His) and QOR2 (Leu-Leu-His), also have unusual 
active site triads (Figure 5.11 and Table 5.6). Thus, SimC7, TMR and QOR2 
share an I/LxxxH motif and have substrates with extensively conjugated pi-
systems (Figure 5.11). No enzyme-substrate complex crystal structures 
have been described for TMR or QOR2 and no firm proposals exist for their 
catalytic mechanisms, but their substrate structures (Figure 5.11) and the 
data provided here suggest they are also likely to employ non-canonical 
mechanisms. The data from this study therefore point to members of the 
extended SDR subfamily having I/LxxxH active site motifs as a source of 
new biochemistry. 
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6.1 Introduction 
The natural producer of simocyclinones, S. antibioticus Tü6040, is highly 
resistant to SD8 (>100 μg/mL) (Schimana et al., 2000). The two membrane 
transport proteins SimEx1 and SimEx2 from the sim biosynthetic gene 
cluster were assumed to confer resistance to simocyclinones (Galm et al., 
2002; Trefzer et al., 2002). Unexpectedly, introduction of the sim cluster into 
S. coelicolor M1152 strongly impaired growth and sporulation of the strain. 
The reason for this toxicity to the heterologous host remained unclear. 
Here I describe several alternative approaches I took in an attempt to 
improve manipulation and heterologous production of simocyclinones. I have 
evidence that production of simocyclinone intermediates is toxic to the 
heterologous hosts. My experiments indicate that early simocyclinone 
intermediates lacking the tetraene linker and the aminocoumarin may have 
inhibitory activity against unknown intracellular targets. Sequencing of the 
genome of S. antibioticus Tü6040 revealed a vast range of secondary 
metabolite gene clusters but no further obvious resistance mechanisms 
against simocyclinones could be identified. 
 
6.2 Addition of the adsorptive hydrophobic resin HP20 
Adsorptive polymeric resins have been shown to improve production of 
specific secondary metabolites (Nielsen et al., 2010; Gonzalez-Menendez et 
al., 2014). The application of polymeric resins dates back to the 1970s and 
they have since been used during fermentation processes for bacteria and 
fungi to significantly increase the yield of secondary metabolites, prevent 
their degradation or decrease their toxic side effects (Phillips et al., 2013). 
Therefore, I added an adsorptive hydrophobic resin (5% w/v of Diaion® 
HP20) to the production medium and grew the improved heterologous host 
expressing the mutant sim cluster (S. coelicolor M1152ex1::12IΔC7) as 
described. Extracts from culture supernatants and the hydrophobic resin 
were analysed by LC-MS-UV and compared to cultures grown in parallel 
from the same pre-cultures without hydrophobic resin. 
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Addition of the adsorptive resin HP20 strongly repressed mycelial growth. 
Furthermore, cultures produced less of a dark pigment, which was generally 
observed for M1152 and M1152ex1 expressing the sim cluster with simC7 
deleted. Unfortunately, the total yield of 7-oxo-SD8 extracted from cultures 
grown in the presence of the HP20 resin was ~4-8-fold reduced 
(0.3-0.5 mg/mL) compared to cultures grown without resin (2.0-2.6 mg/mL) 
(Figure 6.1). In addition, concentrated crude extracts from cultures grown in 
the presence of HP20 appeared green in colour in contrast to the typical 
yellow-brown colour of concentrated simocyclinone extracts (Figure 6.1). 
The reason for this colour change remained unclear but was not caused by 
changes in pH or temperature.  
In summary, addition of an adsorptive hydrophobic resin did not improve 
heterologous production of simocyclinones. Instead, the presence of HP20 
resin decreased culture growth and production of simocyclinones, which 
could have been caused by mechanical stress in addition to the strongly 
impaired growth phenotype of S. coelicolor M1152 and M1152ex1. 
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Figure 6.1  
Production of 7-oxo-SD8 in absence and presence of an absorptive 
hydrophobic resin.  
Cultures of M1152ex1::12IΔC7 were grown in the absence (left) and 
presence (right) of HP20 resin (Diaion®; 5% w/v). Cultures were grown in 
triplicate for 6 days at 30 °C and concentrated extracts with a mixture of 
simocyclinone intermediates were analysed by LC-MS-UV. Crude extracts 
(2.5-fold concentrated in methanol) from cultures grown with HP20 resin had 
a green colour (bottom right) compared to normal extracts (bottom left). 
Estimated yields of 7-oxo-SD8 are indicated for each culture. Masses (m/z) 
and putative simocyclinone intermediates (A-G) are indicated. The origin of 
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the additional absorbance peak at 11 minutes of cultures grown with HP20 
resin shows a different absorbance spectrum compared to early 
angucyclinone intermediates. The most abundant ion (m/z 503.1) however 
implies that it could be simocyclinone A2. 
 
6.3 Spontaneous resistant mutants of S. coelicolor M1152 
Spontaneous resistant mutants often arise around threshold levels of 
antimicrobial agents as a consequence of genomic mutations (Edwards et 
al., 2009; Toprak et al., 2012). Once a bacterial strain has acquired 
resistance, it is able to grow in the presence of the antimicrobial agent and 
can gradually increase its resistance threshold by acquiring additional 
mutations, which can result in a highly resistant strain.  
Previous results have shown that the outer membrane-permeable E. coli 
strain NR698, which is sensitive to SD8, spontaneously develops resistance 
to SD8 when exposed to concentrations slightly above its MIC threshold. 
Sequencing revealed that this resistance is mediated by point mutations in 
the SD8 binding pocket of DNA gyrase, which was confirmed by assaying 
the mutant DNA gyrases in the presence of SD8 in vitro, and by structural 
studies (Edwards et al., 2009; Hearnshaw et al., 2014). Since these mutants 
were simple to isolate in E. coli, a similar approach was used to select for 
resistant mutants of S. coelicolor M1152. A confluent lawn of M1152 was 
grown for 6 days at 30 °C (~105 spores) in the presence of low amounts of 
SD8 applied to paper discs, which were placed directly on the plates (0/ 0.25/ 
0.5/ 1/ 5/ 10 μg/mL). Resistant colonies, which grew within the zone of 
inhibition, were picked and cultured separately. The increased resistance of 
these mutants was confirmed against higher amounts of SD8 (30 μg/mL and 
60 μg/mL) using paper disc assays on SMMS agar (Figure 6.2). All the SD8-
resistant S. coelicolor M1152 colonies were analysed for mutations in the N-
terminal domain of GyrA by PCR amplification and sequencing of the 
relevant part of the gyrA gene. However, none of the selected colonies 
contained mutations in gyrA, suggesting they arose from decreased 
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membrane permeability or increased efflux of SD8. However, since the SD8-
resistant mutants could still be advantageous as an optimised heterologous 
system, the sim cluster (i.e. PAC-12I) was introduced twice into all 24 tested 
strains (Table 6.1). Although each mutant strain showed increased 
resistance against externally applied SD8, expression of the sim gene cluster 
still impaired the growth and sporulation of all the mutant strains to 
approximately the same degree as for the parent M1152 strain. Thus, the 
acquired mutations did not improve intracellular resistance to simocyclinone 
intermediates, consistent with the hypothesis that the mutant strains had 
decreased membrane permeability to SD8. Interestingly, several mutated 
strains with strongly increased resistance to SD8 also showed a delay in 
development or were affected in sporulation before introduction of the sim 
gene cluster (Table 6.1). However, there was no correlation between strain 
viability before and after introduction of the sim gene cluster. 
In conclusion, S. coelicolor M1152 is able to develop spontaneous resistance 
to SD8 after exposure to low amounts of SD8, but the mutations responsible 
did not occur in gyrA as previously observed for SD8-resistant E. coli 
mutants. Further, the mutations did not confer resistance against intercellular 
simocyclinones, suggesting they cause changes in membrane permeability. 
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Figure 6.2  
Spontaneous mutants of S. coelicolor M1152 with increased resistance to SD8.  
Strains (SP-1 to SP-24) were grown on SMMS agar for 6 days at 30 °C in presence of 30 μg or 60 μg of SD8 on a paper disc 
before evaluation of the resistance levels compared to M1152 (red circles). Controls strains M1152 (sensitive) and M1152ex1 
(resistant) were added on each plate. 
201 
 
Table 6.1  
Spontaneous mutant strains of S. coelicolor M1152 with increased SD8 
resistance.  
Spore development and sporulation are indicated before introduction of the 
sim gene cluster. Sporulation was strongly impaired for all mutant strains 
(SP-1 to SP-24) after introduction of the sim gene cluster. 
  
M1152 
mutant 
SD8 
resistance 
Spore 
development 
Sporulation Exconjugants 
(1st/ 2nd test) 
SP-1 high 3 days good 151 / 40 
SP-2 high 3 days low/ no spores 55 / 2 
SP-3 high 3 days low/ no spores 7 / 0 
SP-4 medium 7 days low/ no spores n/a / 0 
SP-5 high 3 days good 121 / 30 
SP-6 very low 3 days good 50 / 0 
SP-7 low 3 days good 16 / 1 
SP-8 medium 4 days low/ no spores 208 / 11 
SP-9 low 3 days low/ no spores 7 / 0 
SP-10 high 3 days low/ no spores 62 / 1 
SP-11 high 3 days good 202 / 2 
SP-12 high 4 days low/ no spores 7 / 0 
SP-13 medium 4 days low/ no spores >>300 / >>300 
SP-14 very low 3 days good 10 / 1 
SP-15 low 3 days good 60 / 9 
SP-16 low 3 days low/ no spores 31 / 1 
SP-17 high 4 days low/ no spores 38 / 2 
SP-18 medium --- no spores n/a / n/a 
SP-19 high 4 days low/ no spores 12 / 60 
SP-20 high 3 days good 103 / 461 
SP-21 medium 7 days low/ no spores n/a / 7 
SP-22 medium --- no spores n/a / n/a 
SP-23 high 3 days good 8 / 310 
SP-24 high 3 days good 3 / 141 
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6.4 Alternative heterologous hosts 
The strategy of using heterologous hosts has led to the discovery of multiple 
natural products and vastly facilitates the analysis and manipulation of 
biosynthetic pathways. The engineered heterologous host S. coelicolor 
M1152 is generally an excellent choice for this kind of work. Deletion of the 
endogenous antibiotic gene clusters in M1152 usually causes increased 
heterologous metabolite production because the endogenous antibiotics 
otherwise serve as major sinks for carbon. In addition, M1152 has no anti-
microbial activity and has a much simplified extracellular metabolite profile 
for HPLC and LC-MS analyses (Gomez-Escribano and Bibb, 2011). 
Nevertheless, the increased production of introduced secondary metabolite 
gene clusters can have adverse effects on M1152 (J. P. Gomez-Escribano, 
personal communication). As a consequence, I also investigated 
heterologous hosts other than S. coelicolor M1152.  
Commonly used heterologous hosts include Streptomyces albus (Sanchez et 
al., 2002; Gullon et al., 2006; Yan et al., 2012), Streptomyces lividans 
(Motamedi and Hutchinson, 1987; Lacalle et al., 1992; Fischer et al., 2003), 
and Streptomyces venezuelae (Park et al., 2009). In particular, the 
angucyclinone and antitumor agent oviedomycin from 
Streptomyces antibioticus ATCC 11891™, which is structurally related to the 
angucyclinone moiety of SD8, has been characterised using the 
heterologous host S. albus (Mendez et al., 2002). Three further structurally 
related polyketides, namely tetrangulol, tetrangomycin and the tricyclic 
fridamycin from Streptomyces rimosus NRRL 3016, have been analysed 
heterologously in S. lividans (Hong et al., 1997). 
Therefore, I attempted to introduce PAC-12I carrying the sim gene cluster 
into the potential heterologous hosts Streptomyces venezuelae 
ATCC 10712™, Streptomyces albus J1074, and Streptomyces lividans 1326. 
Conjugations were performed using the methylation-deficient E. coli strain 
ET12567 carrying the self-transmissible helper plasmid pR9406. No 
exconjugants were obtained for S. venezuelae and S. albus. Several 
potential exconjugants of S. lividans were later shown to be false positives 
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that did not contain the sim gene cluster. In fact, only S. coelicolor derived 
strains yielded exconjugants reliably.  
In conclusion, none of the tested alternative strains was suitable for 
heterologous expression of simocyclinones. This might be due to 
phylogenetic differences of these strains or the fact that wildtype S. coelicolor 
produces more secondary metabolites, which could have facilitated survival 
for M1152 in comparison to the three tested alternative hosts. 
 
6.5 Mutational analysis of the sim gene cluster in S. antibioticus 
Tü6040 
Although the natural producer is difficult to manipulate, I tested if the desired 
mutations could be made in S. antibioticus Tü6040. This was feasible in 
principle given that prior to my arrival in the lab, Tung Le had succeeded in 
making a null mutation in the gene encoding the transcriptional regulator 
SimReg3, which is directly next to simC7. The simReg3 gene was replaced 
with an apramycin resistance cassette using double homologous 
recombination with a sim cluster-containing cosmid (1K3-neo; T. Le., 
unpublished). Thus, the same approach was used to delete simC7, which is 
present on the same cosmid. The mutant construct was conjugated into 
S. antibioticus Tü6040 from E. coli ET12567/pR9406, however no 
exconjugants were obtained, despite varying numerous parameters 
individually (i.e. concentration of spores, different spore stocks, ratio between 
E. coli and S. antibioticus, time to dry conjugation plates, time of antibiotic 
overlay, amount of antibiotics used). 
As an alternative approach, a 5.2-kb DNA fragment containing a central 
apramycin resistance cassette, which replaced simC7 (simC7::apr), was 
cloned into the HindIII site of plasmid pGM1190-Kan-oriT (N. Holmes, 
unpublished). This plasmid is a derivative of pGM1190, a temperature-
sensitive and non-integrative plasmid with intermediate copy number, which 
was successfully conjugated into S. antibioticus Tü6040. Unfortunately, 
exconjugant colonies did not grow at temperatures above 32 °C, which was 
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required for loss of the temperature-sensitive plasmid to select for 
recombinant colonies. Further growth tests with S. antibioticus Tü6040 at 
different temperatures revealed a narrow temperature range for growth 
around 25-32 °C, which might reflect the adaption of this strain to its natural 
environment in Argentina, South America (Schimana et al., 2000).  
In summary, mutational analysis of S. antibioticus Tü6040 was not 
successful, even after multiple attempts to delete simC7 from the genome. 
These attempts confirm the genetic intractability of strain Tü6040. 
 
6.6 Evidence that simocyclinone intermediates are the cause of 
the toxicity to S. coelicolor M1152, and that their target is not 
DNA gyrase  
Several test conjugations were carried out during optimisation of the 
heterologous system. Among others, a mutant sim cluster was introduced 
into M1152 and M1152ex1 carrying an in-frame deletion in three genes 
(PAC-12IΔC1ABC) encoding a type I PKS predicted to be responsible for 
biosynthesis of the tetraene linker. Production of C- and D-group 
simocyclinones was completely abolished due to the absence of the PKS 
enzymes involved in tetraene linker biosynthesis. Simocyclinones of the 
A-group (i.e. aglycones) and B-group (i.e. angucyclinone with deoxysugar) 
were detectable by LC-MS analysis, although none of these intermediates 
accumulated in the culture supernatant. Unexpectedly, the absence of C- 
and D-group simocyclinones did relieve the toxicity to the heterologous host, 
which remained impaired in growth and sporulation, similar to M1152 
expressing the wild-type sim cluster. E. coli DNA gyrase is only very weakly 
inhibited by simocyclinone intermediates lacking the aminocoumarin end of 
the molecule (Edwards et al., 2009). These results provide evidence that one 
or more intermediates of the A- and/or B-group are highly toxic to 
S. coelicolor, and that their target is unlikely to be DNA gyrase.  
Interestingly, the number of exconjugants obtained with PAC-12IΔC1ABC 
was consistently more than 100-fold higher than with PAC-12I carrying the 
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wildtype sim cluster. Given this is not caused by the relief of toxicity, it is 
possible that strongly improved conjugation efficiency is simply a 
consequence of the reduced size of this construct (~24 kb removed). 
 
6.7 Genome sequencing reveals S. antibioticus Tü6040 to be a 
‘talented producer’ of secondary metabolites 
The genome of S. antibioticus Tü6040 was sequenced, in part to look for 
further potential simocyclinone resistance mechanisms, such as gyrA genes 
encoding simocyclinone-insensitive GyrA subunits. Therefore, genomic DNA 
was isolated and the quality and concentration was determined via pulsed-
field gel electrophoresis (PFGE) and NanoDrop spectrophotometer, 
respectively. The sample was of high purity and good quality as reflected by 
a ratio of absorbance at 260 nm and 280 nm (260/280) of 1.85 (expected: 
1.80) and pulse-field or normal gel electrophoresis (Figure 6.3). The sample 
was pre-diluted 10-fold (~200 ng/μL) before Pacific Biosciences (PacBio)-
based sequencing using three SMRT cells. The sequencing statistics are 
summarised in Table 6.2. 
One single assembled sequence covered most of the draft genome (contig 0, 
9,731,730 bp, Table 6.2) whereas the remaining six assembled sequences 
were of comparably short lengths (2.5-180 kb) and either aligned internally to 
the longest sequence (contigs 1 and 5) or did not match a continuous 
alignment (contigs 3-6, and 9). This has been observed previously and was 
identified as systematic error for this sequencing method (Gomez-Escribano 
et al., 2015). Therefore, the remaining short sequences were not considered 
for the draft genome. The open reading frames of the genome sequence 
(contig_0) were identified and annotated using Prodigal and RAST (Aziz et 
al., 2008; Hyatt et al., 2010). The draft genome contained a total of 8,872 
predicted genes including 93 RNA-encoding genes (21 rRNAs and 
72 tRNAs). It is likely that the ~10 Mb draft genome sequence covers most of 
the genome of S. antibioticus Tü6040, given a genome size range of 8.7-
11.9 Mb for the Streptomyces genus (Zhou et al., 2012). In order to identify 
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the ends of the genome, I analysed all sequences for terminal inverted 
repeats (TIRs) and helicase genes, which are typically found at the end of 
the linear genomes of this genus (Bey et al., 2000). The absence of both 
indicated that the ends of the S. antibioticus Tü6040 genome were not 
sequenced.  
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Figure 6.3  
Purity and quality of isolated genomic DNA from S. antibioticus Tü6040.  
Genomic DNA (gDNA) was isolated as described and dissolved in TE-buffer 
overnight. DNA was separated by agarose gel electrophoresis (A) and pulse-
field gel electrophoresis (B). 
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Table 6.2  
Summary of sequencing results for genomic DNA from S. antibioticus 
Tü6040. 
Metric Value 
Total sequences (raw data) 225,083 
Sequence length (raw data) 500-28,119 bp 
GC content (raw data) 68% 
Polished contigsa 7 
   Contig_0 9,731,730 bp 
   Contig_1 25,696 bp 
   Contig_3 101,892 bp 
   Contig_4 23,779 bp 
   Contig_5 15,175 bp 
   Contig_6 180,596 bp 
   Contig_9 2,521 bp 
Number of reads 188,099 
Max contig length 9,731,730 bp 
N50 contig lengthb 9,731,730 bp 
Sum of contig lengths 10,081,389 bp 
a) Automated assembly by the Earlham Institute(Norwich, UK). 
b) Shortest sequence length at 50% of the genome. 
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Since SD8 targets DNA gyrase, my first aim was to identify and compare the 
GyrA and GyrB protein sequences from the natural simocyclinone producer 
S. antibioticus Tü6040 and the heterologous host S. coelicolor. I compiled 
the predicted proteome of S. antibioticus Tü6040 in a database and 
searched for homologs of GyrA (Sco3873) and GyrB (Sco3874) from 
S. coelicolor using a protein-based BLAST search (Altschul et al., 1990; 
Camacho et al., 2009). In total, four genes were identified, encoding the 
subunits of DNA gyrase (GyrA and GyrB) and the structurally related enzyme 
Topo IV (ParC and ParE). As expected, the genes encoding DNA gyrase 
were located in a single operon (GyrA encoded by sant4394: 
4,915,060::4,917,654; GyrB encoded by sant4395: 4,917,697::4,919,766) 
and genes encoding for Topo IV were located in proximity to each other in 
the genome (ParC encoded by sant2337: 2,634,569::2,637,028 ; ParE 
encoded by sant2357: 2,655,425::2,657,548) (Figure 6.4).  
Sequence alignments revealed high similarity between the two GyrA proteins 
(95% identical, 810/857; 98% positive, 837/857; 0% gaps 0/857) and 
between the two GyrB proteins (91% identical, 626/686; 95% positive, 
654/686; 1% gaps, 5/686), with lower similarities between GyrA and ParC 
(43% identical, 339/790; 59% positive, 465/790; 6% gaps, 457/790) and 
between GyrB and ParE (47% identical, 331/710; 61% positive, 430/710; 8% 
gaps, 58/710). Importantly, there were no amino acid sequence differences 
in the aminocoumarin- and angucyclinone-binding pockets between GyrA 
from S. antibioticus and S. coelicolor (Figure 6.5). Furthermore, no additional 
obvious resistance genes such as membrane transport proteins could be 
identified in the entire draft genome or the remaining short contigs. 
The draft genome was analysed for secondary metabolite gene clusters 
using antiSMASH v3.0 (Weber et al., 2015), which identified 74 potential 
gene clusters (Figure 6.4 and Table 6.3). This makes S. antibioticus Tü6040 
a metabolically ‘talented’ producer dedicating ~23% of its genome for 
secondary metabolism, which is substantially more compared to other 
genomes. Less than 7% of prokaryotic species devote more than 7.5% of 
their genome to secondary metabolite biosynthesis including other natural 
product producing Streptomyces species (Cimermancic et al., 2014). Despite 
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the fact that the ClusterFinder algorithm used by the antiSMASH software 
detects mostly putative saccharide gene clusters, which may not produce 
any metabolites with anti-microbial activity, the remaining 39 gene clusters 
constitute ~15% of the S. antibioticus genome, which is still much more 
compared to other sequenced strains. The sim gene cluster was located 
near the centre of the genome (predicted by antiSMASH: 
4,518,198::4,434,712; proposed minimal sim cluster: 4,437,587::4,509,853). 
The sequence of the sim gene cluster of the genome draft showed no 
significant differences compared to the previously sequenced PAC-12I clone 
and the original published sequences (Galm et al., 2002; Trefzer et al., 
2002). Several further gene clusters shared remarkable sequence similarities 
with genes of biosynthetic enzymes involved in simocyclinone or 
aminocoumarin biosynthesis. These similarities include biosynthetic genes 
for the simocyclinone tetraene linker (gene cluster 13; simC1ABC, simC2, 
simA7; 46-54% protein sequence identity), the simocyclinone angucyclic 
polyketide (gene cluster 38; simA1-6; 49-61% protein sequence identity), and 
the aminocoumarin deoxysugar noviose (gene clusters 5 and 24; 
nov/clo/couW-V-U-T-S-P; 51-63% and 50-77% protein sequence identity).  
Remarkably, the longest protein encoded in the draft S. antibioticus genome 
has a length of 7,118 amino acids (751 kDa). This enormous protein is part 
of an unusual non-ribosomal peptide synthetase trans-acyltransferase 
polyketide synthase (NRPS-transAT-PKS) cluster (cluster 64). In addition, 
this large enzyme shares similarity with LnmJ (7,349 amino acids) from the 
biosynthetic gene cluster of the anticancer agent leinamycin (LNM) (Tang et 
al., 2004). In fact, cluster 64 shares further sequence similarity with the 
leinamycin biosynthetic gene cluster, although it can reasonably be assumed 
that the two products are structurally distinct because there are also 
substantial differences between the two clusters (Table 6.3). 
In summary, genome sequencing of the natural simocyclinone producer 
S. antibioticus Tü6040 revealed a large genome (~10 Mb) with more than 70 
potential secondary metabolite gene clusters. No obvious further 
simocyclinone resistance genes lying outside the sim cluster could be 
identified bioinformatically. Intriguingly, the GyrA and GyrB subunits of 
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S. antibioticus Tü6040 are nearly identical to those of the simocyclinone-
sensitive heterologous host S. coelicolor. It thus remains unclear why the sim 
cluster is so toxic to S. coelicolor but not to S. antibioticus Tü6040.  
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Figure 6.4  
Circular representation of the S. antibioticus Tü6040 genome.  
From outside to inside: open reading frames (cyan), secondary metabolite 
gene clusters predicted by antiSMASH v3 (green), GC-plot (above average 
in yellow; below average in purple), GC-skew (above average in yellow; 
below average in purple). The graph was created with DNAPlotter. 
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Figure 6.5  
Comparison of the SD8 binding site in the DNA gyrase subunit A 
(GyrA).  
The amino acid sequence alignment is shown for the highly similar GyrA 
proteins from S. coelicolor and S. antibioticus Tü6040. For comparison, the 
identified SD8 binding site and respective SD8-resistance mutations are 
highlighted for GyrA from E. coli (compare with Figure 1.8).  
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Table 6.3  
Predicted biosynthetic gene clusters from S. antibioticus Tü6040.  
Gene clusters were predicted by antiSMASH (Weber et al., 2015). (Cf: cluster identified by ClusterFinder; yellow: simocyclinone 
biosynthetic gene cluster; orange: cluster containing homologs to genes involved in simocyclinone biosynthesis). 
Cluster Type (predicted) From To Length Most similar known cluster 
1 Lantipeptide 8,953 31,736 22,783 Labyrinthopeptin A1-A3 gene cluster 
2 T1pks 399,560 447,632 48,072 Laidlomycin biosynthetic gene cluster 
3 Terpene 570,719 591,711 20,992 Kirromycin biosynthetic gene cluster 
4 Cf_fatty_acid 673,476 694,729 21,253 - 
5 Cf_saccharide-lantipeptide-bacteriocin 795,487 860,780 65,293 Informatipeptin biosynthetic gene cluster 
6 Cf_saccharide 1,161,628 1,183,112 21,484 Tetronasin biosynthetic gene cluster 
7 Cf_fatty_acid 1,231,232 1,258,058 26,826 Pristinamycin biosynthetic gene cluster 
8 Terpene-cf_saccharide 1,454,017 1,484,381 30,364 Hopene biosynthetic gene cluster 
9 Cf_saccharide 1,626,230 1,647,411 21,181 - 
10 Cf_fatty_acid 1,672,687 1,693,673 20,986 - 
11 Cf_saccharide 1,726,463 1,748,082 21,619 Kanamycin biosynthetic gene cluster 
12 Siderophore 1,997,164 2,010,270 13,106 - 
13 Cf_fatty_acid -t1pks 2,024,216 2,119,853 95,637 Rifamycin biosynthetic gene cluster 
14 Terpene 2,326,886 2,349,042 22,156 - 
15 Bacteriocin 2,383,692 2,395,041 11,349 - 
16 T1pks-cf_fatty_acid 2,478,711 2,534,195 55,484 Tetronasin biosynthetic gene cluster 
17 Siderophore 2,684,184 2,696,130 11,946 - 
18 Microcin 2,772,636 2,792,730 20,094 - 
215 
 
Cluster Type (predicted) From To Length Most similar known cluster 
19 Cf_saccharide 2,977,683 2,998,603 20,920 - 
20 Cf_saccharide 3,142,948 3,163,760 20,812 A-503083 biosynthetic gene cluster 
21 Terpene 3,412,973 3,434,160 21,187 Albaflavenone biosynthetic gene cluster 
22 Cf_saccharide 3,473,223 3,495,055 21,832 - 
23 Microcin 3,581,388 3,601,482 20,094 Avilamycin A biosynthetic gene cluster 
24 Cf_saccharide 3,667,891 3,708,105 40,214 Clorobiocin biosynthetic gene cluster 
25 Cf_saccharide 3,779,772 3,806,537 26,765 - 
26 Microcin 4,287,295 4,307,389 20,094 - 
27 Cf_saccharide 4,380,643 4,401,545 20,902 Gilvocarcin biosynthetic gene cluster 
28 Aminocoumarin-t2pks-t1pks-
cf_fatty_acid 
4,434,712 4,532,592 97,880 Simocyclinone biosynthetic gene cluster 
29 Siderophore 4,534,375 4,547,729 13,354 - 
30 Bacteriocin 4,693,312 4,705,588 12,276 - 
31 Cf_saccharide 4,712,140 4,735,109 22,969 - 
32 Cf_saccharide 4,746,848 4,767,549 20,701 - 
33 Cf_saccharide 4,896,386 4,917,921 21,535 Granaticin biosynthetic gene cluster 
34 Cf_saccharide 5,074,533 5,096,863 22,330 - 
35 Microcin 5,187,631 5,207,725 20,094 - 
36 Butyrolactone 5,226,150 5,237,091 10,941 Methylenomycin gene cluster 
37 Cf_saccharide 5,298,875 5,320,278 21,403 - 
38 T2pks 5,318,146 5,360,670 42,524 Spore pigment biosynthetic gene cluster 
39 Cf_saccharide 5,369,628 5,390,650 21,022 - 
40 T1pks-nrps-cf_fatty_acid 5,627,392 5,695,424 68,032 Elaiophylin biosynthetic gene cluster 
41 Cf_saccharide 5,912,882 5,933,910 21,028 - 
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Cluster Type (predicted) From To Length Most similar known cluster 
42 Microcin 5,944,750 5,964,844 20,094 - 
43 Cf_saccharide 5,980,001 6,021,221 41,220 - 
44 Cf_saccharide 6,186,009 6,208,063 22,054 - 
45 Siderophore 6,246,518 6,258,887 12,369 Desferrioxamine B gene cluster 
46 Cf_saccharide 6,434,666 6,456,057 21,391 - 
47 Cf_saccharide 6,547,762 6,568,976 21,214 - 
48 Terpene 6,772,088 6,795,621 23,533 Kanamycin biosynthetic gene cluster 
49 Cf_fatty_acid 6,805,740 6,828,449 22,709 Fredericamycin biosynthetic gene cluster 
50 Cf_saccharide 6,884,506 6,905,951 21,445 Herboxidiene biosynthetic gene cluster 
51 Cf_saccharide 7,114,485 7,135,663 21,178 - 
52 Cf_saccharide 7,172,762 7,193,850 21,088 - 
53 Cf_saccharide 7,245,235 7,266,494 21,259 Herboxidiene biosynthetic gene cluster 
54 Ectoine 7,485,301 7,496,152 10,851 Ectoine biosynthetic gene cluster 
55 Microcin-cf_saccharide 7,572,312 7,611,006 38,694 Amychelin biosynthetic gene cluster 
56 Cf_saccharide 7,654,318 7,676,278 21,960 - 
57 Other 7,714,241 7,758,101 43,860 Pristinamycin biosynthetic gene cluster 
58 Cf_saccharide 7,840,751 7,861,701 20,950 Streptomycin biosynthetic gene cluster 
59 Cf_saccharide 7,920,499 7,941,695 21,196 - 
60 Cf_saccharide 8,036,666 8,070,375 33,709 - 
61 Microcin 8,088,906 8,109,000 20,094 - 
62 Hglks-t1pks 8,162,601 8,214,979 52,378 Cinnamycin biosynthetic gene cluster 
63 T3pks 8,288,570 8,329,694 41,124 Herboxidiene biosynthetic gene cluster 
64 Nrps-transatpks-cf_fatty_acid 8,392,372 8,474,411 82,039 Leinamycin biosynthetic gene cluster 
65 Cf_saccharide 8,679,410 8,701,785 22,375 - 
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Cluster Type (predicted) From To Length Most similar known cluster 
66 Cf_saccharide-t3pks 8,724,532 8,780,918 56,386 - 
67 Cf_fatty_acid 8,777,125 8,798,417 21,292 - 
68 Nrps 8,950,075 8,993,329 43,254 Stenothricin biosynthetic gene cluster 
69 Cf_saccharide 9,054,511 9,075,668 21,157 - 
70 Nrps-t1pks 9,158,635 9,214,423 55,788 - 
71 Terpene-melanin 9,237,694 9,264,599 26,905 Melanin biosynthetic gene cluster 
72 Other 9,362,573 9,403,283 40,710 Kanamycin biosynthetic gene cluster 
73 Nrps-lantipeptide 9,407,925 9,482,796 74,871 Herboxidiene biosynthetic gene cluster 
74 Lantipeptide 9,608,484 9,631,393 22,909 - 
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7.1 The role of SimC7 during angucyclinone biosynthesis  
Since the simocyclinone biosynthetic pathway remains largely hypothetical, it 
is unknown in which order the angucyclinone is assembled and modified. 
Consequently, it is possible that reduction of the C-7 carbonyl group by 
SimC7 might not be the last step in angucyclinone biosynthesis. So, as a 
speculative example, it might be that in S. antibioticus epoxide formation 
occurs after the C-7 carbonyl group is reduced, but that the angucyclinone 
carrying the epoxide is still accepted as substrate by SimC7 in vitro (Figure 
7.1). Acid-induced hydrolysis of the epoxide group in the angucyclinone was 
observed in early crystal structures after prolonged incubation of protein 
crystals under acidic conditions. Hydrolysis of the epoxide group was 
accompanied by increased flexibility of the A- and B-ring as indicated by a 
reduced electron density, whereas the position of the C- and D-ring remained 
unchanged (data not shown). Mass spectrometry analysis of SD8 and 
7-oxo-SD8 incubated under equivalent acidic conditions revealed that the 
angucyclic polyketide skeleton remained intact but hydrolysis occurred of the 
epoxide group as well as the amide bond and the two carboxylic acid esters.  
Thus, although acid-induced hydrolysis proceeded very slowly and almost 
certainly happened after crystal formation, it shows that the enzyme locks the 
C- and D-ring of the substrate in place for the reaction, whereas the 
remaining part of the substrate may adopt different conformations. 
Biosynthesis of angucyclin(on)es is generally very complex and involves 
multiple tailoring enzymes that catalyse cyclisation, aromatisation, oxidation 
and reduction reactions. The predicted tailoring enzymes involved in 
biosynthesis of the angucyclinone in simocyclinone include two cyclases 
(SimA4 and SimA5) to generate the characteristic angucyclic ring system, 
three oxygenases (SimA7, SimA8, and SimA13) that introduce two hydroxyl 
groups and the epoxide, as well as four ketoreductases (SimC7, SimA6, 
SimA9, and SimA10) to reduce various carbonyl groups (Galm et al., 2002; 
Trefzer et al., 2002) (Figure 7.1).  
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Figure 7.1   
Putative biosynthetic pathway for the angucyclinone moiety of 
simocyclinone. 
Biosynthesis of the angucyclinone begins with a polyketide skeleton, which is 
made by a type II PKS (KS, CLF, ACP) and subsequently cyclised to an 
angucyclic intermediate with four hexameric rings. The angucyclic 
intermediate is subsequently decarboxylated, oxygenated and reduced in 
multiple steps. The pathway is based on studies on close homologs and the 
results of this study. The order of oxygenation and ketoreduction is unknown 
and could be different than shown. The incorporated acetate units are 
highlighted in bold for the initial polyketide chain (compare with Figure 4.8). 
(KR, ketoreductase; TE, thioesterase; DC, dicarboxylase) 
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The D-ring of angucyclinones is cyclised first, followed by the C-ring, so that 
the core structure of the SimC7 substrate, an aromatic 8-phenyl adjacent to a 
7-carbonyl, is generated very early in the pathway (Zhou et al., 2010). The 
product of the minimal type II PKS, a linear poly-β-ketone, is extremely 
reactive and cyclises spontaneously. Consequently, the first regio-selective 
intramolecular aldol condensation has to follow immediately after completion 
of the polyketide chain as it determines the structure of the final molecule. 
The first cyclisation step and the corresponding cyclases have been well 
characterised and the most common patterns for aromatic polyketides are 
C7-C12 and C9-C14 cyclisations (Zhou et al., 2010). In jadomycin 
biosynthesis for example, the cyclase JadD initiates cyclisation of the D-ring 
of the final angucyclinone by catalysing an aldol condensation between 
positions C-7 and C-12 of the polyketide chain. After cyclisation of the D-ring, 
JadD cyclises the C-ring and passes the intermediate on to a second cyclase 
named JadI, which subsequently cyclises the remaining two rings (Kulowski 
et al., 1999). Homologs of JadD and JadI are present in the sim gene cluster 
(SimA5 and SimA4, respectively), suggesting a similar mechanism during 
simocyclinone biosynthesis (Figure 7.1). 
Based on their structures (Figure 7.2), there are four other angucyclinones 
where a SimC7-like mechanism might generate a C-7 hydroxyl group –
panglimycin A from Streptomyces sp. ICBB8230, its related stereoisomer 
elmycin A from Streptomyces sp. DSM4201 and DSM4202 (Fotso et al., 
2008), and the recently identified angucyclinones kiamycin and grisemycin 
from the marine isolate Streptomyces griseus sp. M268 (Xie et al., 2012; Xie 
et al., 2016) (Figure 7.2). However, the biosynthetic gene clusters for these 
four compounds have yet to be reported, and so it is not known whether a 
SimC7-like enzyme is involved in their synthesis. 
Interestingly, most other angucyclin(on)es have a carbonyl group at position 
C-7. The urdamycins (Rohr et al., 1989), the landomycins (Weber et al., 
1994) and the saquayamycins (Uchida et al., 1985) are quinones, but 
intermediates in their biosynthetic pathways have a hydroxyl group at 
position C-7. However, these C-7 hydroxyl groups arise from 
cyclisation/aromatisation of the C-ring, not from ketoreduction (Figure 7.2). 
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The cyclases from several gene clusters have been characterised, including 
JadI (see above), TcmN, and PgaF (Kulowski et al., 1999; Metsa-Ketela et 
al., 2003; Thompson et al., 2004). For example, the 7-hydroxyl group of 
prejadomycin (a shared intermediate in the biosynthesis of the jadomycins, 
landomycins and oviedomycin) originates from cyclisation of the C-ring and 
subsequent aromatisation via enol tautomerisation (Lombo et al., 2009; 
Kharel and Rohr, 2012). This is also the case for the angucyclinone 
azicemicin A (Ogasawara and Liu, 2009), as well as the angucyclin(on)e-
related tetracenomycins, chromomycin A3 and mithramycins (Menendez et 
al., 2004; Thompson et al., 2004). Similarly, the 7-hydroxyl group in 
urdamycin C and D is a consequence of lactone formation at position C-12 
and subsequent enol tautomerisation (Rohr et al., 1988). 
Among the vast range of known angucyclin(on)es are several compounds 
with structures similar to the known SimC7 substrate 7-oxo-SD8. These 
include angucyclinones such as oviedomycin, rabelomycin, gaudimycin, and 
chemomicin A as well as angucyclines such as landomycins, urdamycins, 
aquayamycin, and moromycins (Figure 7.2). In addition, various other 
natural product classes including flavonoids, anthraquinones and 
tetracyclines share a structurally-related carbon skeleton similar to 
angucyclinones with a carbonyl group adjacent to and in plane with a phenyl 
ring system (Figure 7.3). Depending on the substrate specificity of SimC7, 
these structurally related compounds could serve as potential SimC7 
substrates, which would allow engineering of novel natural products. This 
could result in a range of novel angucyclin(on)e derivatives with a 7-hydroxyl 
group, which could be screened for improved biological activities. In case 
SimC7 accepts more diverse substrates such as for example the plant-
derived flavonoids (Figure 7.3), these novel derivatives could also be 
screened for their biological activities. The substrate specificity of SimC7 
could be tested by introducing the simC7 complementation construct 
(pGM1190-pB7-NB-C7) into producer strains. Alternatively, substrate 
conversion could be analysed in a purified in vitro system as described in this 
study, where purified substrates are available. 
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Figure 7.2  
Potential angucyclin(on)e substrates for SimC7 and examples of 
angucyclin(on)es with 7-hydroxyl group.  
Angucyclin(on)es with a 7-carbonyl group (red) are commonly found in 
bacteria and there are few examples of compounds with a 7-hydroxyl group 
(blue) as shown in the upper and lower panel, respectively. Reduction of the 
7-carbonyl group arises generally from C-ring cyclisation/aromatisation (e.g. 
prejadomycin and azicemicin A), not from ketoreduction. Angucyclinones 
with a SimC7-like mechanism (i.e. a non-aromatic C-ring) include 
panglimycin A, elmycin A, grisemycin, and kiamycin. 
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Figure 7.3   
Further potential SimC7 substrates with related structural motifs. 
 
Several flavonoids, anthraquinones and tetracyclines have an 
angucyclinone-related carbon skeleton with a carbonyl group (orange) 
adjacent to a phenyl ring system. Depending on the substrate-specificity of 
SimC7, respective compounds could be reduced by SimC7.  
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7.2 Tetraene biosynthesis 
The fact that SimC7 is not involved in the biosynthesis of the tetraene linker 
of simocyclinone leaves unanswered the question as to how tetraene 
biosynthesis proceeds. One speculative possibility is that the type I PKS 
SimC1ABC contains at least one iterative module to produce a longer 
polyketide intermediate (Figure 7.4).  
One piece of evidence consistent with this speculation is the predicted 
dioxygenase function of SimC4. Dioxygenases incorporate both atoms of 
molecular oxygen into the reaction product. For example, β-carotene 
dioxygenase cleaves a central double bond of β-carotene to generate two 
aldehydes (retinaldehyde, also known as all-trans-retinal) (Bugg, 2003). 
Consequently, the tetraene intermediate would be at least one acetyl-group 
longer than the final product. Cleavage of this intermediate would result in a 
tetraene linker with an aldehyde derived from molecular oxygen on one end 
and a carboxylic acid derived from acetate on the other end. The acetyl 
precursor units would remain complete after cleavage, which would result in 
a labelling pattern identical to the proposed terminally introduced aldehyde 
and thus cannot be distinguished experimentally in the 13C-labelling data 
obtained in this and previous studies (Holzenkampfer et al., 2002).  
Another indication for a potential iterative PKS module involved in tetraene 
biosynthesis can be found in fumagillin, a meroterpenoid produced by the 
pathogenic fungus Aspergillus fumigatus (Lin et al., 2013). Fumagillin 
contains a tetraene (i.e. decatetraenedioic acid), which is structurally 
identical to the tetraene produced during simocyclinone biosynthesis. In 
A. fumigatus, the tetraene is produced by a single iterative PKS module 
(fma-PKS) as a C12 polyketide product, which is released by an α,β-
hydrolase (fma-AT) and subsequently modified into a dicarboxylic acid (Lin et 
al., 2013). Strikingly, the iterative PKS from A. fumigatus has identical 
domain architecture to SimC1B, including the non-functional enoyl reductase 
domain. This further supports the prediction of a longer polyketide 
intermediate in tetraene linker biosynthesis in S. antibioticus Tü6040. 
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Figure 7.4   
Potential biosynthetic pathway for the simocyclinone tetraene linker. 
Tetraene linker biosynthesis in S. antibioticus Tü6040 involves a modular 
type I PKS (SimC1A-C) and several additional monofunctional enzymes. It 
remains unknown if the linker contains a longer starter unit (A) or if the PKS 
has an iterative module (B, highlighted in pink), which would result in a 
longer intermediate. This putative intermediate is then cleaved into two 
aldehydes by the dioxygenase SimC4. Figure adapted from Trefzer et al. 
(2002) (see Figure 1.5). 
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In order to investigate the biosynthesis of the simocyclinone tetraene linker 
(Figure 1.5 and Figure 7.4) it would be necessary to analyse the assembly 
of the polyketide intermediate made by the type I PKS enzyme SimC1ABC. 
This can be done in vivo by chemical chain termination, a method specifically 
developed for determination of polyketide intermediates (Tosin et al., 2010). 
Chemical probes such as the non-hydrolysable analogues malonyl 
(carba)dethia coenzyme A and N-acetylcysteamine thioesters (SNACs) 
compete with acyl carrier protein bound substrates (β-keto ACP thioesters) 
for chain elongation and cause premature release of truncated polyketide 
intermediates. Because these intermediates are not reloaded onto the 
polyketide, they accumulate and can be characterised by LC-MS analysis 
(Tosin et al., 2010). Feeding cultures with synthetic chain terminators is a 
convenient method that is widely used in current mutasynthetic approaches. 
For example, this method led to the identification of intermediates from a 
non-iterative type I PKS involved in biosynthesis of erythromycin A (Tosin et 
al., 2011), a partially reducing iterative type I PKS involved in biosynthesis of 
micacocidin (Kage et al., 2015), and an iterative type I PKS involved in 
biosynthesis of 6-methylsalicylic acid (Parascandolo et al., 2016). 
There are two challenges to overcome to investigate tetraene linker 
biosynthesis via this approach. First, simocyclinone biosynthesis involves 
two PKS-based pathways and second, inactivation of the type II PKS for the 
angucyclinone completely abolishes simocyclinone production and most 
likely production of the tetraene intermediate (Trefzer et al., 2002). These 
two problems could be overcome by comparing the polyketide intermediates 
generated by the wild-type sim cluster with those from a mutant lacking the 
biosynthetic genes for the tetraene linker (ΔsimC1ABC). In addition, 
biosynthesis of the simocyclinone tetraene could be further analysed by 
inactivating or removing domains or modules from the type I PKS enzyme 
SimC1ABC. Alternatively, the simC1ABC could be expressed separately in a 
heterologous system, which would simplify the metabolite profile and 
facilitate mutagenesis. Cloning and engineering of the large PKS genes 
(~22 kb) could be facilitated by using the recently developed strategy of 
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transformation-associated recombination (TAR) cloning (Yamanaka et al., 
2014). 
Since I have shown that SimC7 is a ketoreductase involved in angucyclinone 
biosynthesis, the tetraene dehydratase (initially predicted to be SimC7) 
remains unidentified. One explanation could be that dehydration occurs 
spontaneously. Aldols (also named β-hydroxy ketones) can spontaneously 
convert into α,β-unsaturated carbonyls. The driving force for this 
spontaneous dehydration is the formation of a conjugated system with the 
adjacent carbonyl group. Dehydration proceeds even more rapidly under 
acidic conditions or at increased temperatures. Indeed, non-enzymatic 
dehydration of polyketide natural products has been observed previously 
(Kitao et al., 1980; Fu et al., 1994; Kulowski et al., 1999) or was predicted to 
occur spontaneously based on the absence of dehydratase enzymes in the 
corresponding gene clusters (Nowak-Thompson et al., 1997; Chiang et al., 
2011). If non-enzymatic dehydration occurs spontaneously during 
simocyclinone biosynthesis, it could be identified by the above mentioned 
chain termination approach, which should reveal the predicted tetraene linker 
intermediates. 
A recent alternative hypothesis is that the tetraene linker is made by an 
iterative minimal PKS rather than a modular type I PKS (Bilyk et al., 2016). 
Bilyk et al. (2016) identified Kitasatospora sp. (smc gene cluster) and 
Streptomyces sp. NRRL B-24484 (sml gene cluster) as new simocyclinone 
producers. Strikingly, however, they found there were no homologs of 
simC1ABC in the smc and sml biosynthetic gene clusters, or anywhere else 
on the chromosome. Therefore, they proposed that the tetraene linker in 
these two strains is made by a fatty acid related PKS enzyme, comprised of 
an acyl carrier protein (ACP, encoded by smcP in Kitasatospora sp.) and 
three 3-oxoacyl-ACP-synthases (I-III: smcKSI, smcKSII, and smcX5 in 
Kitasatospora sp.) (Bilyk et al., 2016). Homologs of these genes are also 
present at one end of the sim gene cluster in S. antibioticus Tü6040 (orf1-3 
and simX5, Figure 1.6) but it remains to be tested experimentally whether 
these fatty acid-related PKS genes are involved in tetraene linker 
biosynthesis in S. antibioticus Tü6040. Deletion of the simC1ABC genes in 
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S. antibioticus Tü6040 abolished production of simocyclinones that contained 
the tetraene linker (C- and D-group simocyclinones) but the deletion had no 
effect on earlier simocyclinone intermediates (A- and B-group 
simocyclinones), suggesting the type I PKS encoded by these genes is 
essential for tetraene linker biosynthesis (data not shown). Nevertheless, it 
would be interesting to test the involvement of orf1-3 and simX5 in tetraene 
biosynthesis in S. antibioticus Tü6040 by deleting them. The alternative 
model for tetraene linker formation in Kitasatorspora sp. would require 
dehydration of the entire polyketide chain and it was speculated that one or 
more dehydratases from fatty acid biosynthesis might be recruited for this 
purpose (Bilyk et al., 2016).  
 
7.3 Ketoreductases involved in simocyclinone biosynthesis 
In addition to the novel angucyclinone ketoreductase SimC7 described here, 
there are three further SDR ketoreductases predicted to be involved in 
simocyclinone biosynthesis – SimA6, SimA9, and SimA10 (Galm et al., 2002; 
Trefzer et al., 2002). Close homologs of SimA6 (i.e. ActKR and HedKR) and 
SimA9 (i.e. LanV and UrdMred) have been characterised that act on the C-9 
and C-6 positions, respectively (see chapter 5). In contrast, the function of 
SimA10, an NAD(P)H-dependent flavin mononucleotide (FMN) 
ketoreductase, remains unknown. SimA10 has homologs in other 
angucycline gene clusters, for example UrdO and SaqO from urdamycin and 
saquayamycin biosynthesis, respectively (Faust et al., 2000; Erb et al., 
2009), but their biosynthetic roles remain unknown. SimA10 could be 
involved in recycling the cofactor for another biosynthetic enzyme. For 
example, the related FMN reductase JadY from jadomycin biosynthesis is 
involved in recycling oxidised flavin mononucleotide (FMN) and flavin 
adenine dinucleotide (FAD) back to their reduced forms (FMNH2 and 
FADH2). The reduced cofactor is required for JadG, an oxygenase that 
catalyses a unique B-ring opening C-C bond cleavage reaction needed for 
formation of an N-heterocycle (Fan et al., 2012). Because SimA10 is related 
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to JadY (30% identity; 40% similarity) it is possible that SimA10 assists 
another enzyme during simocyclinone biosynthesis (Figure 7.1). 
It would be interesting to investigate the potential involvement of SimA10 in 
simocyclinone biosynthesis since there is nothing known about its function. 
This could be done by mutagenesis of simA10, provided that the 
heterologous host carrying the mutagenized PAC is viable (see below).  
 
7.4 Natural resistance mechanism against simocyclinones 
One of the most important challenges that needs to be addressed is the 
toxicity of simocyclinones to heterologous hosts. Since the natural producer 
of simocyclinone is difficult to manipulate, an efficient heterologous system is 
crucial for successful studies on simocyclinone biosynthesis. This raises the 
obvious question: What is the resistance mechanism of the natural 
simocyclinone producer S. antibioticus Tü6040? So far, only constitutive 
overexpression of the simocyclinone efflux pump SimEx1 has been shown to 
confer significant levels of resistance to SD8 (Le et al., 2009). Perhaps high-
level transcription of simEx1 requires additional transcriptional regulators that 
are not encoded on the PAC-12I clone, but are encoded elsewhere on the 
S. antibioticus genome. Regulatory crosstalk may even exist between the 
gene clusters for simocyclinone biosynthesis and other secondary 
metabolites, as observed for example in Aspergillus nidulans, where 
overexpression of a positive regulator from the silent inp gene cluster on 
chromosome II induces expression of a second gene cluster for 
asperfuranone biosynthesis on chromosome VIII (Bergmann et al., 2010). 
Alternatively, there may well be an additional resistance mechanism in the 
natural simocyclinone producer that is absent from S. coelicolor. Evidence 
for this idea comes from the impaired development of the S. coelicolor 
heterologous host expressing a tetraene linker deletion construct (PAC-
12IΔC1ABC). The absence of the type I PKS genes (simC1ABC) makes this 
mutant unable to produce C- and D-group simocyclinones, yet the strain is 
still very sick. This seems to imply that the angucyclinone moiety of 
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simocyclinone inhibits a cellular target other than DNA gyrase in 
S. coelicolor.  
The biological activities of angucyclines and angucyclinones are varied, 
covering cytotoxicity (including antitumor activity), enzyme inhibition, 
inhibition of platelet aggregation (thrombocytes), antibacterial activities, and 
antiviral activities (Rohr and Thiericke, 1992; Kharel et al., 2012). Most 
interesting are the enzyme inhibitory activities of structurally related 
angucyclin(on)es (Figure 7.2). For example, aquayamycin is a non-
competitive inhibitor of tyrosine hydroxylase (noradrenaline biosynthesis), 
dopamine β-hydroxylase (adrenaline biosynthesis), and tryptophan 
5-monooxygenase. Vineomycin A1 is a non-competitive inhibitor of prolyl 
hydroxylase, an essential enzyme for collagen biosynthesis (Rohr and 
Thiericke, 1992). Vineomycin C and saquayamycin A1 weakly inhibit the 
inducible nitric oxide synthase (iNOS). Several glycol-modified urdamycins 
were found to have potent activity against xanthine oxidase at sub-
micromolar concentrations. Gephyromycin, which contains an ether-bridged 
structure between C-3 and C-12a, is a strong glutaminergic agonist, causing 
influx of Ca2+ ions into neurons and the eventual release of glutamate and 
aspartate into the extracellular space (Kharel et al., 2012). Furthermore, 
structural homologs of the angucyclinone moiety of simocyclinone have 
antitumor activity (landomycins, oviedomycin, saquayamycins), antibacterial 
activity (Gram positive: saquayamycins; Gram-positive and Gram-negative: 
urdamycins, rabelomycins, 8-O-methyl-rabelomycin), and weak antifungal 
activity (elmycins, emycin A, and sakyomicins) (Kharel et al., 2012). 
Additional factors that contribute to simocyclinone resistance could be 
identified by screening a genomic library for resistant colonies. This could be 
done using the genomic PAC library created by Bio S&T (Montreal, Canada) 
or by generating a new cosmid library, which has the advantage of screening 
much shorter DNA fragments than the ~110-kb inserts of the PAC-library. 
The screening could be carried out in S. coelicolor or S. lividans against 
purified SD8 or crude simocyclinone extracts. In addition, the screening 
could be repeated with (semi-)purified early simocyclinone intermediates to 
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test if toxicity originates from additional cellular targets of the angucyclinone 
moiety.  
Several spontaneous gyrA mutations are known to confer simocyclinone 
resistance in E. coli (Edwards et al., 2009). Equivalent mutations could be 
introduced into gyrA in S. coelicolor, and the high sequence similarity 
between DNA gyrase from E. coli and S. coelicolor implies that they should 
improve resistance to SD8. However, the suggestion that the angucyclinone 
moiety by itself is toxic to S. coelicolor and that its cellular target is not DNA 
gyrase means this approach by itself may not lead to a robust and vigorous 
heterologous expression system for simocyclinones.  
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